CA2136903C - Acetic acid derivatives - Google Patents

Acetic acid derivatives Download PDF

Info

Publication number
CA2136903C
CA2136903C CA002136903A CA2136903A CA2136903C CA 2136903 C CA2136903 C CA 2136903C CA 002136903 A CA002136903 A CA 002136903A CA 2136903 A CA2136903 A CA 2136903A CA 2136903 C CA2136903 C CA 2136903C
Authority
CA
Canada
Prior art keywords
methyl
alkyl
ethyl
group
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002136903A
Other languages
French (fr)
Other versions
CA2136903A1 (en
Inventor
Leo Alig
Paul Hadvary
Marianne Hurzeler Muller
Marcel Muller
Beat Steiner
Thomas Weller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2136903A1 publication Critical patent/CA2136903A1/en
Application granted granted Critical
Publication of CA2136903C publication Critical patent/CA2136903C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/10Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C07C251/16Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40Y being a hydrogen or a carbon atom
    • C07C323/42Y being a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02Monothiocarbamic acids; Derivatives thereof
    • C07C333/04Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/071,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2454Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2479Compounds containing the structure P(=X)n-N-acyl, P(=X)n-N-heteroatom, P(=X)n-N-CN (X = O, S, Se; n = 0, 1)
    • C07F9/2491Compounds containing the structure P(=X)n-N-acyl, P(=X)n-N-heteroatom, P(=X)n-N-CN (X = O, S, Se; n = 0, 1) containing the structure P(=X)n-N-N (X = O, S, Se; n = 0, 1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Acetic acid derivatives of the formula (see formula 1) wherein L, M, T and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive proteins to blood platelets and by blood platelet aggregation and cell-cell adhesion. They are manufactured by cleaving protecting groups in the corresponding protected compounds or by converting the cyano group into the amidino group in corresponding nitriles.

Description

The present invention is concerned with novel acetic acid s derivatives, a process for their manufacture, pharmaceutical preparations which contain such compounds as well as the use of these compounds for the production of pharmaceutical prepar-ations.
w In particular, the invention is concerned with acetic acid derivatives of the formula L~M~O~T I
O O
wherein L is a group of formula L1 to L5:
A~W~ Ll ~O G
A~W~ L2 G
O

H G
G
A
H
O
H O G
E'- N -i ~ ~ Ls E -N
of M~JSo 1.11.94 ~1~6903 in which a carbonyl group present in the L group andlor between the L and M groups which is not bonded in the form of an amide can also be present as an oxime, A is a group of formula A1 to A4:
E'- N

E'- N
\ / Aa X-Y
(CH2)m \
E'-N~ rD-CH2 A3 (CH2)n (CH2)p E~-N' ~(CH2)q /
to E1 and E2 are H, lower-alkyl, OH, lower-alkoxy, lower-alkoxy-lower-alkyl, carboxy-lower-alkyl, P(O)(O-lower-alkyl)2; C(O)OR1, OC(O)R1, OC(O)OR1 or C(O)SR~, provided that at least one of E~ and E2 is H, or ~5 E~ and E2 together with the N atoms to which they are attached are a (5,5-dimethyl or 5-oxo)-4,5-dihydro-1,2,4-oxadiazol-3-yl group, R~ is lower-alkoxy-lower-alkyl, lower-alkyl, lower ~o alkyl substituted by OH, COOH, lower-alkoxycarbonyl, lower-alkanoyloxy, lower-alkenoyloxy, by optionally substituted benzoyloxy or by lower-alkyl-CONH, or phenyl which is optionally substituted and optionally bonded via lower-alkylene, or cycloalkyl optionally 25 interupted by O, one of X and Y is CH and the other is CH, C-lower-alkyl, C-lower-alkoxy or N, s D is a group (CH2)S or (CH2)t0, s is 1 to 4, m and n are 0 to 5 and w t is 0 to 3, but m + n are 1 to 5 and each of m + t and n + t is at least 1, p and q are 0 to 5, but p + q is 2 to 5, W1 is CH2, alkyl-CH, lower-alkyl-OC(O)CH, NH, lower alkyl-N or lower-alkoxy-lower-alkyl-N, W2 is O, NH, acyl-N or lower-alkyl-OC(O)-N, G is H or the characterizing group of an a-aminocarbox-ylic acid, M is 1,4-piperidinylene bonded via the N atom to the 25 keto group or 1,4-phenylene optionally substituted by lower-alkyl, lower-alkoxy, OCH2COOH or OCH2C00-lower-alkyl, Q is O, CH2, NH, acyl-N or lower-alkyl OC(O)N, T is NH2, NH-lower-alkyl, NH-lower-alkyl (COOH or COO-lower-alkyl), lower-alkoxy or lower-alkenyloxy substituted by lower-alkoxy, COOH, COO-lower-alkyl, lower-alkyl-COO or lower-alkyl-OCOO, or a group OT', T' is H, lower-alkyl, phenyl or pyridyl optionally bonded ~1~6903 via lower-alkylene or cycloalkyl optionally bonded via lower-alkylene and optionally interrupted by O, NH or NCOO-lower-alkyl, with the provisos that s a) T' is different from H, lower-alkyl and phenyl-lower-alkyl where L is a group of the formula a~w~ Li Zp O G
A is a group of the formula E'- N

\ /

one of E~ and E2 is hydrogen and the other is hydrogen, tert butoxycarbonyl or benzyloxycarbonyl, one of X and Y is CH and the other is CH or N and W~ is NH, lower-alkyl-N or lower-alkoxy-lower-alkyl-N, G has the above significance, 25 M is 1,4-piperidinylene bonded via the N atom to the keto group and Q is O, and b) T' is different from H, lower-alkyl, phenyl and phenyl-lower-alkyl where L is a group of formula L11, L3~ or L41:

~1~~J0 Ro I
A~N~ L11 '~O' Go O

Go A-y/''~
s A is a group of the formula E'- N
Ai one of E1 and E2 is hydrogen and the other is hydrogen, tert-~o butoxycarbonyl or benzyloxycarbonyl, one of X and Y is CH and the other is CH, C-lower-alkyl, C-lower-alkoxy or N, R~ and G~ are H or lower-alkyl, W4 is C=O or C=NOH, M is 1,4-phenylene optionally substituted by lower-2fl alkyl, lower-alkoxy, OCH2COOH or OCH2C00-lower-alkyl and Q is O, CH2 or NH, 2~ as well as hydrates or solvates and physiologically usable salts thereof.
In the scope of the present invention "lower" denotes straight-chain or branched groups with 1 to 6, preferably 1 to 4, so C atoms. Thus, methyl, ethyl, propyl, isopropyl, n-, s- and t-butyl and hexyl are examples of lower-alkyl; methoxy and ethoxy are examples of lower-alkoxy; acetyl and propionyl are examples of ~1369U3 lower-alkanoyl. Methacryloyl is an example of lower-alkenoyl and pentenyloxy is an example of lower-alkenyloxy.
Halogen and lower-alkoxy are examples of substituents on a s phenyl group R1. Benzyl and C3_6-cycloalkyl optionally interrupt-ed by O, such as tetrahydropyranyl, are other examples of groups R~. Lower-alkanoyloxy groups such as acetoxy are examples of substituents on a benzoyl group present in R~ .
w Examples of cycloalkyl groups T' optionally bonded via lower-alkylene and optionally interrupted by O, NH or NCOO-lower-alkyl are those with 3 to 6 C atoms in the cyclic part, such as cyclopropyl, cyclohexyl, tetrahydropyranyl, piperidinyl and N-(t-butoxycarbonyl)piperidinyl.
The term "characterizing group of an alpha-aminocarboxylic acid" denotes the group G in a natural or synthetic alpha-amino acid of the formula H2NCH(G)COOH. Groups G present in natural a-amino acids are methyl (in alanine), isopropyl (in valine), benzyl 20 (in phenylalanine), p-hydroxybenzyl (in tyrosine), CH2SH (in cysteine), CH20H (in serine), 1-hydroxyethyl (in threonine) and the like. Further, G is, for example, a lower-alkyl group option-ally substituted by OH, SH, lower-alkylthio, aryl, NH2, NH-Ra, N(Ra, Rb) or ORa, wherein Ra and Rb are lower-alkyl, lower-alkoxy-25 lower-alkyl, acyl or lower-alkoxycarbonyl. Further, a lower-alkyl group G can be substituted by CONH2 or CONH-lower-alkyl.
The above aryl is e.g. phenyl or phenyl substituted by OH, NH2, NH-Ra, N(Ra, Rb) or ORa. The above acyl is e.g. lower-alkanoyl, aroyl or heteroaroyl in which aroyl is an aryl group as defined above which 3o is bonded via CO, such as benzoyl or lower-alkanoyloxybenzoyl, and heteroaroyl is e.g. a 5- to 6-membered, O- or NH-containing heteroaromatic group which is bonded via CO, such as furoyl.
The compounds of formula I can be solvated, especially hydrated. The hydration can be effected in the course of the manufacturing process or can occur gradually as a consequence of hygroscopic properties of an initially anhydrous compound of formula I.

Examples of physiologically usable salts of the compounds of formula I are salts with physiologically compatible mineral acids such as hydrochloric acid, sulphuric acid or phosphoric acid;
s or with organic acids such as methanesulphonic acid, acetic acid, trifluoroacetic acid, citric acid, fumaric acid, malefic acid, tartaric acid, succinic acid or salicylic acid. The compounds of formula I having a free carboxy group can also form salts with physiologically compatible bases. Examples of such salts are ~o alkali metal, alkaline earth metal, ammonium and alkylammonium salts such as the Na, K, Ca or tetramethylammonium salt. The compounds of formula I can also be present in the form of zwitterions.
The compounds of formula I which contain one or more asymmetric C atoms can be present as enantiomers, as diaster-eomers or as mixtures thereof, e.g. as racemates.
The compounds in accordance with the invention can be 2o divided into the following groups:
a) those wherein L is a group L1 in which A is a group A~ and of the formula E'- N O O
/. \ ~~ W' M~ O~ T I A
E N x-Y
O G
wherein E~, E2, X, Y, W1, G, M, Q and T have the above significance, ~o b) those wherein L is a group L1 in which A is a group A3 and of the formula (CHp)m ' ~
E'-N D W M~O~T I-B
~(CH ) 2n O G

s 2136~0~
wherein E1, m, n, D, W1, G, M, Q and T have the above significance, c) those wherein L is a group Li in which A is a group A2 and s of the formula _ 0 0 H
E'- ~ ~ W' M~ O v ' T I-C
X-Y I
O G
wherein E~ , X, Y, W~ , G, M, Q and T have the above signific-w ance, especially wherein Q is O and T is OH or lower-alkoxy, d) those wherein L is a group L~ in which A is a group A4 and of the formula >s (CH2)P
E'-N~ ~ ~ O O I-D
(CH~q ~ ~ W~ M~ v _T
O G
wherein E1, p, q, W1, G, M, Q and T have the above signific-ance, especially wherein M is 1,4-phenylene, Q is O and T
2o is lower-alkoxy, e) those wherein L is a group L2 in which A is a group A1 and of the formula E'- N O O
W2 O~ I-E
E2- N X-Y Mi v 'T

wherein E~, E2, X, Y, W2, G, M, Q and T have the above signif-icance, especially wherein M is 1,4-piperidinylene bonded via the N atom to the keto group, Q is O and T is lower-so alkoxy, .2136903 f ) those wherein L is a group L3 in which A is a group A~ and of the formula E'- N O O O
E2- N ~ ~ M, Q~T I-F
X-Y FI I
G
wherein E1, E2, X, Y, G, M, Q and T have the above signific-ance, especially wherein M is 1,4-piperidinylene bonded via the N atom to the keto group, Q is O and T is lower-alkoxy, w g) those wherein L is a group L4 in which A is a group A1 and of the formula E'- N G O O
II I-G
E2- N X-Y N~ Mi Q~ T
O H
wherein E~, E2, X, Y, G, M, Q and T have the above signific-ance, especially wherein M is 1,4-phenylene, Q is O and T is lower-alkoxy, h) those wherein L is a group L5 and of the formula E~- N O G
T
E2- N ~ ~ N ~ I_H

wherein E~ , E2, G, M, Q and T have the above significance, especially wherein M is 1,4-piperidinylene bonded via the N
atom to the keto group, Q is O and T is lower-alkoxy.
Examples of acetic acid derivatives of the present invention are those in which L is a group of the formula A~w~ Li 3p O G

A is a group A~ , A2 or A3o:
E'- N
\ / Ai E2- N x-Y
E'- N
\ /
X-Y
(CH2)m I-N~ ~ (CH2)tOCH2 A30 (CH2)n one of E1 and E2 is H and the other is H, lower-alkyl, OH, lower-alkoxy, lower-alkoxy-lower-alkyl, carboxy-lower-alkyl, PO(O-lower-alkyl)2, C(O)ORS or OC(O)OR~, w R1 is lower-alkoxy-lower-alkyl, lower-alkyl, lower-alkyl substituted by OH, COOH or lower-alkenoyloxy, or phenyl which is optionally substituted and option-ally bonded via lower-alkylene, or cycloalkyl option-ally interrupted by O, one of X and Y is CH and the other is CH or N, m and n are 0 to 5 and t is 0 to 3, but m + n is 1 to 5 and each ~o ofm+tandn+tisatleastl, W~ is CH2, lower-alkyl-OCOCH, NH, lower-alkyl-N or lower-alkoxy-lower-alkyl-N, 25 G is H or the characterizing group of an a-amino-carboxylic acid, M has the significance given earlier, 3o Q is oxygen, T is a group OT" and T" is H, lower-alkyl, lower-alkoxy-lower-alkyl or cyclo-alkyl optionally bonded via lower-alkylene and option-ally interrupted by O, with the provisos that s a) T" is different from H, lower-alkyl and phenyl-lower-alkyl where A is a group of the formula to E'- N
Ai \ /

E1 and E2 are hydrogen, tert-butoxycarbonyl or benzyloxy-carbonyl, X, Y, G and Q have the above significance, W~ is NH, lower-alkyl-N or lower-alkoxy-lower-alkyl-N
and M is 1,4-piperidinylene bonded via the N atom to the keto group, and b) T" is different from H, lower-alkyl, phenyl and phenyl-lower-alkyl where L is a group of formula L~ 1:

I
A~N~ L11 ~~OI( G°
A is a group of the formula E'- N

\ /

E~ and E2 are hydrogen, tert-butoxycarbonyl or benzyloxy-carbonyl, s X, Y and Q have the above significance, R~ and G~ are H or lower-alkyl and 13 2136'903 M is 1,4-phenylene optionally substituted by lower-alkyl, lower-alkoxy, OCH2COOH or OCH2C00-lower-alkyl, s and physiologically usable salts thereof.
Preferred compounds of formula I are those in which one of E1 and E2 is H and the other is H, OH, C(O)ORS or io OC(O)OR1 and/or R ~ is lower-alkyl, such as ethyl, butyl or isobutyl, lower-alkoxy-lower-alkyl, such as methoxyethyl, lower-alkyl substit-uted by benzoyloxy or lower-alkanoyloxy, such as benzoyloxy-methyl, acetoxymethyl, acetoxyethyl or pivaloyloxymethyl, or phenyl and/or one of X and Y is CH and the other is CH or N and/or W~ is NH
or CH2 and/or Q is O or CH2 and/or G is H, lower-alkyl, such as methyl or ethyl, or lower-alkoxycarbonylamino-lower-alkyl, such as ethoxycarbonylamino-propyl, and/or 2~ M is 1,4-piperidinylene bonded via the N atom to the keto group, 1,4-phenylene or 1,4-phenylene substituted by OCH2C00-lower-alkyl, such as methoxycarbonylmethoxy, and/or T is lower-alkoxy, such as methoxy, ethoxy, isopropoxy, ~o isobutoxy, tert-butoxy or hexyloxy, lower-alkoxy-lower-alkoxy, such as methoxyethoxy, lower-alkenyloxy substituted by COO-lower-alkyl, such as 2-isobutoxycarbonyl-2-pentenyloxy, lower-alkoxy substituted by lower-alkyl-COO, such as pivaloyloxy-methoxy, lower-alkyl substituted by lower-alkyl-OCOO, such as 1-isopropoxycarbonyloxy-ethoxy, cycloalkoxy optionally interrupted by O, such as tetrahydropyranyloxy, pyridyl bonded via lower-alkyleneoxy, such as 3- or 4-pyridylmethoxy, or cycloalkyl bonded via lower-alkyleneoxy and optionally interrupted by NCOO-lower-alkyl, such as 1-tert-butoxycarbonyl-3 or 4-piperidyl-methoxy.
Examples of such compounds are those from the following s group:
ethyl (S)-4-[2-[4-[imino-2-(methoxy-ethoxycarbonyl-amino)-methyl]-benzoylamino]-propionyl]-phenoxyacetate, ethyl (Z)-(R,S)-4-[2-[4-[amino-hydroxyimino-methyl]-io benzoylamino]-propionyl]-phenoxyacetate, tetrahydropyran-4-yl (S)-4-[2-[4-(ethoxycarbonylamino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, ethyl (Z)-(R,S)-4-[2-[4-[amino-ethoxycarbonyloximino-methyl]-benzoylamino]-propionyl]-phenoxyacetate, ethyl (S)-4-[2-[4-(imino-phenoxycarbonylamino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, 2-methoxy-ethyl (S)-4-[2-[4-[imino-(2-methoxy-ethoxy-carbonylamino)-methyl]-benzoylamino]-propionyl]-phenoxy-acetate, 2o ethyl (Z)-(S)-4-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, isopropyl (E/Z)-(S)-1-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate, isopropyl (E/Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate, isopropyl [1-[4-[4-(ethoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, isopropyl (RS)-[1-[4-[4-(isobutoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-3a acetate and especially ethyl (E/Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidi n-4-yloxyacetate as well as from the #ollowing group:
(R/S)-1-isopropoxycarbonyloxy-ethyl (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxy]-acetate, _ 15 ~136~03 pyridin-3-ylmethyl (R)-(E)/(Z)-[1-[4-[4-(amino-hydroxy-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, pyridin-4-ylmethyl (R)-(E)/(Z)-[1-[4-[4-(amino-hydroxy-s imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, tert-butyl (E)- or (Z)-(RS)-3-[1-[(R)-4-[4-(amino-hydroxy-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxyacetoxymethyl]-piperidine-1-carboxylate, w ethyl (R)-[1-[4-[4-(benzoyloxymethoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyrylJ-piperidin-4-yloxy]-acetate, ethyl (R)-[1-[4-[4-(imino-pivaloyloxymethoxycarbonyl-amino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxyJ-acetate, tert-butyl (E)- or (Z)-(R)-4-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy-acetoxymethyl]-piperidine-1-carboxylate, ethyl (S)-[4-[2-[4-[(2-acetoxy-ethoxy-carbonylimino)-2o amino-methylJ-benzoylamino]-propionyl]-phenoxy]-acetate and acetoxymethyl (S)-4-[2-(4-ethoxycarbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoylmethoxyJ-piperidine-1-carboxylate.
25 The following are further examples of compounds of formula I:
cyclopropylmethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, 3o cyclohexyl (S)-4-[2-[4-(amino-imino-methyl)-benzoyl-amino]-propionyl]-phenoxyacetate, ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylaminoJ-3-hydroxy-propionyl]-phenoxyacetate, (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-(4-methoxy-phenyl)-propionyl]-phenoxyacetic acid, ethyl (2S,3R)-4-[2-[4-(amino-imino-methyl)-benzoyl-aminoJ-3-hydroxy-butyryl]-phenoxyacetate, 2-methoxy-ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-acetoxy-propionyl]-phenoxyacetate, ethyl (R,S)-4-[2-[4-(ethoxycarbonylamino-imino-methyl)-s benzoylamino]-3-methylsulphanyl-propionyl]-phenoxyacetate, ethyl (S)-4-[2-[4-(diethoxyphosphorylamino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, isopropyl (E/Z)-(S)-1-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-3-(4-ethoxycarbonyloxy-phenyl}-w propionyl]-piperidin-4-yloxyacetate, (E/Z)-(S)-4-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-3-(4-isopropoxycarbonylmethoxy-piperidin-1-yl)-3-oxo-propyl]-phenyl 2-amino-benzoate, (E/Z)-(S)-4-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-3-(4-isopropoxycarbonylmethoxy-piperidin-1-yl)-3-oxo-propyl]-phenyl furan-2-carboxylate, (E/Z)-(S)-4-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-3-(4-isopropoxycarbonylmethoxy-piperidin-1-yl)-3-oxo-propyl]-phenyl 2-acetoxy-benzoate, ~o tetrahydropyran-4-yl (S)-1-[2-(5-amino-imino-methyl-pyridin-2-ylcarbonylamino)-propionyl]-piperidin-4-yloxy-acetate and isopropyl (S)-1-[2-(5-aminomethyl-pyridin-2-ylcarbonyl-amino)-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yloxy-acetate.
The acetic acid derivatives in accordance with the invention can be manufactured by so a) cleaving the protected amino or amidino group in a compound of the formula L~M~O~T
~O - ~O
a~ wherein L~ is a group of one of formulae L1 o to L5o ~i3s~o~
A°\ 'W' / Lio ~O ~G
A°~W~ L20 G
O

H G
G
A° ~ L40 H
O
O G
Lso s in which A~ is a group A containing a protected amino or amidino group, A, W~ , W2, G, M, Q and T have the above significance and Ao1 is a protected amidino group, or w b) converting the free amidino group in a compound of formula III
III
O O
wherein L~ oo is a group of one of formulae L~ o~ to LSO

A'° \ 'w' / Llol ~O ~G
A'~ ~W~ L201 G
O
A' ° ~ L301 H G
G
A' ~~ ~ L401 H
O

Lsol J
in which A10o is a group A containing a free amidino group s and A, W1, W2, G, M, Q and T have the above significance, or in a salt thereof into an amidino group substituted by a group E~ or E2, or c) converting the cyano group present in L11 in a compound of to formula IV
L1y Mw O~ T IV
IO' O
wherein L> > is a group of one of formulae L> > 1 to L115 >5 r~ c ~ ~ w' Liii X=Y
O G
t~E c ~ ~ ~w2 L112 X=Y
G
O
nE c ~ ~ Lies X=Y H I
G
G
1~ c ~ ~ ~ L114 X=Y I H
O
O G
tic ~ Lies in which X, Y, W1, W2, G, M, Q and T have the above s significance, into an amidino group optionally substituted by E1 or E2, or d) reacting an amine of the formula RZ O O
I
MiO~T V
G
wherein RZ is H, lower-alkyl or lower-alkoxy-lower-alkyl and G, M, Q and T have the above significance, with an acid A-COOH or a functional derivative thereof, or e) if desired, functionally modifying a reactive group present in a compound of formula I, and 20 21~6J0~
f ) if desired, converting a compound of formula I into a physiologically compatible salt or converting a salt of a compound of formula I into the free acid or base.
s Examples of cleavable protected amino or amidino groups A~
present in compounds II are NH-Boc and NH-Z or C(NH)NH-Boc, C(N-Boc)N(Boc)2, C(N-Boc)NH-Boc and C(NH)NH-Z. Amino and amidino groups protected by Boc can be cleaved e.g. with an acid such as formic acid or trifluoroacetic acid, if desired in a solvent ~o such as dichloromethane, at a temperature up to 40~C, preferably at room temperature. A hydroxy group present in a group A~ can also be protected by a tri-lower-alkyl-silanyl group such as tert-butyl-dimethyl-silanyl. Such groups can be cleaved by means of tetrabutylammonium fluoride in an ether such as diethyl ether and/or THF at a temperature up to 40~C, preferably at room temperatu re.
The conversion b) of an amidino group present in compound III or a salt thereof, e.g. the trifluoroacetate, into an amidino 2o group substituted by a group E~ or EZ can be carried out in a solvent such as dichloromethane, if desired in the presence of a base such as NaHCOg or Na2COg, with a compound of the formula R10C(O)CI or CIP(O)(O)-lower-alkyl)2.
2s In order to convert the cyano group into an amidino group optionally substituted by E1 or E2 according to process variant c), a nitrite of formula IV can be reacted in pyridine and triethyl-amine with H2S and the resulting compound which is substituted by thiocarbamoyl H2NC(S) can be methylated, e.g. in acetone with 3o methyl iodide at boiling temperature, to the corresponding compound substituted by methylthioformimidoyl HN=C(SCH3).
Reaction of the latter compound with a compound E-NH2, wherein E is H, lower-alkyl or lower-alkoxy-lower-alkyl, or with an acid addition salt thereof such as the hydrochloride or the acetate in a a~ solvent such as THF or methanol while heating, conveniently to the boiling point of the reaction mixture, yields the corresponding amidine of formula I. Reaction of a nitrite IV with hydroxylamine hydrochloride in a solvent such as methanol or DMSO in the 21 ~136~03 presence of a base such as sodium methanolate or triethylamine results in the corresponding compound I in which the group A (in L) contains a hydroxylated amidino group.
s Reaction d) can be conveniently carried out using a salt, e.g.
the hydrochloride, of the amine V in the presence of a base such as pyridine in a solvent such as an ether at a temperature up to 40~C, preferably at room temperature.
w A tert-butoxycarbonyl group COOT1 present in an ester of formula I obtained according to variants a) to d) can be cleaved to a corboxy group by means of an acid such as formic acid.
Functional modifications of reactive groups according to process variant e) are (1 ) the cleavage of lower-alkoxycarbonyl groups such as COOT1; (2) the cleavage of ether groups present e.g. in group G (in L); (3) the conversion of an unsubstituted amidino group (E1 = E2 = H) present in a group A1 (in L) or L5 into a substituted amidino group; (4) the conversion of a hydroxy group 20 (one of E~ and E2 is OH and the other is H) present in a group A1 (in L) or L5 into a R~ OC(O)O group.
These conversions can be carried out in a manner known per se, for example cleavage (1) in a solvent such as an aqueous 25 lower-alkanol, e.g. aqueous methanol or ethanol, with a base such as sodium hydroxide; cleavage (2) of ether groups such as the tent-butoxy group in dichloromethane by means of trifluoroacetic acid; conversions (3) and (4) in a solvent such as dichloromethane in the presence of Na2COg by means of a compound of the formula 3o R~ OC(O)CI or in DMF in the presence of triethylamine by means of R1 OC(O)O-p-N02C6H~.
Further modifications such as the esterification of a carboxy group in an acid of formula I (T = OH), the esterification of a hydroxy group present in group G (in L) to an aminobenzoyl-oxy, furoyloxy, acetoxy or acetoxybenzoyloxy group, the cleavage of the hydroxy group from a hydroxylated amidino group present in group A (in L) and the conversion of a group O=C= which is not bonded in the form of an amide and which is present in group L
and/or between L and M into the HON=C= group can be carried out in a manner known per se as described in detail in the Examples.
s A hydroxylated amidino group present in group A (in L) can be converted into the (5,5-dimethyl or 5-oxo)-4,5-dihydro-1,2,4-oxadiazol-3-yl group in acetone by means of formic acid while heating or in the presence of methylmorpholine in dichloro-methane by means of triphosgene while cooling. the conversion of w an amidino group present in group A (in L) into an amidino group substituted by -C(O)SR~ can be carried out in dichloromethane in the presence of NaHC03 by means of the corresponding chloro-thioformate CIC(O)SR~ .
A N-unsubstituted group A3 or A4, wherein E~ is H, present in a group of formula L, can be converted firstly by means of acrylonitrile in ethanol into the corresponding N-(2-cyanoethyl) group A3 or A4, wherein E1 stands for 2-cyanoethyl, and the latter group A3 or A4 can be converted in dichloromethane by means of m-chlorobenzoic acid into the corresponding N-hydroxy-substituted group A3 or A4, wherein E~ is OH.
The compounds of formula II can be prepared in a manner known per se. Thus, those wherein L is a N-containing group L~ o 25 and Q stands for O and of the formula R2 0 o II-A
O
~~ M~ T
O G
wherein A~, G, M and T have the above significance and R2 is 3o H, lower-alkyl or lower-alkoxy-lower-alkyl, can be prepared starting from compounds of formula VI

W-N OOH
M
G

wherein W is a protecting group such as Boc and R2, G and M
have the above significances, via compounds of the formula Rz o o V-A
w-Mi ~ T
G
The reaction VI~V-A can be carried out by means of a bromide BrCH2C(O)T in the presence of a base such as K2C03 in a solvent such as DMF. By cleavage of the protecting group W in the w compound of formula V-A there is obtained a compound of formula V. This or an acid addition salt thereof, e.g. the hydrochloride, is then converted into the compound II-A with a functional deriv-ative of an acid A~COOH, e.g. the acid chloride, in the presence of a base such as N-methylmorpholine in a solvent such as THF.
The compounds VI in which M is optionally substituted 1,4-phenylene are known or can be prepared in a manner known per se, e.g. starting from the compounds VII
z R O
w-N N, OCH3 ~ OCH3 G
via those of formula VI-A

R o I VI-A
W- ~ OSi - R5 M
G Ra wherein R3, R4 and R5 are lower-alkyl.
The reaction VII- VI-A can be carried out by means of a bromide Br-M-OSi(R3,R4,R5) in a solvent such as THF at a low temper-ature, e.g. -78~C, in the presence of n-butyllithium in hexane. The ~o compound VI is obtained after cleavage of the silanyl group, e.g.

24 ~~2~3~~Q3 in a solvent such as diethyl ether by means of tetrabutyl-ammonium fluoride in THF.
The compounds of formula V-A in which M is 1,4-piperi-s dinylene can be prepared by reacting an acid of formula VIII with an amine of formula IX:

I
W-N MI~O~T
O ~/ ~H
G O
VBI IX
~o Such compounds V-A can be converted via the compounds V
into the corresponding compounds II in which M is 1,4-piperi-dinylene.
Nitrites of formula IV are obtainable e.g. by reacting compounds of formula V-A (after cleavage of the protecting group W) with an acid chloride N. c ~ ~ ci x X=Y
O
2o Nitrites of formula IV in which M is 1,4-piperidinylene can also be prepared by reacting an acid of the formula L> >-COOH, which is activated e.g. with 2-chloro-4,6-dimethoxy-1,3,5-triazine and N-methylmorpholine, with an amine of formula IX-A:
I-o~t ~ T IX_A

A further method for the preparation of the nitrites IV
comprises reacting a ketone of formula XI with a bromide of formula XII

N- C / ~ Br ~O~ COOT' X=Y ~ ' COOT2 ~M
O G
XI
wherein T2 is lower-alkyl and X, Y, G, M and T1 have the above significance.
In a variant, an acid chloride of formula X is converted via an ester of formula XI, wherein T2 is tert-butyl, with the bromide XII into a compound of formula XIII:
o-tBu o M/O~ COOT' x=Y I I
O G

and the t-butoxycarbonyl group is cleaved off from the compound XIII.
Hydrogenation of a nitrite IV in which W~ (in L> > ) is NH, N-ls lower-alkyl or lower-alkoxy-lower-alkyl-N, e.g. over a Pd/C
catalyst in methanol/water/ethyl acetate gives a compound of formula I in which group A (in L) has the formula Ao 1 H2N ~ ~ A01 X=Y
The acid starting materials L~ 1-COOH which are substituted by cyano in R~ 1 are obtainable by a Sandmeyer reaction with the corresponding amino-substituted acid. Acid starting materials of formula L1 ~ 5-COOH can be prepared starting from 4-cyanosali-2~ cylic acid via compounds of the formula O G
N= C / \ N~ COO-tBu OH HO

2s X136903 Moreover, many of the Examples hereinafter contain detail-ed information concerning the preparation of certain starting materials and intermediates.
The compounds of formula I, their solvates and their salts inhibit not only the binding of fibrinogen, fibronectin and the Willebrand factor to the fibrinogen receptor of blood platelets (glycoprotein Ilb/Illa), but also the binding of these and further ~o adhesive proteins such as vitronectin, collagen and laminin to the corresponding receptors on the surface of the different types of cell. The said compounds therefore influence cell-cell and cell-matrix interactions. In particular, they prevent the formation of blood platelet thrombi and can be used in the control or prevent-ion of illnesses such as thrombosis, stroke, cardiac infarct, inflammation and arteriosclorosis. Further, these compounds have an effect on tumour cells in that they inhibit their metast-asis. Accordingly, they can also be used as antitumour agents.
Further, they can accelerate wound healing. Since they also 2fl prevent bone degradation, they can be used in the treatment of osteoporosis.
The activity of the compounds can be demonstrated as follows:
After oral administration of a compound in accordance with the invention to mice the plasma or a dilution thereof (1 part) is mixed with platelet-rich human plasma (human PRP, 3 parts). The volume of mouse plasma which is required to inhibit by 50% the 3o ADP-induced platelet aggregation in this mixture is determined in an aggregometer. This volume {ICSO) is divided by the total volume of the mixture and multiplied by the administered dose.
The thus-extrapolated IDSp values in the following Table corr-espond to that dose of test substance which must be administered orally in order to inhibit by 50% the ADP-induced ex vivo aggre-gation of platelets in human PRP.

Product of Exam 1e 3 4 9 1 2 22 24 27 28 29 I D5p m /k 2.7 2.1 1.4 3.1 2.4 1.8 2.3 4.3 0.3 1.0 Product of Exam 1e 30 3 33 3 3 38 40 41 49 50 ID~p m /k 3.9 0.2 0.6 0.5 0.5 2.9 0.6 0.2 1.2 1.3 Product of Exam 1e 51 5 60 6 7 76 80 85 IDSp m /k 3.9 1.5 0.3 1.1 2.7 0.2 0.7 0.4 As mentioned earlier, medicaments containing a compound s of formula I, a solvate thereof or a salt thereof are also objects of the present invention, as is a process for the production of such medicaments which comprises bringing one or more of the said compounds and, if desired, one or more other therapeutically valuable substances into a galenical administration form. The ~o medicaments can be administered enterally, e.g. orally in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, or rectally, e.g. in the form of suppositories; or as a spray. The administration can, however, also be effected parenterally, e.g. in the form of injection solutions or as an infusion.
The active substance can be mixed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees and hard gelatine capsules.
2o Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used e.g. as such excipients for tablets, dragees and hard gelatine capsules. Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols; depending on the nature of the active substance no excipients are, however, usually required in the case of soft gelatine capsules. Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar and glucose; suitable excipients for injection solutions are 2$ ~1~6903 e.g. water, alcohols, polyols, glycerol and vegetable oils, and suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Moreover, the pharmaceutical preparations can contain preservatives, solubil-s izers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, coating agents or antioxidants.
For the control or prevention of the illnesses referred to io above, the dose of active substance can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral adminis-tration a dose of about 0.1 to 20 mg/kg, preferably of about 0.5 to 4 mg/kg, per day should be appropriate for adults, although the upper limit just given can also be exceeded should this be found to be indicated.
Exam Ip a 1 20 0.2 ml of iodotrimethylsilane in 2 ml of dichloromethane is added to a solution of 0.5 g of ethyl (S)-4-(2-tert-butoxy-carbonylamino-3-phenyl-propionyl)-phenoxyacetate in 2.5 ml of dichloromethane and the mixture is stirred at room temperature for 15 min. The reaction solution is treated with 30 ml of HCI
2~ in methanol (4N) and concentrated. The residue is dissolved in ml of pyridine and stirred with 275 mg of p-amidinobenzoyl chloride hydrochloride at room temperature for 24 h. The sus-pension is suction filtered, the mother liquor is concentrated and the evaporation residue is chromatographed on silylated silica gel RP18 {THF/water gradient). There are obtained 222 mg of methyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylaminoJ-3-phenyl-propionyl]-phenoxyacetate hydrochloride, [a) p = +31.1 ~ (c = 1, methanol).
The starting material can be prepared as follows:
a) 29 ml of t-butyllithium (1.4M in pentane) are added to a solution of 11.5 g of p-bromo-tert-butyldimethylsilylphenol in 160 ml of THF at -78~C with the exclusion of water and the mix-ture is stirred at -78~C for 15 min. Subsequently, the solution is treated at -78~C with 4 g of (S)-2-tert butoxycarbonylamino-N-methoxy-N-methyl-3-phenylpropionamide in 40 ml of THF, s stirred at -78C for 1 h. and poured into 300 ml of 1 M phosphoric acid. The aqueous phase is extracted with ether, the ether phases are washed with sat. NaCI solution, dried and concentrated. After chromatography of the evaporation residue on silica gel (hexane ethyl acetate 9:1 ) there are obtained 2.95 g of tert-butyl (S)-[1-~a benzyl-2-(4-tert-butyl-dimethyl-silanyloxy-phenyl)-2-oxo-ethylJ-carbamate as a colourless oil, [a] p = +40.3 (c = 0.8, chloroform).
b) A solution of 2.24 g of the product from a) in 30 ml of THF
is stirred at room temperature for 16 h. with 0.75 g of caesium fluoride in 2.5 ml of water and the mixture is concentrated.
Chromatography of the residue on silica gel (hexane/ethyl acetate 2:1) gives 2.47 g of tert butyl (S)-[1-benzyl-2-(4-hydroxy-phenyl)-2-oxo-ethyl]-carbamate, [a] p = +67.0 (c = 0.7, ~o chloroform).
c) A suspension of 2.44 g of the product from b), 2.39 g of ethyl bromoacetate and 2.97 g of potassium carbonate in 20 ml of DMF is stirred at room temperature for 4 h., the precipitate is 25 filtered off under suction and the mother liquor is concentrated.
Chromatography of the residue on silica gel (hexane/ethyl acetate 5:1 ) gives 7.44 g of ethyl (S)-4-(2-tert-butoxycarbonylamino-3-phenyl-propionyl)-phenoxy acetate, [a] p = +40.6 (c = 1, chloroform).
Exam~he 2 A solution of 263 mg of 2-methoxy-ethyl 4-tert-butoxy-carbonylaminoacetyl-phenoxyacetate in 10 ml of dichloro-a~ methane and 5 ml of trifluoroacetic acid is stirred at room temperature for 2 h. and concentrated. The residue is suspended in ether, the crystals are filtered off under suction, dissolved in ml of pyridine and stirred at room temperature with 219 mg of 30 ~13b003 amidinobenzoyl chloride hydrochloride for 18 h. Concentration of the reaction solution and chromatography of the residue on silyl-ated silica gel RP18 (THF/water gradient) gives 35 mg of 2-methoxy-ethyl 4-[4-(amino-imino-methyl)-benzoylaminoacetyl]-s phenoxyacetate, MS (El): 414 (M+H)+.
The starting material can be prepared as follows:
a) A suspension of 476 mg of tert-butyl (R,S)-2-hydroxy-2-(4-hydroxyphenyl)-ethylcarbamate, 287 mg of (2-methoxy-ethyl)chloroacetate and 260 mg of potassium carbonate in 13 ml of DMF is stirred at 50~C for 2 h., cooled to room temperature and diluted with 100 ml of water. The aqueous phase is extracted with ether, the ether phases are washed with sat. NaCI solution, dried and concentrated. Chromatography of the residue on silica gel (hexane/ethyl acetate 1:2) gives 349 mg of 2-methoxy-ethyl (R,S)-4-(2-tert-butoxycarbonylamino-1-hydroxy-ethyl)-phenoxy-acetate, MS (El): 312 (M-57).
~o b) Oxidation of 316 mg of the product from a) in 10 ml of dichloromethane with 224 mg of pyridine chlorochromate for 3 h. at room temperature gives, after concentration of the reaction solution and chromatography of the residue on silica gel (hexane/ethyl acetate 1:1, 1:2) 284 mg of 2-methoxy-ethyl 4-25 tert-butoxycarbonylaminoacetyl-phenoxyacetate, MS (El): 294 (M-73).
Exam Ip a 3 3o A solution of 550 mg of cyclopropylmethyl (S)-4-(2-tert-butoxycarbonylamino-propionyl)-phenoxyacetate in 10 ml of dichloromethane is stirred at OoC with 0.2 ml of trimethylsilyl iodide for 15 min., treated with 0.5 ml of HCI in dioxan (4M) and concentrated. The residue is reacted with 330 mg of p-amidino-a~ benzoyl chloride hydrochloride analogously to Example 1. After chromatography of the crude product on silylated silica gel RP18 (THF/water gradient) there are obtained 313 mg of cyclopropyl-methyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-~1~6~U3 propionyl]-phenoxyacetate hydrochloride (1:0.4) hydroiodide (1:0.6), m.p. 125~C, [a] p = +56.6 (c = 0.5, DMSO).
The starting material can be prepared as follows:
a) 94 ml of n-butyllithium (1.6M in hexane) are added drop-wise to a solution of 43.05 g of p-bromo-tert-butyldimethylsilyl phenol in 150 ml of THF at -78~C with the exclusion of moisture and the mixture is stirred at -78~C for 15 min. Subsequently, w 11.61 g of (S)-2-tert-butoxycarbonylamino-N-methoxy-N-methyl-propionamide in 150 ml of THF are added at -78~C in 30 min., stirred at -78~C for 0.5 h. and the reaction solution is poured into 400 ml of 1 M phosphoric acid. The aqueous phase is extracted with ether, the ether phases are washed with sat. NaCI
~5 solution, dried and concentrated. After chromatography of the evaporation residue on silica gel (hexane/ethyl acetate 9:1 ) there are obtained 17.85 g of tert-butyl (S)-1-(4-tert-butyl-dimethyl-silanyloxy-benzoyl)-ethylcarbamate as a colourless oil, Rf = 0.43 (hexane/ethyl 5:1 ).
b) 47 ml of tetrabutylammonium fluoride (1 M in THF) are added to a solution of 17.85 g of the product from a) in 180 ml of ether and stirred at room temperature for 1 h. The reaction solution is extracted with 1 M phosphoric acid, washed with sat.
25 NaCI solution, dried and concentrated. There are obtained 12.03 g of (S)-1-(4-hydroxy-benzoyl)-ethylcarbamate, m.p. 166-168~C, [a] p = +24.9 (c = 1, chloroform).
c) Reaction of 400 mg of the product from b) with cyclo-3o propylmethyl bromoacetate analogously to Example 1 c gives, after chromatography on silica gel (hexane ethyl acetate 3:1 ), 580 mg of cyclopropylmethyl (S)-4-(2-tert-butoxycarbonyl-amino-propionyl)-phenoxyacetate [a] p = +12.4 (c = 0.9, chloroform).

ExamQle 4 Analogously to Example 3, 500 mg of cyclohexyl (S)-4-(2-tert-butoxycarbonylamino-propionyl)-phenoxyacetate are reacted s with 0.17 ml of trimethylsilyl iodide and subsequently with 320 mg of p-amidinobenzoyl chloride hydrochloride and give, after chromatography on silylated silica gel RP18 (THF/water gradient), 330 mg of cyclohexyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate hydrochloride ~o (1:0,6) hydroiodide (1:0.4), m.p. 11 O~C, [a] o = +56.7 (c = 0.55, DMSO).
The starting material can be prepared as follows:
Reaction of 530 mg of tert-butyl (S)-1-(4-hydroxy-benzoyl)-ethylcarbamate with 660 mg of cyclohexyl bromo-acetate analogously to Example 1 c gives, after chromatography on silica gel (hexane ethyl acetate 5:1 ), 735 mg of cyclohexyl (S)-4-(2-tert-butoxycarbonylamino-propionyl)-phenoxyacetate, [a] p -20 +12.0 (c = 0.5, chloroform).
Exam Ip a 5 As in Example 3, 680 mg of tetrahydropyran-4-yl (S)-4-(2-25 tert-butoxycarbonylamino-propionyl)-phenoxyacetate are reacted with 1.7 ml of trimethylsilyl iodide (1 M in dichloromethane) and subsequently with 438 mg of p-amidinobenzoyl chloride hydro-chloride and give, after chromatography on silylated silica gel RP18 (THF/water gradient), 430 mg of tetrahydropyran-4-yl (S)-30 4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phen-oxyacetate hydrochloride (1:0.8) hydroiodide (1:0.4), [a] p -+50.3~ (c = 1, dimethyl sulphoxide).
The starting material can be prepared as follows:
a) Reaction of 530 mg of tert-butyl (S)-1-(4-hydroxy-benzoyl)-ethylcarbamate with 670 mg of 4-tetrahydropyranyl bromoacetate analogously to Example 1c gives, after chromat-33 ~f~sgo3 ography on silica gel (hexane/ethyl acetate 2:1 ), 736 mg of tetrahydropyran-4-yl (S)-4-(2-tert-butoxycarbonylamino-propionyl)-phenoxyacetate, [a]2o = +11.1 ~ (c = 0.7, chloroform).
Exam Ip a 6 A solution of 120 mg of methyl (S)-4-[2-[4-(amino-imino-methyl)-benzoyl-amino]-3-phenyl-propionyl]-phenoxyacetate hydrochloride and 80 mg of sodium hydroxide in 20 ml of w methanol and 5 ml of water is stirred at room temperature for 1 h. 15 min., acidified with 1 N HCI and concentrated. Chroma-tography of the residue on silylated silica gel RP18 (THF/water gradient) gives 60 mg of (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-phenyl-propionyl]-phenoxyacetic acid, m.p.
~,5 >200°C, MS (ISP): 446 (M+H)+.
Exam Ip a 7 Reaction of 800 mg of ethyl 4-[(S)-3-tert-butoxy-2-tert-2~ butoxycarbonylamino-propionyl]-phenoxyacetate with 450 mg of trimethylsilyl iodide and 497 mg of p-amidinobenzoyl chloride hydrochloride analogously to Example 3 gives, after chromatog-raphy on silylated silica gel RP18 (THF/water gradient), 540 mg of ethyl 4-(S)-2-[4-(amino-imino-methyl)-benzoylamino]-3-25 tert-butoxy-propionyl]-phenoxyacetate hydrochloride (1:0.5) hydroiodide (1:0.4), m.p. 144~C, [a] p = +34.2 (c = 0.5, DMSO).
The starting material can be prepared as follows:
3o a) A suspension of 10 g of N-tert-butoxycarbonyl-O-tert-butyl-L-serine dicyclohexylammonium salt in 100 ml of THF is stirred at room temperature with 5.5 ml N-methylmorpholine, 10.3 g of HBTU and 2.2 g of N,O-dimethylhydroxylamine hydro-chloride for 21 h. and concentrated. Chromatography of the residue on silica gel (hexane/ethyl acetate 1:1 ) gives 6.02 g of tert-butyl (S)-2-tert-butoxy-1-(N-methoxy-N-methyl-carbamoyl)-ethylcarbamate [a] D = +18.6 (c = 0.65, chloroform).

b) A solution of 3.7 g of the product from a) is reacted analogously to Example 3a with 7.82 g of p-bromo-tert-butyl-dimethylsilylphenol and 26 ml of tert-butyllithium (1.4M in pentane). Chromatography of the residue on silica gel (hexane/
s ethyl acetate 5:1 ) gives 3.58 g of tert-butyl (S)-2-tert-butoxy-1-(4-tert-butyl-dimethyl-silanyloxy-benzoyl)-ethylcarbamate, [a] p = +28.3 (c = 0.6, chloroform).
c) Cleavage of the silyl protecting group from 2.5 g of the w product from b) with 840 mg of caesium fluoride is effected according to Example 1 b. After chromatography on silica gel (hexane/ethyl acetate 3:1 there are obtained 1.08 g of tert-butyl (S)-2-tert-butoxy-1-(4-hydroxy-benzoyl)-ethylcarbamate, [a] p = +41.5 (c = 1, chloroform).
d) Reaction of 1 g of the product from c) with 0.5 ml of ethyl bromoacetate and 1.23 g of potassium carbonate analogously to Example 1 c gives, after chromatography on silica gel (hexane/
ethyl acetate 3:1 ), 1.19 g of ethyl 4-[(S)-3-tert-butoxy-2-tert-2o butoxycarbonylamino-propionyl]-phenoxyacetate, [a] p = +27.3 (c - 0.8, chloroform).
Exam Ip a 8 Analogously to Example 3, 778 mg of ethyl (S)-4-[2-tert-butoxycarbonylamino-3-(4-methoxy-phenyl)-propionyl]-phenoxy-acetate are reacted with 0.28 ml of trimethylsilyl iodide and 450 mg of p-amidinobenzoyl chloride and the crude product is chromatographed on silylated silica gel RP18 (THF/water 3o gradient). There are obtained 272 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-(4-methoxy-phenyl)-propionyl]-phenoxyacetate hydrochloride (1:0.3) hydroiodide (1:0.3), m.p. 129~C, [a] p = +20.0 (c = 0.6, DMSO).
The starting material can be prepared as follows:
a) Reaction of 3.5 g of tert-butyl (S)-1-(N-methoxy-N-methyl-carbamoyl)-2-(4-methoxy-phenyl)-ethylcarbamate with 8.9 g of p-bromo-tert-butyldimethylsilylphenol and 22.2 ml of tert-butyllithium (1.4M in pentane) according to Example 3a and chromatography of the evaporation residue on silica gel (hexane/
ethyl acetate 5:1) gives 3.66 g of (S)-1-[4-(tert-butyl-dimethyl-s silanyloxy)-benzoyl]-2-(4-methoxy-phenyl)-ethylcarbamate, [a] p = +23.8 {c = 0.5, chloroform).
b) A solution of 2.5 g of the product from a) is deprotected as described in Example 3b). After chromatography on silica gel w (hexane/ethyl acetate 3:1, 2:1 ) there are obtained 1.42 g of tert-butyl (S)-1-(4-hydroxy-benzoyl)-2-(4-methoxy-phenyl)-ethyl-carbamate, m.p. 133-135~C, [a] p = +47.3 (c = 0.9, chloroform).
c) Reaction of 1.0 g of the preceding step product with ethyl bromoacetate according to Example 1c) and chromatography of the residue on silica gel (hexane/ethyl acetate 2:1 ) gives 1.21 g of ethyl (S)-4-[2-tert-butoxycarbonylamino-3-{4-methoxy-phenyl)-propionyl]-phenoxyacetate, m.p. 95-97~C, [a] p = +22.6 (c = 0.5, chloroform).
Exam Ip a 9 A solution of 300 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-tert-butoxy-propionyl]-phenoxyacetate 25 hydrochloride (1:0.5) hydroiodide (1:0.4) in 3 ml of dichloro-methane is treated with 1 ml of trifluoroacetic acid, stirred at room temperature for 4 h. and concentrated. Chromatography of the residue on silica gel (chloroform/ethanol/water 60:30:5) gives 100 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-3o benzoylamino]-3-hydroxy-propionyl]-phenoxyacetate trifluoro-acetate, [a] p = +52.0 {c = 0.3, dimethyl sulphoxide).
Exam Ip a 10 a~ A solution of 260 mg of ethyl (S)-4-[2-(4-tert-butoxy-carbonylaminomethyl-benzoylamino)-propionyl]-phenoxyacetate in 3 ml of dichloromethane and 1.5 ml of trifluoroacetic acid is stirred at room temperature for 1 h. and concentrated. The 36 ~1~~903 residue corresponds to 260 mg of ethyl (S)-4-[2-(4-amino-methyl-benzoylamino)-propionyl]-phenoxyacetate, [a] p = +43.0 (c = 0.3, DMSO).
s The starting material can be prepared as follows:
a) Reaction of 530 mg of tent-butyl (S)-1-(4-hydroxy-benzoyl)-ethylcarbamate with ethyl bromoacetate analogously to Example 1c) gives, after chromatography on silica gel (hexane/
w ethyl acetate 5:1 ), 582 mg of ethyl (S)-4-(2-tert-butoxy-carbonylamino-propionyl)-phenoxyacetate, [a] p = -1.8~ (c = 0.5, ethanol).
b) Deprotection of 620 mg of the product from a) analogously to Example 3 gives ethyl (S)-4-(2-amino-propionyl)-phenoxy-acetate hydrochloride which is reacted further as the crude product. A solution of 443 mg of 4-tert-butoxycarbonylamino-methyl-benzoic acid and 0.43 ml of N-methylmorpholine in 5 ml of THF is treated with 800 mg of HBTU at O~C, stirred at O~C for 1 h. and subsequently added to 0.3 ml of N-methylmorpholine and the aforementioned ethyl (S)-4-(2-amino-propionyl)-phenoxy-acetate dissolved in 6 ml of THF. After stirring at room temper-ature for 3.5 h. the solution is concentrated and the residue is chromatographed on silica gel (hexane/ethyl acetate 1:1 ). There are obtained 463 mg of ethyl (S)-4-[2-(4-tert-butoxycarbonyl-aminomethyl-benzoylamino)-propionyl]-phenoxyacetate, [a] p -+50.0~ (c = 0.5, chloroform).
Fxam Ip a 11 A solution of 630 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-(4-methoxy-phenyl)-propionyl]-phenoxyacetate hydrochloride (1:0.3) hydroiodide (1:0.3) (Example 8) and 330 mg of sodium hydroxide in 15 ml of water and 30 ml of ethanol is stirred at room temperature for 3 h. and subsequ-ently concentrated. After chromatography on silylated silica gel RP18 (THF/water gradient) there are obtained 32 mg of (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-(4-methoxy-pheny1)-propionyl]-phenoxyacetic acid, microanalysis: calc. C 65.68, H
5.30, N 8.84; found C 65.77, H 5.12, N 8.73.
(Reference Exam Ip a 12 A solution of 1 g of ethyl (S)-4-[2-[4-{tert-butoxycarbonyl-amino-imino-methyl)-benzoylamino]-3-methyl-butyryl]-phenoxy-acetate in 10 ml of dichloromethane and 5 ml of trifluoroacetic acid is stirred at room temperature for 3 h. and concentrated.
w Chromatography on silylated silica gel RP18 (THF/water gradient) gives 789 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-methyl-butyryl]-phenoxyacetate trifluoro-acetate m.p. 202~C, [a] p = +95.5 (c = 1, DMSO).
~5 The starting material can be prepared as follows:
a) 2.6 g of (S}-2-tert-butoxycarbonylamino-N-methoxy-N,3-dimethyl-butyramide are reacted with 8.6 g of p-bromo-tert-butyldimethylsilylphenol analogously to Example 3a). After 2o chromatography on 200 g of silica gel (hexane/ethyl acetate 95:5) there are obtained 3.0 g of tert-butyl (S)-1-{4-tert-butyl-dimethyl-silanyloxy-benzoyl)-2-methyl-propylcarbamate, [a] p -+83.0~ (c = 0.5, chloroform).
2~ b) Cleavage of the protecting group from 3.0 g of the product from a) analogously to Example 3b) gives 1.88 g of tert-butyl {S)-1-(4-hydroxy-benzoyl)-2-methyl-propylcarbamate, [a] p =
+107.9 (c = 0.7, chloroform).
3o c) Reaction of 1.88 g of the product from b) with ethyl bromo-acetate as in Example 1 c and subsequent chromatography on silica gel (hexane/ethyl acetate 5:1 ) gives 2.02 g of ethyl (S)-4-(2-tert-butoxycarbonylamino-3-methyl-butyryl)-phenoxyacetate, [a] p = +86.1 ~ (c = 1, chloroform).
d) 13.96 g of di-tert-butyl Bicarbonate in 70 ml of dioxan are added at O~C to a suspension of 7 g of 4-amidinobenzoic acid in 120 ml of dioxan and 88 ml of 1 N NaOH and the mixture is subse-3s 216903 quently stirred at room temperature for 1.5 h. The precipitate is filtered off under suction, the mother liquor is extracted twice with 100 ml of ether, adjusted to pH 6 with 1 N HCI and concen-trated. Chromatography of the residue on silylated silica gel s RP18 (THF/water gradient) gives 4.2 g of N-tert-butoxycarbonyl-4-amidinobenzoic acid, m.p. > 200~C.
e) 410 p.1 of trimethylsilyl iodide are added to a solution of 1.14 g of ethyl (S)-4-(2-tert-butoxycarbonylamino-3-methyl-io butyryl)-phenoxyacetate in 10 ml of anhydrous dichloromethane at O~C, stirred at O~C for 15 min., the yellow solution is treated with 1.5 ml of HCI in dioxan (4N) and the solvent is subsequently evaporated. The residue is dissolved in 10 ml of THF, treated with 793 mg of N-tert-butoxycarbonyl-4-amidinobenzoic acid, 1.0 ml of triethylamine and 1.33 g of HBTU and stirred at room temperature for 16 h. The resulting suspension is concentrated and the residue is chromatographed on silica gel. There are obtained 1.07 g of ethyl (S)-4-[2-[4-(tert-butoxycarbonylamino-imino-methyl)-benzoylamino]-3-methyl-butyryl]-phenoxyacetate, 2o MS (ISP): 526 (M+H)+.
Exam Ip a 13 In analogy to Example 12, from 250 mg of ethyl (S)-4-[2-25 [4-(tert-butoxycarbonylamino-imino-methyl)-benzoylamino]-3-[4-(2-methoxy-ethoxy)-phenyl]-propionyl]-phenoxyacetate and chromatography on silylated silica gel RP18 (THF/water gradient) there are obtained 66 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-[4-(2-methoxy-ethoxy)-phenyl]-so propionyl]-phenoxyacetate trifluoroacetate, MS (ISP): 548 (M+H)+
The starting material can be prepared as follows:
a) The phase transfer reaction of 2.2 g of tert-butyl (S)-2-(4-hydroxy-phenyl)-1-(methoxy-methyl-carbamoyl)-ethylcarbamate with 2.5 g of 2-chloroethyl methyl ether in 10 ml of toluene and ml of 50% NaOH in the presence of 50 mg of tetrabutyl-ammonium hydrogen sulphate has finished after 1 h. The aqueous 39 ~13~9U3 phase is extracted with ether, the combined organic phases are washed with saturated NaCI solution, dried and concentrated.
Chromatography of the residue on silica gel gives 1.11 g of tert-butyl (S)-2-[4-(2-methoxy-ethoxy)-phenyl]-1-(methoxy-methyl-s carbamoyl)-ethylcarbamate, [a] p = +17.6 (c = 1, chloroform).
b) By reacting 1 g of the preceding step product according to Example 3a there are obtained, after chromatography on silica gel (hexane/ethyl acetate 9:1), 326 mg of tert-butyl (S)-1-[4-(tert-w butyl-dimethyl-silanyloxy)-benzoyl]-2-[4-(2-methoxy-ethoxy)-phenyl]-ethylcarbamate, MS (ISP): 530 (M+H)+.
c) By reacting 310 mg of the product from b) as in Example 3b and alkylating the product analogously to Example 1 c there are obtained, after chromatography on silica gel (hexane/ethyl acetate 2:1 ), 273 mg of ethyl (S)-4-[2-tert-butoxycarbonyl-amino-3-[4-(2-methoxy-ethoxy)-phenyl]-propionyl]-phenoxy-acetate, MS (ISP): 502 (M+H)+.
2o d) Reaction of 250 mg of the preceding step product according to Example 12e leads, after chromatography on silica gel (hexane/
ethyl acetate 1:2), to 267 mg of ethyl (S)-4-[2-[4-(tert-butoxy-carbonylamino-imino-methyl)-benzoylamino]-3-[4-(2-methoxy-ethoxy)-phenyl]-propionyl]-phenoxyacetate, MS (ISP): 648 (M+H)+.
Reference Exam Ip a 14 A solution of 400 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-methyl-butyryl]-phenoxyacetate 3o trifluoroacetate (Example 12) in 65 ml of ethanol and 17 ml of water is treated with 200 mg of NaOH, stirred at room temper-ature for 1 h., acidified with 7 ml of 1 N HCI and concentrated.
After chromatography on silylated silica gel RP18 (THF/water gradient) the residue gives 287 mg of (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-methyl-butyryl]-phenoxyacetic acid hydrochloride (1:0.4), MS (ISP): 398 (M+H)+.

40 21~6~0~
Exam Ip e-15 66 mg of 2-methoxy-ethyl chloroformate are added to a suspension of 250 mg of ethyl (S)-4-[2-[4-(amino-imino-s methyl)-benzoylamino]-3-hydroxy-propionylJ-phenoxyacetate trifluoroacetate in 4 ml of dichloromethane and 4 ml of satur-ated Na2C03 solution and the mixture is subsequently stirred at room temperature for 5 min. The aqueous phase is extracted with dichloromethane, the dichloromethane phases are washed w with water, dried and concentrated. After chromatography of the residue on silica gel (ethyl acetate) there are obtained 55 mg of ethyl (S)-4-[3-hydroxy-2-[4-[imino-(2-methoxy-ethoxycarbonyl-amino)-methyl]-benzoylamino]-propionyl]-phenoxyacetate, MS
(ISP): 516 (M+H)+.
Exam Ip a 16 A solution of 200 mg of tert-butyl {S)-4-[3-tert-butoxy-2-[4-tert-butoxycarbonylamino-imino-methyl)-benzoylamino]-24 propionyl]-phenoxyacetate in 2 ml of dichloromethane and 1 ml of trifluoroacetic acid is stirred at room temperature for 2 h. and concentrated. The residue is suspended in methanol, centrifuged off and washed with ether. There are obtained 41 mg of {S)-4-[2-[4-{amino-imino-methyl)-benzoylamino]-3-hydroxy-propiony1]-25 phenoxyacetic acid trifluoroacetate, MS (ISN): 384 (M-H)-.
The starting material can be prepared as follows:
a) Reaction of 1.35 g of tert-butyl (S)-2-tert-butoxy-1-(4-3o hydroxy-benzoyl)-ethylcarbamate with tert-butyl bromoacetate analogously to Example 1 c gives 417 mg 1.19 g of tert-butyl (S)-4-{2-tert-butoxycarbonylamino-3-tert-butoxy-propionyl)-phenoxyacetate, (ISN): 450 (M-H)-.
b) Reaction of 400 mg of the preceding step product with N-tert-butoxycarbonyl-4-amidinobenzoic acid as in Example 12a gives, after chromatography on silica gel (hexane/ethyl acetate 1:1 ), 230 mg of tert-butyl (S)-4-[3-tert-butoxy-2-[4-(tert-41 ~~.~~1~~'~
butoxycarbonylamino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, MS (ISN): 596 (M-H)-.
Exam Ip a 17 Reaction of 100 mg of ethyl (S)-4-[2-[4-(amino- imino-methyl)-benzoylamino]-3-hydroxy-propionyl]-phenoxyacetate trifluoroacetate (Example 9) with 54 ~.I of isobutyl chloroformate as in Example 15 gives, after chromatography (ethyl acetate), w 65 mg of ethyl (S)-4-[3-hydroxy-2-[4-(imino-isobutoxycarbonyl-amino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, [a] p -+ 47.0 (c = 0.7, DMSO).
Exam I~e 18 ~5 By reaction of 170 mg of ethyl (S)-4-[2-[4-(tert-butoxy-carbonylamino-imino-methyl)-benzoylamino]-3-methoxy-propionyl]-phenoxyacetate with trifluoroacetic acid as in Example 12 and crystallization of the residue with ether there 2o are obtained 124 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-methoxy-propionyl]-phenoxyacetate trifluoro-acetate, MS (ISP): 428 (M+H)+.
The starting material can be prepared as follows:
a) Reaction of 1.18 g of (S)-2-tert-butoxycarbonylamino-N,3-dimethoxy-N-methyl-propionamide with p-bromo-tert-butyl-dimethylsilylphenol analogously to Example 3a gives, after chromatography on silica gel (hexane/ethyl acetate 8:1 ), 872 mg 30 of tert-butyl (S)-1-[4-(tert-butyl-dimethyl-silanyloxy)-benzoyl]-2-methoxy-ethylcarbamate, MS (ISP): 410 (M+H)+.
b) Cleavage of the silyl protecting group from 850 mg of the preceding step product according to Example 3b and alkylation of the product according to Example 1 c leads to 546 mg of ethyl (S)-4-(2-tert-butoxycarbonylamino-3-methoxy-propionyl)-phenoxy-acetate, MS (El): 308 (M-73).

42 ~1~~~~~
c) Reaction of 530 mg of the preceding step product with N-tert-butoxycarbonyl-4-amidinobenzoic acid according to the procedure of Example 12e and chromatography on silica gel (hexane/ethyl acetate 1:2) gives 170 mg of ethyl (S)-4-[2-[4-s (tert-butoxycarbonylamino-imino-methyl)-benzoylamino]-3 methoxy-propionyl]-phenoxyacetate, MS (ISP): 528 (M+H)+.
Example 19 w From 510 mg of (S)-sec-butyl (S)-4-[3-tert-butoxy-2-[4-(tert-butoxycarbonylamino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate there are obtained according to Example 12 and after chromatography of the crude product on silylated silica gel RP18 (THF/water gradient) 280 mg of (S)-sec-butyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-hydroxy-propionyl]-phenoxyacetate trifluoroacetate, m.p. 85-87~C, [a] p = +55.7 (c = 0.3, dimethyl sulphoxide).
The starting material can be prepared as follows:
a) From 790 mg of tert-butyl (S)-2-tert-butoxy-1-(4-hydroxy-benzoyl)-ethylcarbamate there are obtained with (S)-sec-butyl bromoacetate according to Example 1 c and after chromatography on silica gel (hexane/ethyl acetate 9:1) 780 mg 25 of (S)-sec-butyl (S)-4-(3-tert-butoxy-2-tert-butoxycarbonyl-amino-propionyl)-phenoxyacetate, [a] p = +35.3 (c = 0.45, chloroform).
b) Reaction of 720 mg of the preceding step product with 30 510 mg of N-tert-butoxycarbonyl-4-amidinobenzoic acid analogously to Example 12e gives, after chromatography on silica gel (hexane/ethyl acetate (3:1, 2:1 ), 570 mg of (S)-sec-butyl (S)-4-[3-tert-butoxy-2-[4-(tert-butoxycarbonylamino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, [a] p = +51.3 (c = 1, chloroform).

Exam Ip a 20 From 650 mg of ethyl (2S,3R)-4-[3-tert-butoxy-2-[4-(tert-butoxycarbonylamino-imino-methyl)-benzoylamino]-butyryl]-s phenoxyacetate there are obtained according to Example 12 and after chromatography on silylated silica gel RP18 (THF/water gradient) 350 mg of ethyl (2S,3R)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-hydroxy-butyryl]-phenoxyacetate trifluoroacetate, m.p. 95-97~C, [a] p = +98.8 (c = 0.4, DMSO).
w The starting material can be prepared as follows:
a) From 15 g of tert-butyl (1 S,2R)-2-tert-butoxy-1-carboxy-propylcarbamate there are obtained in analogy to Example 7a, after chromatography on silica gel (hexane/ethyl acetate 5:1, 3:1 ), 11.19 g of tert-butyl (1 S,2R)-2-tent-butoxy-1-(methoxy-methyl-carbamoyl)-propylcarbamate, [a] p = +30.0 (c = 0.7, chloroform).
~o b) Reaction of 17 g of the preceding step product with p-bromo-tert-butyldimethylsilylphenol analogously to Example 3a gives, after chromatography on silica gel (hexane/ethyl acetate 9:1 ), 4.76 g of tert-butyl (1 S,2R)-2-tert-butoxy-1-[4-(tert-butyl-dimethyl-silanyloxy)-benzoyl]-propylcarbamate, [a] p° -25 +61.0 (c = 0.3, chloroform).
c) Cleavage of the silyl protecting group from 4.74 g of the preceding step product according to Example 3b and alkylation of the product according to Example 1 c leads, after chromatography 30 on silica gel (hexane/ethyl acetate 5:1 ), to 3.34 g of ethyl (2S,3R)4-(3-tert-butoxy-2-tert-butoxycarbonylamino-butyryl)-phenoxyacetate, [a] p = +71.0 (c = 0.3, chloroform).
d) Reaction of 1.09 g of the preceding step product with N-tert-butoxycarbonyl-4-amidinobenzoic acid according to Example 12e and chromatography on silica gel (hexane/ethyl acetate 2:1, 1:1 ) gives 660 mg of ethyl (2S,3R)-4-[3-tert-butoxy-2-[4-(tert-butoxycarbonylamino-imino-methyl)-benzoylaminoJ-butyryl]-phenoxyacetate, [a] p = +126.0 (c = 0.3, chloroform).
Exam Ip a 21 From 2 g of 2-methoxy-ethyl (S)-4-[2-[4-(tert-butoxy-carbonylamino-imino-methyl)-benzoylamino]-3-tert-butoxy-propiony!]-phenoxyacetate there are obtained, after deprotection analogously to Example 12 and chromatography on silylated silica ~o gel RP18 (THF/water gradient), 600 mg of 2-methoxy-ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-hydroxy-propionyl]-phenoxyacetate trifluoroacetate, m.p. 174~C, [a] p -+51.6~ (c = 0.5, DMSO).
~5 The starting material can be prepared as follows:
a) Alkylation of 1.64 g of tert-butyl (S)-2-tert-butoxy-1-(4-hydroxy-benzoyl)-ethylcarbamate with 2-methoxy-ethyl bromo-acetate according to Example 1 c leads, after chromatography on 2o silica gel, to 1.58 g of 2-methoxy-ethyl (S)-4-[3-tert-butoxy-2-tert-butoxycarbonylamino-propionyl]-phenoxyacetate, MS (ISP):
454 (M+H)+.
b) Reaction of 1.55 g of the preceding step product with N-tert-butoxycarbonyl-4-amidinobenzoic acid according to Example 12e and chromatography on silica gel (hexane/ethyl acetate 2:1, 1:1) gives 2.0 g of 2-methoxy-ethyl (S)-4-[2-[4-(tert-butoxy-carbonylamino-imino-methyl)-benzoylaminoJ-3-tert-butoxy-propionyl]-phenoxyacetate, MS (ISP): 600 (M+H)+.
Example 22 From 4.7 g of 2-methoxy-ethyl (S)-4-[2-[4-(tert-butoxy-carbonylamino-imino-methyl)-benzoylamino]-propionyl]-phenoxy-acetate there are obtained according to Example 12 and after chromatography on silylated silica gel RP18 (THF/water gradient) 1.67 g of 2-methoxy-ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, [a] o = +60.0o (c = 0.4, DMSO).
The starting of material can be prepared as follows:
s a) Reaction of 3.98 g of tert-butyl (S)-1-(4-hydroxy-benzoyl)-ethylcarbamate with 3.25 g of 2-methoxy-ethyl bromoacetate analogously to Example 1 c gives, after chromatography on silica gel (hexane ethyl acetate 2:1 ), 3.31 g of 2-methoxy-ethyl (S)-4-io (2-tert-butoxycarbonylamino-propionyl)-phenoxyacetate, Rf -0.29 (hexane ethyl acetate 1:1 ).
b) Reaction of 3.3 g of the preceding step product according to Example 12e leads, after chromatography on silica gel (hexane/
ethyl acetate 1:2), to 4.76 g of 2-methoxy-ethyl (S)-4-[2-[4-(tert-butoxycarbonylamino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, MS (ISP): 528 (M+H)+.
Example 23 Reaction of 199 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoro-acetate with ethyl chloroformate according to Example 15 leads, after chromatography on silica gel (hexane/ethyl acetate 1:2), to 25 137 mg of ethyl (S)-4-[2-[4-(ethoxycarbonylamino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, MS (ISP): 470 (M+H)+.
The starting material can be prepared as follows:
a) Reaction of 530 mg of tert-butyl (S)-1-(4-hydroxy-benzoyl)-ethylcarbamate with ethyl bromoacetate analogously to Example 1c gives, after chromatography on silica gel (hexane ethyl acetate 5:1 ), 582 mg of ethyl (S)-4-(2-tert-butoxy-carbonylamino-propionyl)-phenoxyacetate, [a]top = -1.8~ (c = 0.5, ethanol).

b) Reaction of 702 mg of the product from a) with N-tert-butoxycarbonyl-4-amidinobenzoic acid and cleavage of the protecting group according to Example 12 gives, after chromatog-raphy on silylated silica gel RP18 (THF/water gradient), 487 mg s of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoroacetate, m.p. 180~C, [a] p -+54.2~ (c = 0.6, DMSO).
Exam Ip a 24 w Cleavage of the protecting groups in 1 g of ethyl (E,Z)-(S)-4-[3-acetoxy-2-[4-[(di-tert-butoxycarbonylamino)-tert-butoxy-carbonylimino-methyl]-benzoylamino]-propionyl]-phenoxyacetate analogously to Example 12 gives, after crystallization with ether, 760 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoyl-amino]-3-acetoxy-propionyl]-phenoxyacetate trifluoroacetate, MS
(ISP): 456 (M+H)+.
The starting material can be prepared as follows:
a) A solution of 440 mg of ethyl 4-[(S)-3-tert-butoxy-2-tert-butoxycarbonylamino-propionyl]-phenoxyacetate in 10 ml of dichloromethane is stirred with 0.28 ml of trimethylsilyl iodide at room temperature for 3 h., treated with 1 ml of HCI in dioxan 2~ (about 4M) and concentrated. The residue is dissolved in 10 ml of THF, treated with 464 mg of (E,Z)-4-(tri-tert-butoxycarbonyl-amidino) benzoic acid, 253 mg of N-methylmorpholine [and], 379 mg of HBTU and stirred at room temperature for 16 h. The resulting suspension is concentrated and the residue is chromato-3o graphed on silica gel (hexane/ethyl acetate 1:1 ). There are obtained 320 mg of ethyl (E,Z)-(S)-4-[2-[4-[(di-tert-butoxy-carbonylamino)-tert-butoxycarbonylimino-methyl]-benzoyl-amino]-3-hydroxy-propionyl]-phenoxyacetate, MS (ISP): 714 (M+H)+.
b) Acetylation of 1.42 g of the preceding step product with 0.156 ml of acetyl chloride in the presence of 223 mg of triethylamine in 30 ml of ether for 1 h. at room temperature gives a suspension. The precipitate is filtered off under suction, the mother liquor is concentrated and the residue is chromato-graphed on silica gel. There are obtained 1.13 g of ethyl (E,Z)-{S)-4-[3-acetoxy-2-(4-[(di-tert-butoxycarbonylamino)-tert-s butoxycarbonylimino-methyl]-benzoylamino]-propionyl]-phenoxyacetate, MS (ISP): 756 (M+H)+.
Exam Ip a 25 w Reaction of 1 g of methyl 4-[4-(amino-imino-methyl)-benzoylaminoacetyl]-phenoxyacetate (Example 25 in EP
0 381 033) with ethyl chloroformate analogously to Example 15 gives, after crystallization in methanol/THF, 810 mg of methyl 4-[4-{ethoxycarbonylamino-imino-methyl)-benzoylaminoacetyl]-phenoxyacetate, MS (ISP): 442 {M+H)+.
Exam lip a 26 From 400 mg of ethyl (E,Z)-(R,S)-4-[2-[4-[(di-tert-butoxy-2o carbonylamino)-tert-butoxycarbonylimino-methyl]-benzoyl-aminoJ-3-methylsulphanyl-propionyl]-phenoxyacetate there are obtained, after cleavage of the protecting groups according to Example 12 and crystallization with ether, 190 mg of ethyl (R,S)-4-(2-[4-{amino-imino-methyl)-benzoylamino]-3-methyl-25 sulphanyl-propionyl]-phenoxyacetate trifluoroacetate, MS (ISP):
444 (M+H)+:
The starting material can be prepared as follows:
3o A suspension of 713 mg of ethyl (E,Z)-(S)-4-[3-acetoxy-2-[4-((di-tert-butoxycarbonylamino)-tert-butoxycarbonylimino-methyl]-benzoylamino]-propionyl]-phenoxyacetate (Example 24b) and 140 mg of sodium methanethiolate in 10 ml of acetonitrile is stirred at room temperature for 45 min. Insoluble material is a5 filtered off under suction, the mother liquor is evaporated and the residue is chromatographed on silica gel (hexane/ethyl acetate 2:1 ). There are obtained 407 mg of ethyl (E,Z)-(R,S)-4-[2-[4-[(di-tert-butoxycarbonylamino)-tert-butoxycarbonylimino-48 ~13~903 methyl]-benzoylamino]-3-methylsulphanyl-propionyl]-phenoxy-acetate, MS (El): 744 (M+H)+.
Exam Ip a 27 From 119 mg of ethyl (R,S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-3-methylsulphanyl-propionyl]-phenoxyacetate trifluoroacetate there are obtained in analogy to Example 15 with 28 mg of ethyl chloroformate and chromatography on silica gel ~n {hexane/ethyl acetate 2:3) 78 mg of ethyl {R,S)-4-[2-[4-(ethoxy-carbonylamino-imino-methyl)-benzoylamino]-3-methylsulphanyl-propionyl]-phenoxyacetate, MS (El): 516 (M+H)+.
Exam Ip a 28 Reaction of 511 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoro-acetate with 2-methoxy-ethyl chloroformate analogously to Example 15 and chromatography of the residue on silica gel 20 (hexane/ethyl acetate 1:2) gives 280 mg of ethyl (S)-4-[2-[4-[imino-2-(methoxy-ethoxycarbonylamino)-methyl]-benzoyl-amino]-propionyl]-phenoxyacetate, MS (ISP): 500 (M+H)+.
Exam Ip a 29 Cleavage of the protecting groups in 850 mg of tert-butyl {S)-4-[2-(4-ethoxycarbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoylmethoxy]-piperidine-1-carboxylate analogously to Example 12 gives, after chromatography on silylated silica gel 3o RP18 (THF/water gradient), 437 mg of ethyl {S)-4-(2-piperidin-4-yloxyacetylamino-propionyl)-phenoxyacetate trifluoroacetate (sic), MS (ISP): 393 (M+H)+.
The starting material can be prepared as follows:
A solution of 702 mg of ethyl (S)-4-(2-tert-butoxy-carbonylamino-propionyl)-phenoxyacetate in 10 ml of dichloro-methane is stirred at O~C with 0.27 ml of trimethylsilyl iodide 49 213~6~03 for 15 min., treated with 1 ml of HCI in dioxan (4M) and concen-trated. The residue is dissolved in 10 ml of dichloromethane. A
solution of 518 mg of 1-tert-butoxycarbonyl-piperidin-4-yl-oxyacetic acid, 594 mg of TPTU and 0.55 ml of N-methylmorph-s oline in 10 ml of dichloromethane is stirred at O~C for 30 min.
and subsequently treated with the residue described above. After stirring at room temperature for 2 hours the reaction solution is concentrated and the residue is chromatographed on silica gel (hexane/ethyl acetate 1:1, 1:2). There are obtained 873 mg of w tert-butyl (S)-4-[2-(4-ethoxycarbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoylmethoxy]-piperidine-1-carboxylate, MS (ISP): 493 (M+H)+.
Exam In a 30 Reaction of 511 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoro-acetate with diethyl chlorophosphate analogously to Example 15 and chromatography of the residue on silica gel (dichloro-2o methane/ethanol 9:1 ) gives 340 mg of ethyl (S)-4-[2-[4-(diethoxyphosphorylamino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, MS (ISP): 534 (M+H)+.
Exam Ip a 31 A solution of 1 g of ethyl (S)-4-[2-(4-cyano-benzoylamino)-propionyl]-phenoxyacetate in 10 ml of pyridine and 1 ml of triethylamine is gassed with hydrogen sulphide and stirred at room temperature for 16 h. The reaction solution is concen-so trated, the residue is dissolved in ethyl acetate, washed with sodium hydrogen carbonate solution, potassium hydrogen sulphate solution and sat. sodium chloride solution, dried and concentrated.
With ether the residue gives 580 mg of ethyl (S)-4-[2-[4-(thio-carbamoyl)-benzoylamino]-propionyl]-phenoxyacetate. This is filtered off under suction, dissolved in 65 ml of acetone and 3.3 ml of methyl iodide and stirred at boiling temperature for 3 h. Concentration of the solution and crystallization of the residue in ether gives 609 mg of ethyl (S)-4-[2-[4-(1-methyl-50 ~13v~03 thioformimidoyl)-benzoylaminoJ-propionyl]-phenoxyacetate hydroiodide. 314 mg of this ester are dissolved in 10 ml of THF, treated with 110 mg of 2-methoxy-ethylamine and stirred at room temperature for 64 h. Concentration of the solution and s chromatography of the residue on silylated silica gel RP18 (THF/water gradient) gives 80 mg of ethyl (R,S)-4-[2-[4-[imino-(2-methoxy-ethyl)-amino-methyl]-benzoylamino]-propionyl]-phenoxyacetate hydroiodide. MS (ISP): 456 (M+H)+.
w The starting material can be prepared as follows:
Coupling of 5.62 g of ethyl (S)-4-(2-tert-butoxycarbonyl-amino-propionyl)-phenoxyacetate with 2.82 g of 4-cyanobenzoic acid in analogy to Example 12e gives, after chromatography on silica gel (hexane/ethyl acetate 3:2), 3.67 g of ethyl (S)-4-[2-(4-cyano-benzoylamino)-propionylJ-phenoxyacetate, MS (El): 381 (M+H)+.
Exam Ip a 32 Cleavage of the protecting group in 160 mg of ethyl (R,S)-4-[2-[4-[(tert-butyl-dimethyl-silanyloxyamino)-imino-methyl]-benzoylaminoJ-propionyl]-phenoxyacetate with tetrabutylammon-ium fluoride analogously to Example 3b gives, after crystalliz-25 ation of the residue in ethyl acetate/hexane, 70 mg of ethyl (Z)-(R,S)-4-[2-[4-[amino-hydroxyimino-methyl]-benzoylamino]-propionylJ-phenoxyacetate, MS (ISP): 414 (M+H)+.
The starting material can be prepared as follows:
A solution of 300 mg of ethyl (S)-4-[2-[4-(1-methyl-thioformimidoyl)-benzoylamino]-propionyl]-phenoxyacetate (Example 31 ) and 175 mg of O-tert-butyl-dimethylsilyl-hydroxylamine in 10 ml of THF is stirred at room temperature for 16 h., concentrated and the residue is chromatographed on silica gel (hexane/ethyl acetate 3:2). There are obtained 95 mg of ethyl (R,S)-4-[2-[4-[(tert-butyl-dimethyl-silanyloxyamino)-imino-51 ~1~6~0~
methyl]-benzoylamino]-propionyl]-phenoxyacetate, MS (El): 528 (M+H)+.
Exam Ip a 33 s From 350 mg of tetrahydropyran-4-yl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl)-phenoxyacetate hydrochloride (1:0.8) hydroiodide (1:0.4) and 80 mg of ethyl chloroformate there are obtained according to Example 15 and after chromatography of the residue on silica gel (hexane/ethyl ~o acetate 1:2) 204 mg of tetrahydropyran-4-yl (S)-4-[2-[4-(ethoxycarbonylamino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, MS (ISP): 526 (M+H)+.
Exam Ip a 34 From 2.2 g of ethyl (S)-4-[2-(6-tert-butoxycarbonylamino-methyl-pyridin-3-ylcarbonylamino)-propionyl]-phenoxyacetate there are obtained according to Example 12 and after chromatog-raphy of the residue on silylated silica gel RP18 (THF/water 2o gradient) 863 mg of ethyl (S)-4-[2-(6-aminomethyl-pyridin-3-ylcarbonylamino)-propionyl]-phenoxyacetate, MS (ISP): 386 (M+H)+.
The starting material can be prepared as follows:
Coupling of 1.97 g of deprotected ethyl (S)-4-(2-tert-butoxycarbonylamino-propionyl)-phenoxyacetate with 1.7 g of 6-tert-butoxycarbonylaminomethyl-pyridine-3-carboxylic acid in the presence of 2 g of TPTU and 1.25 g of N-methylmorpholine ~o gives, according to Example 12e and after chromatography on silica gel (hexane/ethyl acetate 1:2) 2.28 g of ethyl (S)-4-[2-(6-tert-butoxycarbonylaminomethyl-pyridin-3-ylcarbonylamino)-propionyl]-phenoxyacetate, MS (ISP): 486 (M+H)+.
Exam Ip a 35 From 90 mg of ethyl (Z)-(R,S)-4-[2-[4-(amino-hydroxy-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate and ~13b903 25 mg of ethyl chloroformate there are obtained according to Example 15 and after crystallization of the residue in ethyl acetate/hexane 57 mg of ethyl (Z)-(R,S)-4-[2-[4-(amino-ethoxy-carbonyloximino-methyl]-benzoylam ino]-propionyl]-phenoxy-s acetate, MS (ISP): 486 (M+H)+.
Exam Ip a 36 Reaction of 500 mg of ethyl (S)-4-[2-[4-(amino-imino w methyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoro acetate with phenyl chloroformate according to Example 15 leads, after chromatography on silica gel (hexane/ethyl acetate 1:2), to 211 mg of ethyl (S)-4-[2-[4-(imino-phenoxycarbonylamino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, MS (ISP): 518 (M+H)+.
Exam Ip a 37 Reaction of 511 mg of ethyl (S)-4-[2-[4-(amino-imino-~o methyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoro-acetate with 4-methoxyphenyl chloroformate according to Example 15 leads, after chromatography on silica gel (hexane/
ethyl acetate 1:2), to 145 mg of ethyl (S)-4-[2-[4-[imino-(4-methoxy-phenoxycarbonylamino)-methyl]-benzoylamino]-25 propionyl]-phenoxyacetate, MS (ISP): 548 (M+H)+.
Exam lia a 38 98 mg of triphosgene in 5 ml of dichloromethane are added 3o at O~C to a solution of 102 mg of tetrahydro-2H-pyran-4-of and 101 mg of 4-methoxymorpholine in 10 ml of dichloromethane and the mixture is subsequently stirred at room temperature for 2 h.
This solution is added to a suspension of 511 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoroacetate in 10 ml of dichloromethane and ml of saturated sodium carbonate solution, stirred at room temperature for 5 min. and the reaction mixture is worked up as in Example 15. Chromatography of the residue on silica gel (ethyl 53 ~l~~~a~
acetate) gives 350 mg of ethyl (S)-4-[2-[4-[imino-(tetrahydro-pyran-4-yloxycarbonylamino)-methyl]-benzoylamino]-propionyl]-phenoxyacetate, MS (ISP): 526 (M+H)+.
Exam Ip a 39 540 mg of tetrahydropyran-4-yl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl)-phenoxyacetate trifluoro-acetate (Example 5) are also reacted in analogy to Example 38.
~o After chromatography of the residue an silica gel (ethyl acetate) there are obtained 378 mg of tetrahydropyran-4-yl (S)-4-[2-[4-[imino-(tetrahydro-pyran-4-yloxycarbonylamino)-methyl]-benzoylamino]-propionyl]-phenoxyacetate, MS (ISP): 582 (M+H)+.
i.5 Exam Ip a 40 Reaction of 920 mg of 2-methoxy-ethyl (S)-4-[2-[4-(amino-iminomethyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoroacetate with 2-methoxy-ethyl chloroformate according 2o to Example 15 leads after chromatography on silica gel (hexane/
ethyl acetate 1:3) to 430 mg of 2-methoxy-ethyl (S)-4-[2-[4-[imino-(2-methoxy-ethoxy-carbonylamino)-methyl]-benzoyl-amino]-propionyl]-phenoxyacetate, MS (ISP): 530 (M+H)+.
25 Exam~he 41 Cleavage of the protecting group from 160 mg of ethyl (S)-4-[2-[4-[(tert-butyl-dimethyl-silanyloxyamino)-imino-methyl]-benzoylamino]-propionyl]-phenoxyacetate with tetrabutyl-3o ammonium fluoride analogously to Example 3b gives, after crystallization of the residue in ethyl acetate/hexane, 187 mg of ethyl (Z)-(S)-4-[2-[4-(amino-hydroxyimino-methyl)-benzoyl-amino]-propionyl]-phenoxyacetate, MS (ISP): 414 (M+H)+, [a] o -+68.8~ (c = 0.5, DMSO).
The starting material can be prepared as follows:

From 2 g of 4-cyanobenzoic acid there is obtained by analogous reactions as in Example 32a N-tert-butyl-dimethyl-silyloxy-amidinobenzoic acid. This is used directly as the raw material for the coupling of ethyl (S)-4-(2-tert-butoxycarbonyl-s amino-propionyl)-phenoxyacetate in the presence of TPTU accord-ing to Example 12e. After chromatography of the residue on silica gel (hexane/ethyl acetate 1:1 ) there are obtained 561 mg of ethyl (S)-4-[2-[4-[(tert-butyl-dimethyl-silanyloxyamino)-imino-methyl]-benzoylamino]-propionyl]-phenoxyacetate, [a] p = +62.0 ~o (c = 0.5, chloroform).
Exam Ip a 42 Reaction of 500 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoro-acetate with 4-fluorophenyl chloroformate analogously to Example 15 and chromatography of the residue on silica gel (hexane/ethyl acetate 1:2) gives 100 mg of ethyl (S)-4-[2-[4-[(4-fluoro-phenoxycarbonylamino)-imino-methyl]-benzoylamino]-2o propionyl]-phenoxyacetate, MS (ISP): 536 (M+H)+.
Examlhe 4343 Starting from 1 g of ethyl (S)-4-[2-[4-(amino-imino-2~ methyl)-benzoylamino]-propionylJ-phenoxyacetate trifluoro-acetate there are prepared in analogy to Example 38 with 2-tert-butyl-dimethyl-silanyloxyethanol 200 mg of ethyl (S)-4-[2-[4-[amino-2-tert-butyl-dimethyl-silanyloxy-ethoxycarbonylimino-methylJ-benzoylamino]-propionyl]-phenoxyacetate and this is so deprotected as in Example 3a and chromatographed on silica gel (ethyl acetate/ethanol 95:5). There are obtained 56 mg of ethyl (S)-4-[2-[4-[ami no-(2-hyd roxy-ethoxycarbonyli m i no)-methylJ-benzoylamino]-propionyl]-phenoxyacetate, MS (ISP): 486 (M+H)+.
35 Exam Ip a 44 Starting from 527 mg of ethyl (S)-4-(2-tert-butoxy-carbonylamino-propionyl)-phenoxyacetate and 462 mg of 4-55 ~1~6903 (amino-methoxyimino-methyl)-benzoic acid trifluoroacetate there are obtained as in Example 12e and after chromatography on silica gel (hexane/ethyl acetate 2:3) 500 mg of ethyl (E/Z)-(S)-4-[2-[4-(amino-methoxyimino-methyl)-benzoylamino]-propionyl]-s phenoxyacetate trifluoroacetate, MS (ISP): 428 (M+H)+.
The starting material can be prepared as follows:
A solution of 1.47 g of tert-butyl 4-cyanobenzoate is ~o reacted analogously to Example 31 with hydrogen sulphide, methyl iodide and O-methyl-hydroxylamine hydrochloride and the crude product is chromatographed on silica gel (hexane/ethyl acetate 9:1 ). There is obtained 1.0 g of tent-butyl 4-(amino-methoxyimino-methyl)-benzoate. Cleavage of the ester group according to Example 12 with trifluoroacetic acid gives, after crystallization (sic) in ether, 1.13 g of 4-(amino-methoxyimino-methyl)-benzoic acid trifluoroacetate.
Exam Ip a 45 The silyl protecting group is cleaved from 290 mg of ethyl (S)-4-[2-[4-[(tert-butyl-dimethyl-silanyloxyamino)-imino-methyl]-be nzoylam i no]-3-hydroxy-propionyl]-phenoxyacetate with tetrabutylammonium fluoride as in Example 3b. After 2s chromatography on silica gel (ethyl acetate there are obtained 145 mg of ethyl (Z)-(S)-4-[2-[4-[amino-hydroxyimino-methyl]-benzoylamino]-3-hydroxy-propionyl]-phenoxyacetate.
The starting material can be prepared as follows:
The free amine is obtained from a solution of 1.27 g of ethyl 4-[(S)-3-tert-butoxy-2-tert-butoxycarbonylamino-propionyl]-phenoxyacetate in 25 ml of dichloromethane according to Example 24a and is subsequently reacted analogously to Example 41 a with 35 N-tert-butyl-dimethylsilyloxy-amidinobenzoic acid. After chromatography of the residue on silica gel (hexane/ethyl acetate 1:2) there are obtained 290 mg of ethyl (S)-4-[2-[4-[(tert-butyl-dimethyl-silanyloxyamino)-imino-methyl]-benzoylamino]-3-213fi9a3 hydroxy-propionyl]-phenoxyacetate, Rf value: 0.68 (chloroform (sic), methanol, acetic acid, 88:10:2).
Exam Ip a 46 A solution of 0.8 g of [[4-(p-amidino-N-methylbenzamido)-acetyl-o-phenylene]dioxy]diacetic acid (J. Med. Chem. 1992, 35, 4393-4407) in 2-propanol/conc. sulphuric acid (20:1 ) is left to stand overnight. After removing the solvent the residue is taken w up in 50 ml of water, made neutral by adding sodium hydrogen carbonate and covered with 80 ml of dichloromethane. After adding 0.3 g of ethyl chloroformate followed by 20 ml of 0.5N
sodium hydroxide solution the organic phase is separated, washed with water, dried over sodium sulphate and concentrated. After chromatography on silica gel (ethyl acetate) and crystallization (diethyl ether) there is obtained 0.51 g of diisopropyl (E and/or Z)-[[4-((p-amino-ethoxycarbonylimino-methyl)-N-methylbenz-amido)acetyl-o-phenylene]dioxy]diacetate. M.p. 56-58°C. MS (El):
512 (M+H)+.
Exam Ip a 47 From [[1-[N-(p-amidinobenzoyl)-L-tyrosyl]-4-piperidinyl]-oxy]acetic acid (J. Med. Chem. 1992, 35, 4393-4407) there was 25 obtained in an analogous manner to that described in Example 46 ethyl (E/Z)-(S)-1-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-3-(4-hydroxy-phenyl)-propionyl]-piperidin-4-yloxyacetate. [a] p = +18.1 ° (c = 0.8, EtOH). M.p. 84°C. MS
(ISP):
569 (M+H)+.
Exam Ip a 48 From [[1-[N-(p-amidinobenzoyl)-L-tyrosyl]-4-piperidinyl]-oxy]acetic acid (J. Med. Chem. 1992, 35, 4393-4407) there was obtained in an analogous manner to that described in Example 46 isopropyl (E/Z)-(S)-1-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-3-(4-hydroxy-phenyl)-propionyl]-piperidin-4-yloxyacetate. M.p. 88-90°C. MS (ISP): 583 (M+H)+.

Exam~he 49 Isopropyl (E/Z)-(S)-1-[2-(4-(amino-ethoxycarbonylimino-s methyl)-benzoylamino]-3-(4-ethoxycarbonyloxy-phenyl)-propionyl]-piperidin-4-yloxyacetate can be isolated as a byproduct of the reaction described in Example 48. M.p. 71-73°C.
MS (ISP): 655 (M+H)+.
io Exam Ip a 50 From the reaction of ([1-[N-(p-amidinobenzoyl)-L-tyrosyl]-4-piperidinyl]oxy]acetic acid with isatoic anhydride in the presence of potassium carbonate there is obtained, after usual working up and chromatographic purification of the crude product, (E/Z)-(S)-4-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-3-(4-isopropoxycarbonylmethoxy-piperidin-1-yl)-3-oxo-propyl]-phenyl 2-amino-benzoate in the form of a colour-less foam. MS (ISP): 702 (M+H)+.
Exam Ip a 51 From the reaction of [[1-[N-(p-amidinobenzoyl)-L-tyrosyl]-4-piperidinyl]oxy]acetic acid with furan-2-carboxylic acid 2s chloride in the presence of potassium carbonate there is obtained, after usual working up and chromatographic purification of the crude product, (E/Z)-(S)-4-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylami no]-3-(4-isopropoxycarbonylmethoxy-piperidin-1-yl)-3-oxo-propyl]-phenyl furan-2-carboxylate in the 3o form of a light yellow foam. MS (ISP): 677 (M+H)+.
Exam Ip a 52 From the reaction of [[1-[N-(p-amidinobenzoyl)-L-tyrosyl]-4-piperidinyl]oxy]acetic acid with acetic anhydride in the presence of potassium carbonate there is obtained, after usual working up and chromatographic purification of the crude product, isopropyl (E/Z)-(S)-1-[3-[4-acetoxy-phenyl)-2-[4-(amino-5s ~~~694~
ethoxycarbonylimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxy-acetate in the form of a colourless foam. MS
(ISP): 625 (M+H)+.
s Exam Ip a 53 From the reaction of [[1-[N-(p-amidinobenzoyl)-L-tyrosylJ-4-piperidinyl]oxy]acetic acid with acetylsalicyloyl chloride in the presence of triethylamine there is obtained, after usual working w up and chromatographic purification of the crude product, (E/Z)-(S)-4-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-3-(4-isopropoxycarbonylmethoxy-piperidin-1-yl)-3-oxo-propyl]-phenyl 2-acetoxy-benzoate. M.p. 77-80°C. MS (El): 745 (M+H)+.
Exam Ip a 54 From the reaction of tert-butyl [[1-[N-(p-amidinobenzoyl)-L-tyrosyl]-4-piperidinyl]oxy]acetate (EP 505868) with ethyl chloroformate as described in Example 46 followed by treatment ~o with conc. formic acid there is isolated, after usual working up and chromatography, (E/Z)-(S)-1-[2-[4-(amino-ethoxycarbonyl-imino-methyl)-benzoylamino]-3-(4-hydroxy-phenyl)-propionyl]-piperidin-4-yloxyacetic acid. M.p. 134°C. MS (ISN): 539 (M-H)+.
2s ExamQle 55 From the reaction of (S)-1-[2-(5-amidinopyridin-2-ylcarbonyl-amino)-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yloxyacetic acid (EP 505868) in an analogous manner to that 3o described in Example 46 there is obtained ethyl (E/Z)-(S)-1-[2-(5-amino-ethoxycarbonylimino-methylpyridin-2-ylcarbonyl-amino)-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yloxy-acetate. [a]p2° _ +22.6° (c = 1.0, EtOH). M.p. 52-54°C.
MS (ISP):
584 (M+H)+.

59 ~~30003 Exam to a 56 Reaction of tert-butyl (S)-1-[3-(4-hydroxy-phenyl)-2-[4-(imino-propylamino-methyl)-benzoylamino]-propionyl]-piperidin-s 4-yloxyacetate with conc. formic acid gives, after chromato-graphic purification of the crude product on silica gel RP18 with a water/methanol gradient, (S)-1-[3-(4-hydroxy-phenyl)-2-[4-(imino-propylamino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetic acid. M.p. 160°C. MS (ISP): 511 (M+H)+.
~o The starting material can be prepared as follows:
a) Coupling of Z-Tyr-OH with tert-butyl 4-piperidinyloxyacetate (J. Med. Chem. 1992, 35, 4393-4407) followed by hydrogenolytic removal of the Z protecting group gives tert-butyl 1-[[L-tyrosyl]-4-piperidinyloxy]acetate.
b) By reacting the product of the preceding step with 4-cyano-benzoyl chloride in the presence of sodium hydrogen carbonate 2o there is obtained tert-butyl (S)-1-[3-(4-hydroxy-phenyl)-2-[4 cyano-benzoylamino]-propionyl]-piperidin-4-yloxyacetate.
c) By successive subsequent treatment of the product of the preceding step with hydrogen sulphide in pyridine, methyl iodide in acetone and n-propylamine in a mixture of methanol and acetic acid there is obtained tert-butyl (S)-1-[3-(4-hydroxy-phenyl)-2-[4-(imino-propylamino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate. MS (ISP): 567 (M+H)+.
Example 57 Reaction of (S)-4-[[[4-[1-(4-tert-butoxycarbonylmethoxy-piperidin-1-carbonyl)-2-(4-hydroxy-phenyl)-ethylcarbamoyl]-phenyl]-imino-methyl]-amino]-butyric acid with conc. formic acid gives, after chromatographic purification of the crude product, (S)-4-[[[4-[1-(4-carboxymethoxy-piperidine-1-carbonyl)-2-(4-hydroxy-phenyl)-ethylcarbamoyl]-phenyl]-imino-methyl]-amino]-butyric acid. M.p. 156-160°C. MS (ISP): 555 (M+H)+.

b The starting material can be prepared as follows:
By successive subsequent treatment of tert-butyl {S)-1-[3-s (4-hydroxy-phenyl)-2-[4-cyano-benzoylamino]-propionyl]-piperidin-4-yloxyacetate (Example 56b)) with hydrogen sulphide in pyridine, methyl iodide in acetone and 4-aminobutyric acid in a mixture of methanol and acetic acid there is obtained (S)-4-[[[4-[1-(4-tert-butoxycarbonylmethoxy-piperidin-1-carbonyl)-2-(4-~o hydroxy-phenyl)-ethylcarbamoyl]-phenyl]-imino-methyl]-amino]-butyric acid in the form of a colourless foam. MS (ISP): 611 (M+H)+.
Exam Ip a 58 From the reaction of tert-butyl [[1-[N-(p-amidinobenzoyl)-L-alanyl]-4-piperidinyl]oxy]acetate (J. Med. Chem. 1992, 35, 4393-4407) with ethyl chloroformate as described in Example 46 followed by treatment with conc. formic acid there is isolated, 2o after usual working up and chromatography, (ElZ)-(S)-[1-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxy]-acetic acid in the form of a colourless foam.
MS (ISP): 449 (M+H)+.
25 Exams I~ a 59 From [[1-[N-(p-amidinobenzoyl)-L-alanyl]-4-piperidinyl]-oxy]acetic acid (J. Med. Chem. 1992, 35, 4393-4407) there was obtained in an analogous manner to that described in Example 46 3o ethyl (ElZ)-(S)-1-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate in the form of a colourless foam. [a] p = +41.7° (c = 1.0, EtOH). MS (ISP): 477 (M+H)+.
Exam~he 60 From [[1-[N-(p-amidinobenzoyl)-L-alanyl]-4-piperidinyl]-oxy]acetic acid there was obtained in an analogous manner to that 61 ~1~~~~~
described in Example 46 isopropyl (E/Z)-(S)-1-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate in the form of a colourless foam. MS (ISP): 491 (M+H)+.
Fxam Ip a 61 From [[1-[N-(p-amidinobenzoyl)-L-alanyl]-4-piperidinylJ-oxy]acetic acid there was obtained in an analogous manner to that ~o described in Example 46 ethyl (E/Z)-(S)-1-[2-[4-(amino-n-butoxy-carbonylimino-methyl)-benzoylaminoJ-propionyl]-piperidin-4-yloxyacetate in the form of a colourless foam. [a] p = +37.4° (c =
0.8, EtOH). MS (ISP): 505 (M+H)+.
i5 Exam Ip a 62 From [[1-[N-(p-amidinobenzoyl)-L-alanyl]-4-piperidinyl]-oxy]acetic acid there was obtained in an analogous manner to that described in Example 46 ethyl (E/Z)-(S)-1-[2-[4-(amino-methoxy-2o ethoxycarbonylimino-methyl)-benzoylaminoJ-propionyl]-piperidin 4-yloxyacetate in the form of a colourless foam. [a] p = + 40.0°
(c = 0.9, EtOH). MS (ISP): 507 (M+H)+.
Exam Ip a 63 By esterifying (S)-1-[2-(5-amino-imino-methyl-pyridin-2-ylcarbonylamino)-propionyl]-piperidin-4-yloxy-acetic acid (J.
Med. Chem. 1992, 35, 4393-4407) with tetrahydro-2H-pyran-4-of in the presence of p-toluenesulphonic acid there is obtained, 3o after chromatographic purification of the crude product on silica gel RP 18 with a water/acetonitrile gradient, the p-toluene-sulphonate salt of tetrahydropyran-4-yl (S)-1-[2-(5-amino-imino-methyl-pyridin-2-ylcarbonylamino)-propionyl]-piperidin-4-yloxy-acetate. [a] p = +28.8° (c = 0.5, MeOH). MS (ISP): 462 a5 (M+H)+

s2 Exam Ip a 64 From (S)-1-[2-(5-amino-imino-methyl-pyridin-2-yl-carbonylamino)-propionyl]-piperidin-4-yloxy-acetic acid there s was obtained in an analogous manner to that described in Example 46, isopropyl (E/Z)-(S)-1-[2-(5-amino-ethoxycarbonylimino-methyl-pyridin-2-ylcarbonylamino)-propionyl]-piperidin-4-yloxy-acetate. [a] p = +42.6° (c = 1.0, EtOH). M.p. 62-64°C.
MS (El): 492 (M+H)+.
w Exam Ip a 65 From [[1-[(p-amidino-N-methylbenzamido)acetyl]-4-piperi-dinyl]oxy]acetic acid (EP 505868) there was obtained in an analogous manner to that described in Example 46 ethyl (E/Z)-[1-[2-[[4-(amino-ethoxycarbonylimino-methyl)-benzoyl]-methyl-amino]-acetyl]-piperidin-4-yloxy-acetate. MS (!SP): 477 (M+H)+.
Example 66 From tert-butyl (E/Z)-(S)-1-[2-[4-(amino-methoxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate there is obtained by treatment with trifluoroacetic acid in dichloro-methane (E/Z)-(S)-1-[2-[4-(amino-methoxyimino-methyl)-25 benzoylamino]-propionyl]-piperidin-4-yloxyacetic acid. M.p. 193-195°C. MS (ISP): 407 (M+H)+.
The starting material can be prepared as follows:
3o a) Coupling of Z-Ala-OH with tert-butyl 4-piperidinyloxyacetate (J. Med. Chem. 1992, 35, 4393-4407) followed by hydrogenolytic removal of the Z protecting group gives tert-butyl 1-[[L-alanyl]-4-piperidinyloxy]acetate.
b) By reacting the product of the preceding step with 4-cyano-benzoyl chloride in the presence of sodium hydrogen carbonate there is obtained tert-butyl (S)-1-(2-[4-cyano-benzoylamino]-propionyl]-piperidin-4-yloxyacetate.

s3 ~13VJ0 c) By successive subsequent treatment of the product of the preceding step with hydrogen sulphide in pyridine, methyl iodide in acetone and O-methyl hydroxylamine hydrochloride in DMF in s the presence of triethylamine there is obtained tert-butyl (E/Z)-(S)-1-[2-[4-(amino-methoxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate in the form of a viscous, colourless oil. MS (ISP): 463 (M+H)+.
w Exam Ip a 67 By esterifying (E/Z)-(S)-1-[2-[4-(amino-methoxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetic acid in ethanol in the presence of conc. sulphuric acid there is obtained ethyl (E/Z)-(S)-1-[2-[4-(amino-methoxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate as a colourless resin. MS (ISP): 435 (M+H)+.
Example 68 From tert-butyl (S)-1-[2-[4-tert-butoxycarbonylamino-methyl-benzoylamino)-3-(4-hydroxy-phenyl)-propionyl]-piperidin-4-yloxyacetate there is obtained by treatment with formic acid (S)-1-[2-(4-aminomethyl-benzoylamino)-3-(4-hydroxy-phenyl)-propionyl]-piperidin-4-yloxyacetic acid. [a] o -+19.4° (c = 0.5, H20). M.p. 166-168°C. MS (ISN): 454 (M-H)+.
The starting material can be prepared by coupling tert-butyl 1-[[L-tyrosyl]-4-piperidinyloxy]acetate (Example 56a)) with 4-3o tert-butoxycarbonylaminomethyl-benzoic acid in the presence of 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ).
Exam I~ a 69 From tert-butyl (S)-1-[2-[4-tert-butoxycarbonylamino-methyl-benzoylamino)-3-(4-hydroxy-phenyl)-propionyl]-piperidin-4-yloxyacetate (Example 68) by treatment with methyl iodide/potassium carbonate followed by formic acid there is 64 ~1~~~0~
obtained (S)-1-[2-(4-aminomethyl-benzoylamino)-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yloxyacetic acid. [a] p = +11.7°
(c = 0.5, H20). M.p. 130°C. MS (CI): 470 (M+H)+.
s Exam Ip a 70 By esterifying (S)-1-[2-(4-aminomethyl-benzoylamino)-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yloxyacetic acid with isopropanol in the presence of sulphuric acid there is obtained w isopropyl (S)-1-[2-(4-aminomethyl-benzoylamino)-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yloxyacetate as the hemisulphate salt. [a] o = +5.1° (c = 0.8, H20). M.p. 138-140°C.
MS (El}: 512 (M+H)+.
Exam Ip a 71 From tert-butyl (S)-1-[2-(5-aminomethyl-pyridin-2-yl-carbonylamino)-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yloxyacetate by treatment with formic acid there is obtained (S)-20 1-[2-(5-aminomethyl-pyridin-2-ylcarbonylamino)-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yloxyacetic acid. [a] p -+20.0° (c = 0.6, H20). M.p. 174°C (dec.). MS (ISP): 471 (M+H)+.
The starting material can be prepared by catalytically 25 hydrogenating tert-butyl (S)-1-[2-(5-cyano-pyridin-2-yl-carbonylamino)-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yloxyacetate (EP 505 868) over palladium-charcoal in a mixture of methanol/water/acetic acid.
3o Exam Ip a 72 From (S)-1-[2-(5-aminomethyl-pyridin-2-ylcarbonyl-amino)-3-(4-methoxy-phenyl)-propionyl]-piperidin-4-yloxyacetic acid there is obtained by esterification with isopropanol as described in Example 70 and after acidification of the crude product with hydrochloric acid the hydrochloride of isopropyl (S)-1-[2-(5-aminomethyl-pyridin-2-ylcarbonylamino}-3-(4-21~~90~
methoxy-phenyl)-propionyl]-piperidin-4-yloxyacetate. M.p. 82-84°C (from diethyl ether). MS (ISP): 513 (M+H)+.
Exam Ip a 73 From tert-butyl (S)-4-[1-(4-tert-butoxycarbonylmethoxy-piperidin-1 ylcarbonyl)-2-(4-hydroxy-phenyl)-ethylcarbamoyl-methoxy]-piperidine-1-carboxylate by treatment with formic acid there is obtained (S)-1-[3-(4-hydroxy-phenyl)-2-piperidin-w 4-yloxyacetylamino-propionyl]-piperidin-4-yloxyacetic acid, [a]2p = +6.7° (c = 0.7, H20). M.p. 156°C (dec.). MS (ISP): 464 (M+H)+.
The starting material can be prepared as follows:
~5 a) By treating tert-butyl 4-piperidinyloxyacetate (J. Med. Chem.
1992, 35, 4393-4407) with formic acid there is obtained 4-piperidinyloxyacetic acid, which can be converted with di-tert-butyl Bicarbonate in dioxan in the presence of sodium hydroxide 2o into 1-tert-butoxycarbonyl-piperidin-4-yloxyacetic acid.
b) The product of the preceding step can be coupled with tert-butyl 1-[[L-tyrosyl]-4-piperidinyloxy)acetate (Example 56a)) in the presence of 1-ethyloxycarbonyl-2-isobutyloxy-1,2-dihydro-25 quinoline in dichloromethane to give tert-butyl (S)-4-[1-(4-tert-butoxycarbonylmethoxy-piperidin-1-ylcarbonyl)-2-(4-hydroxy-phenyl)-ethylcarbamoylmethoxy]-piperidine-1-carboxylate. MS
(ISP}: 620 (M+H)+.
~o Exam~he 74 By reacting (S)-4-[2-[1-tert-butoxycarbonyl-piperidin-4-yloxyacetylamino]-3-(4-ethoxycarbonylmethoxy-piperidin-1-yl)-3-oxo-propyl]-phenyl 2-acetoxy-benzoate with formic acid there is obtained, after the addition of hydrochloric acid to the crude product, the hydrochloride salt of (S)-4-[2-[piperidin-4-yloxy-acetylamino]-3-(4-ethoxycarbonylmethoxy-piperidin-1-yl)-3-~1~~~0~

oxo-propyl]-phenyl 2-acetoxy-benzoate. M.p. 74-76°C (dec.). MS
(ISP): 654 (M+H)+.
The starting material can be obtained as follows:
s a) Coupling of Z-Tyr-OH with ethyl 4-piperidinyloxyacetate (obtained by trans-esterification of tert-butyl 4-piperidinyloxy-acetate with acid in the presence of 1-ethyloxycarbonyl-2-isobutyloxy-1,2-dihydroquinoline) followed by reaction with w acetylsalicyloyl chloride in the presence of potassium carbonate and subsequent hydrogenolytic removal of the Z protecting group gives (S)-4-[2-amino-3-(4-ethoxycarbonylmethoxy-piperidin-1-yl)-3-oxo-propyl]-phenyl 2-acetoxy-benzoate.
b) By coupling the product of the preceding step with 1-tert-butoxycarbonyl-piperidin-4-yloxyacetic acid (Example 73b)) in the presence of 1-ethyloxycarbonyl-2-isobutyloxy-1,2-dihydro-quinoline in dichloromethane there is obtained (S)-4-[2-[1-tert-butoxycarbonyl-piperidin-4-yloxyacetylamino]-3-(4-ethoxy-~o carbonylmethoxy-piperidin-1-yl)-3-oxo-propyl]-phenyl 2-acetoxy-benzoate. MS (ISP): 754 (M+H)+.
Example 75 25 By esterifying (E/Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetic acid in ethanol in the presence of conc. sulphuric acid there is obtained ethyl (E/Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate in the form of ~o cotton wool-like crystals. M.p. 205-207°C. MS (ISP): 421 (M+H)+.
The starting material can be prepared as follows:
a) By reacting tert-butyl (S)-1-[2-[4-cyano-benzoylamino]-propionyl]-piperidin-4-yloxyacetate (Example 66) with hydroxylamine hydrochloride in methanol in the presence of sodium methanolate there is obtained, after stirring overnight and usual working up, tert-butyl (E/Z)-(S)-1-[2-[4-(amino-~~13~9~~

hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate. M.p. 193-194°C. MS (ISP): 449 (M+H)+.
b) By treating the product of the preceding step with formic acid s at 50°C there is obtained, after crystallization from ethyl acetate, (E/Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetic acid. M.p. 176-178°C. MS (ISN): 391 (M+H)+.
w Exam Ip a 76 By esterifying (E/Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetic acid (Example 75b) in 2-propanol in the presence of conc. sulphuric acid there is obtained isopropyl (E/Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylaminoJ-propionyl]-piperidin-4-yloxyacetate the form of cotton wool-like crystals. M.p. 205-207°C. MS (ISP): 435 (M+H)+.
2o Exam~he 77 220 mg of tert-butyl [1-[4-[4-(tert-butoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxyJ-acetate and 3.4 ml of formic acid are stirred at 20°C for 24 h.
The reaction mixture is evaporated in a vacuum, the residue is dissolved in water and again evaporated. 120 mg of [1-[4-[4-(amino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid, m.p. > 250°C, MS: 362 {100, M+H), crystallize from methanol.
~o The starting material can be obtained as follows.
a) 4-(4-Cyano-phenyl)-4-oxo-butyric acid is activated in THF
with 2-chloro-4,6-dimethoxy-1,3,5-triazine and N-methyl-morpholine and then reacted with tert-butyl piperidin-4-yloxy-acetate to give tert-butyl [1-[4-(4-cyanophenyl)-4-oxo-butyryl]-piperidin-4-yloxy]-acetate.

s8 ~1~~90~
b) This is converted in pyridine and triethylamine with hydrogen sulphide into tert-butyl [1-[4-oxo-4-(4-thiocarbamoyl-phenyl)-butyryl]-piperidin-4-yloxy]-acetate, m.p. 140°C.
s c) The latter is reacted firstly with methyl iodide in acetone, then with ammonium acetate and acetic acid in methanol and finally with di-tert-butyl Bicarbonate in DMF-triethylamine to give tert-butyl [1-[4-[4-(tert-butoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate. MS:
io 518 (100, M+H).
Exam Ip a 78 76 mg of ethyl [1-[4-[4-(tert-butoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate are stirred in 0.5 ml of methylene chloride and 0.5 ml of trifluoro-acetic acid at 20°C for 2 h. The reaction mixture is evaporated in a vacuum, the residue is dissolved in alcohol and again evapor-ated. The crystalline product is triturated with ether, filtered 20 off under suction and dried. There are obtained 74 mg of ethyl [1-[4-[4-(amino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate trifluoroacetate (1:1 ), m.p. 188-190°C .
The starting material can be obtained as follows:
a) [1-[4-[4-(Amino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid is converted in 1 N HCI in ethanol into its ethyl ester.
3o b) This is converted with di-tert-butyl Bicarbonate in DMF-triethylamine into the starting material, m.p. 100°C .
Exam Ip a 79 A mixture of 160 mg of isopropyl [1-[[[4-(amino-imino-methyl)-benzoyl]-(2-methoxyethyl)-amino]-acetyl]-piperidin-4-yloxy]-acetate hydrochloride (1:1 ), 3.2 ml of methylene chloride, 2.6 ml of water and 0.6 ml of saturated sodium carbonate solution 69 ~1~6JU~
is treated with 0.036 ml of ethyl chloroformate and stirred well at 20~C for 2 h. The reaction mixture is diluted with methylene chloride, washed with water and sodium chloride solution, dried and evaporated in a vacuum. Chromatography of the residue on s silica gel with methylene chloride-isopropanol gives 109 mg of isopropyl [1-[[[4-(ethoxycarbonylamino-imino-methyl)-benzoyl]-(2-methoxy-ethyl)-amino]-acetyl]-piperidin-4-yloxy]-acetate as a colourless foam. MS: 535 (100, M+H).
w The starting material is obtained from [1-[[[4-(amino-imino-methyl)-benzoyl]-(2-methoxy-ethyl)-amino]-acetyl]-piperidin-4-yloxy]-acetic acid (EP 505 868) in 1 N HCI in isopropanol at 20~C.
Example 80 In analogy to Example 79, from isopropyl [1-[4-[4-(amino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate iodide acetate there is obtained isopropyl [1-[4-[4-20 (ethoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, m.p. 86-89~C .
The starting material can be prepared as follows:
2~ a) tert-Butyl [1-[4-oxo-4-(4-thiocarbamoyl-phenyl)-butyryl]-piperidin-4-yloxy]-acetate is cleaved in methylene chloride and trifluoroacetic acid to [1-[4-oxo-4-(4-thiocarbamoyl-phenyl)-butyryl]-piperidin-4-yloxy]-acetic acid, m.p. 203-207~C .
3o b) Therefrom with sulphuric acid in isopropanol there is obtained isopropyl [1-[4-oxo-4-(4-thiocarbamoyl-phenyl)-butyryl]-piperidin-4-yloxy]-acetate, m.p. 123-128~C .
c) This is reacted with methyl iodide in acetone and subsequently with ammonium acetate and acetic acid in methanol to give the starting material.

70 2136J0~
Exam Ip a 81 In analogy to Example 79, from isopropyl [1-[4-[4-(amino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-s acetate iodide acetate and isobutyl chloroformate there is obtained isopropyl [1-[4-[4-(isobutoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, m.p.
94~C.
io Exam Ip a 82 1.7 g of tert-butyl (RS)-[1-[4-[4-(tert-butoxycarbonyl-amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate are stirred in 8.5 ml of methylene chloride and 8.5 ml of trifluoroacetic acid at 20~C for 3 h. After evaporation of the solvent in a vacuum the residue is dissolved in water and the solution is again evaporated. After drying the residue is triturated in alcohol, filtered off under suction and dried. There are obtained 1.13 g of (RS)-[1-[4-[4-(amino-imino-2o methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy-acetic acid trifluoroacetate (1:1 ), m.p. 217~C.
The starting material can be obtained as follows:
2s a) 4-(4-Amino-phenyl)-2-methyl-4-oxo-butyric acid is converted via the corresponding diazonium compound (Sandmeyer reaction) into 4-{4-cyano-phenyl)-2-methyl-4-oxo-butyric acid, m.p.
137~C.
3o b) As described in Example 77a), this is coupled with tert-butyl piperidin-4-yloxy-acetate to give tert-butyl (RS)-[1-[4-{4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin]-4-yloxy-acetate, m.p. 114-116~C.
c) tert-Butyl (RS)-[1-[2-methyl-4-oxo-4-(4-thiocarbamoyl-phenyl)-butyryl]-piperidin-4-yloxy]-acetate, m.p. 152-155~C, is obtained therefrom with hydrogen sulphide in pyridine/ triethyl-amine.

71 ~136~03 d) This is reacted firstly with methyl iodide in acetone, then with ammonium acetate and acetic acid in methanol and subsequently with di-tert-butyl Bicarbonate in methylene chloride and aqueous s sodium carbonate solution to give the starting material, MS: 532 (100, M+H).
Exam Ip a 83 w 734 mg of (RS)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid trifluoro-acetate are stirred in 15 ml of 1 N HCI in isopropanol at about 20~C for 19 h. After evaporation of the solvent and drying in a high vacuum there are obtained 650 mg of isopropyl (RS)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate hydrochloride (1:1 ) as a hygroscopic amorphous powder, MS: 376 (100, M+H).
Exam Ip a 84 In analogy to Example 79, from isopropyl (RS)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate hydrochloride there is obtained isopropyl (RS)-[1-[4-[4-(ethoxycarbonylamino-imino-methyl)-25 phenyl-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate as a resinous foam, MS: 490 (100, M+H).
Example 85 3o Likewise, from the same starting material with isobutyl chloroformate there is obtained isopropyl (RS)-[1-[4-[4-(Isobutoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxyJ-acetate as a foam, MS: 518 (100, M+H).

~~~6903 Exam to a 86 209 mg of ethyl (RS)-2-[4-(tert-butoxycarbonylamino imino-methyl)-benzoyl]-4-(4-ethoxycarbonylmethoxy-phenyl)-4 s oxo-butyrate and 4.2 ml of formic acid are left to stand at 20~C
for 6.5 h. The reaction mixture is evaporated, the residue is dissolved in water and again evaporated. The dried residue is triturated in ether and filtered off under suction. There are obtained 158 mg of ethyl (RS)-2-[4-(amino-imino-methyl)-w benzoyl]-4-(4-ethoxycarbonylmethoxyphenyl)-4-oxo-butyrate formate (1:1 ), m.p. 162~C.
The starting material can be obtained as follows:
a) From ethyl 4-cyanobenzoyl acetate and ethyl [4-(bromoacetyl)-phenoxy]-acetate in acetone in the presence of potassium carbonate there is obtained ethyl (RS)-2-(4-cyano-benzoyl)-4-[(4-ethoxycarbonylmethoxy)-phenyl]-4-oxo-butrate; MS: 437 (2, M).
b) This is converted in pyridine and triethylamine with hydrogen sulphide into ethyl (RS)-4-(4-ethoxycarbonylmethoxy-phenyl)-4-oxo-2-(4-thiocarbamoyl-benzoyl)-butyrate; MS: 472 (100, M+H).
c) The latter is reacted firstly with methyl iodide in acetone, then with ammonium acetate and acetic acid in methanol and finally with di-tert-butyl Bicarbonate in methylene chloride and aqueous sodium carbonate solution to give ethyl (RS)-2-[4-(tert-butoxycarbonylamino-imino-methyl)-benzoyl]-4-(4-ethoxy-carbonylmethoxy-phenyl)-4-oxo-butyrate; MS: 555 (100, M+H).
Examhe 87 In analogy to Example 79, from ethyl (RS)-2-[4-(amino-imino-methyl)-benzoyl]-4-(4-ethoxycarbonylmethoxy-phenyl)-4-oxo-butyrate formate and ethyl chloroformate there is obtained ethyl (RS)-2-[4-(ethoxycarbonylamino-imino-methyl)-benzoyl]-~~~~oo~

4-(4-ethoxycarbonylmethoxy-phenyl)-4-oxo-butyrate; MS: 527 (100, M+H).
Exam Ip a 88 3.8 g of ethyl 4-[3-(4-thiocarbamoyl-benzoyl)-propionyl]-phenoxyacetate, 76 ml of acetone and 5.9 ml of methyl iodide are stirred at 45~C for 3 h. The reaction mixture is evaporated, the residue is dissolved in 117 ml of methanol, treated with 2.2 g of w ammonium acetate and 0.54 ml of acetic acid and stirred at 60~C
for 3.5 h. The reaction mixture is concentrated in a vacuum until crystallization begins and is then cooled. The precipitate is filtered off under suction and is purified by trituration in aceto-nitrile. There are obtained 2 g of ethyl [4-(4-[4-(amino-imino-methyl)-phenyl]-4-oxo-butyryl]-phenoxy]-acetate acetate (1:1 ), m.p. 212~C.
The starting material can be obtained as follows:
2o a) 24.4 ml of pyridine are added to a suspension of 14.4 g of anhydrous magnesium chloride in 151 ml of dry methylene chloride and 25.2 ml of tert-butyl acetoacetate at 5~C. After 15 minutes 25 g of 4-cyanobenzoyl chloride are added and the mixture is subsequently stirred at 20~C for 2 h . For the working 25 up, the mixture is diluted with ethyl acetate, washed with ice-cold dilute hydrochloric acid and water, dried and evaporated in a vacuum. The residue is dissolved in 600 ml of tert-butyl methyl ether and treated while stirring vigorously with 160 ml of 10 percent ammonia solution. After 2 h the phases are separated, so washed with water, dried and evaporated in a vacuum. Filtration on silica gel and crystallization from pentane gives 13.1 g of pure tert-butyl 3-(4-cyanophenyl)-3-oxo-propionate, m.p. 82-83~C .
b) This is converted in acetone in the presence of potassium carbonate with ethyl [4-(bromoacetyl)-phenoxy]-acetate into ethyl (RS)-[4-[3-tert-butoxycarbonyl-3-(4-cyano-benzoyl)-propionyl]-phenoxy]-acetate; MS: 465 (1, M).

zi~b~o~

c) The latter is stirred for 4 h. in formic acid at 20~C, evaporated, evaporated with toluene and heated to 70~C for 1.5 h. in toluene.
There is thus obtained ethyl [4-[3-(4-cyano-benzoyl)-propionyl]-phenoxy]-acetate, m.p. 115-116~C.
d) This is converted in pyridine and triethylamine with hydrogen sulphide into ethyl 4-[3-(4-thiocarbamoyl-benzoyl)-propionyl]-phenoxy-acetate, m.p. 179-180~C.
w Exam Ip a 89 In analogy to Example 79, from ethyl [4-[4-[4-(amino-imino-methyl)-phenyl]-4-oxo-butyryl]-phenoxy]-acetate acetate there is obtained ethyl [4-[4-[4-{ethoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]-phenoxy]-acetate; m.p. 167-168~C.
Examlhe 9090 2o By reacting dimethyl [[4-(p-cyano-N-methylbenzamido)-acetyl-o-phenylene]dioxy]diacetate (J. Med. Chem. 1992, 35, 4393-4407) with hydroxylamine hydrochloride in methanol in the presence of sodium methanolate there is obtained, after stirring overnight and working up, dimethyl [[[4-(p-amino-hydroxyimino-2s methyl)-N-methylbenzamido]acetyl-o-phenylene]dioxy]diacetate in the form of a colourless solid. M.p. 58-60~C. MS (ISP): 488 {M+H)+.
Exam Ip a 91 By reacting methyl (S)-[2-[1-[2-[4-cyano-benzoylamino]-propionyl]-piperidin-4-yloxy]-acetylamino]-acetate with hydroxylamine hydrochloride in methanol in the presence of sodium methanolate there is obtained, after stirring overnight, working up and chromatographic purification on silica gel (dichloromethane/methanol 6:1), methyl (Z)-(S)-[2-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-75 ~~'~~l~u~
piperidin-4-yloxy]-acetylamino]-acetate. M.p. 168-172~C. MS
(ISP): 464 {M+H)+.
The starting material can be prepared as follows:
a) Treatment of tert-butyl 1-benzyloxycarbonyl-piperidin-4-yloxy-acetate (J. Med. Chem. 1992, 35, 4393-4407) with formic acid followed by reaction of the resulting product with glycine ethyl ester hydrochloride in the presence of O-benzotriazol-1-yl-w N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) and N-methylmorpholine gives ethyl [[1-benzyloxycarbonyl]-piperidin-4-yloxy-acetylamino]-acetate as a colourless oil. MS (ISP): 379 (M+H)+.
b) By catalytically hydrogenating the product of the preceding step followed by coupling with Z-Ala-OH in the presence of HBTU
and N-methylmorpholine there is obtained {S)-benzyl-[2-[4-[[[[ethoxycarbonyl]methylamino]carbonyl]methoxy]piperidinyl]-1-oxopropyl]carbamate in the form of a light yellow oil. MS (ISP):
20 450 (M+H)+.
c) By catalytically hydrogenating the product of the preceding step followed by coupling with 4-cyanobenzoyl chloride in the presence of sodium hydrogen carbonate there is obtained ethyl 25 {S)-[2-[1-[2-[4-cyano-benzoylamino]-propionyl]-piperidin-4-yloxy]-acetylamino]-acetate in the form of a colourless resin. MS
{ISP): 445 (M+H)+.
Exam Ip a 92 By esterifying (Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetic acid (Example 75) in 1-hexanol in the presence of conc. sulphuric acid there is obtained n-hexyl (Z)-(S)-1-[2-[4-(amino-hydroxyimino-a~ methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate in the form of cotton wool-like crystals. M.p. 169-171~C. MS (ISP):
477 {M+H)+.

76 ~13b~0 Exam Ip a 93 By reacting (Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl}-benzoylamino]-propionyl]-piperidin-4-yloxyacetic acid (Example s 75) with isobutyl (E/Z)-2-bromomethyl-pent-2-enoate (J. Anti-biotics 1992, 45, 1358-1364) in the presence of triethylamine there is obtained isobutyl (E/Z)-(S)-2-[[1-[2-[4-[{Z)-amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyJ-acetoxymethyl]pent-2-enoate in the form of colourless w crystals. M.p. 94-96~C. MS (ISP): 561 (M+H)+.
Exam Ip a 94 By reacting (Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetic acid (Example 75) with chloromethyl pivalate in the presence of triethylamine there is obtained tert-butylcarbonyloxy-methyl {Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxy]acetate in the form of colourless crystals. M.p.
~0 126~C. MS (ISP): 507 (M+H)+.
Exam Ip a 95 By reacting (Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-2~ benzoylamino]-propionyl]-piperidin-4-yloxyacetate (Example 75) with 1-iodoethyl isopropyl carbonate (J. Antibiotics 1987, 40, 370-384) in the presence of dicyclohexylamine in dimethylacet-amide there is obtained (R/S)-1-isopropoxycarbonyloxy-ethyl (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-3o propionyl]-piperidin-4-yloxy]acetate as a colourless powder. M.p.
113~C (dec.). MS (ISP): 523 (M+H)+.
Exam~he 96 By reacting (Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetic acid (Example 75) with methanol as described in Example 75 there is obtained methyl (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoyl-77 ~136!~(~3 amino]-propionyl]-piperidin-4-yloxy]acetate as a colourless powder. M.p. 177-178~C (dec.). MS (ISP): 407 (M+H)+.
Exam Ip a 97 Starting from tert-butyl (S)-1-[2-(5-cyano-pyridin-2-ylcarbonylamino)-propionylJ-piperidin-4-yloxy-acetate (J. Med.
Chem. 1992, 35, 4393-4407) there is obtained in the manner described in Example 75 ethyl (Z)-(S}-[1-[2-[5-(amino-hydroxy-w imino-methyl}-pyridin-2-ylcarbonylamino]-propionyl]-piperidin-4-yloxy]acetate in the form of colourless crystals. M.p. 148-150~C. MS (ISP): 422 (M+H)+.
Exam I
~5 Starting from tert-butyl (S)-1-[3-(4-hydroxy-phenyl)-2-[4-cyano-benzoylamino]-propionylJ-piperidin-4-yloxy-acetate (Example 56 b) there is obtained in the manner described in Example 75 ethyl (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-2o benzoylamino]-3-(4-hydroxyphenyl}-propionylJ-piperidin-4-yloxy]acetate in the form of colourless crystals. M.p. 107-110~C.
MS (ISP): 513 (M+H)+.
Exam Ip a 99 By esterifying [[1-[N2-(p-amidinobenzoyl)-L-ornithyl]-piperidin-4-ylJoxy]acetic acid (J. Med. Chem. 1992, 35, 4393-4407) with ethanol in the presence of hydrochloric acid followed by reaction of the resulting product with ethyl chloroformate as 3o described in Example 46 there is obtained ethyl (E/Z)-(S)-[1-[2 [4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-5 ethoxycarbonylamino-pentanoyl]-piperidin-4-yloxyJacetate as a colourless foam. MS (ISP): 592 (M+H)+.
Exam Ip a 100 By reacting ethyl (S)-[1-[2-[4-cyano-benzoylaminoJ-5-benzoylamino-pentanoylJ-piperidin-4-yloxy]acetate with 78 ~~~~s~o3 hydroxylamine hydrochloride as described in Example 75 there is obtained ethyl (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-5-benzoylamino-pentanoyl]-piperidin-4-yloxy]-acetate as a colourless resin. MS (ISP): 568 (M+H)+.
The starting material can be prepared as follows:
a) By reacting tert-butyl [[1-[N5-(tert-butoxycarbonyl)-L-ornithyl]-piperidin-4-yl]oxyJacetate (J. Med. Chem. 1992, 35, w 4393-4407) with 4-cyanobenzoyl chloride in a two-phase mixture of dichloromethane and saturated sodium hydrogen carbonate solution there is obtained after working up tert-butyl (S)-[1-[2-[4-cyanbenzoylamino]-5-tert-butoxycarbonylamino-pentanoyl]-piperidin-4-yloxy]acetate. MS (ISP): 559 (M+H)+.
b) Reaction of the product of the preceding step with trifluoroacetic acid in dichloromethane gives (S)-[1-[2-[4-cyanbenzoylamino]-5-amino-pentanoylJ-piperidin-4-yloxyJacetic acid as a colourless resin. MS (lSP): 403 (M+H)+.
c) By esterifying the product of the preceding step with ethanol in the presence of conc. sulphuric acid followed by reaction with benzoyl chloride in a two-phase mixture of dichloromethane and saturated sodium hydrogen carbonate 25 solution there is obtained ethyl (S)-[1-[2-[4-cyano-benzoyl-amino]-5-benzoylamino-pentanoyl]-piperidin-4-yloxy]acetate.
MS (El): 348 (M-CgH16N03)+, 188 (CgH18N03).
Exam Ip a 101 By reacting ethyl (S)-[1-[2-[4-cyano-benzoylamino]-5-ethoxycarbonylamino-pentanoyl]-piperidin-4-yloxy]acetate with hydroxylamine hydrochloride in the presence of sodium ethanolate as described in Example 75 there is obtained ethyl (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-5-ethoxy-carbonylamino-pentanoylJ-piperidin-4-yloxy]acetate as a colour-less foam. MS (ISP): 536 (M+H)+.

The starting material can be prepared as follows:
By esterifying (S)-[1-[2-[4-cyanobenzoylamino]-5-amino-pentanoyl]-piperidin-4-yloxy]acetic acid (Example 100) with s ethanol in the presence of conc. sulphuric acid followed by reaction with ethyl chloroformate in a two-phase mixture of dichloromethane and 1 N sodium hydroxide solution there is obtained ethyl (S)-[1-[2-[4-cyano-benzoylamino]-5-ethoxy-carbonylamino-pentanoyl]-piperidin-4-yloxy]acetate. MS (ISP):
w 503 (M+H)+.
Exam Ip a 102 By reacting ethyl (S)-[1-[2-[4-cyano-benzoylamino]-5-(3-butyl-ureido)-pentanoyl]-piperidin-4-yloxy]acetate with hydroxylamine hydrochloride in the presence of sodium ethanolate as described in Example 75 there is obtained ethyl (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-5-(3-butyl-ureido)-pentanoyl]-piperidin-4-yloxy]acetate as a colourless 2o foam. MS (ISP): 563 (M+H)+.
The starting material can be prepared as follows:
By esterifying (S)-[1-[2-[4-cyanobenzoylamino]-5-amino-25 pentanoyl]-piperidin-4-yloxy]acetic acid (Example 100) with ethanol in the presence of conc. sulpuric acid followed by reaction with n-butyl isocyanate in a two-phase mixture of dichloromethane and saturated sodium hydrogen carbonate solution there is obtained ethyl (S)-[1-[2-[4-cyano-benzoyl-3o amino]-5-(3-butyl-ureido)-pentanoyl]-piperidin-4-yloxy]acetate.
MS (ISP): 530 (M+H)+.
Reference Exam Ip a 103 Starting from tert-butyl 4-piperidinyloxy-acetate and (S)-2-benzyloxycarbonyl-amino-butyric acid there is obtained in the manner described in J. Med. Chem. 1992, 35, 4393-4407 the formate of (S)-[1-[2-[4-(amino-imino-methyl)-benzoylamino]-so ~1~G90~
butyryl]-piperidin-4-yloxy]acetic acid in the form of colourless crystals. M.p. 240~C {dec.). MS (ISP): 391 (M+H)+.
Reference Exam~he 104 By esterifying (S)-[1-[2-[4-(amino-imino-methyl)-benzoyl-amino]-butyryl]-piperidin-4-yloxy]acetic acid ( Example 103) in ethanol in the presence of conc. sulpuric acid there is obtained the hemisulphate of ethyl (S)-[1-[2-[4-(amino-imino-methyl)-w benzoylamino]-butyryl]-piperidin-4-yloxy]acetate in the form of colourless crystals. M.p. 256-260~C (dec.). MS (ISP): 419 (M+H)+.
Exam Ip a 105 ~5 By reacting ethyl (S)-[1-[2-[4-(amino-imino-methyl)-benzoylamino]-butyryl]-piperidin-4-yloxy]acetate(Example 104) with n-butyl chloroformate in a two-phase mixture of dichloro-methane and saturated sodium hydrogen carbonate solution there is obtained ethyl (E/Z)-(S)-[1-[2-[4-(amino-n-butoxycarbonyl-2Q imino-methyl)-benzoylamino]-butyryl]-piperidin-4-yloxy]acetate in the form of a colourless foam. MS (ISP): 519 (M+H)+.
Example 106 25 By esterifying (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-butyryl]-piperidin-4-yloxy]acetic acid in ethanol in the presence of conc. sulpuric acid there is obtained ethyl (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoyl-amino]-butyryl]-piperidin-4-yloxy]acetate in the form of a ~o colourless foam. MS (ISP): 435 (M+H)+.
The starting material can be prepared as follows:
a) Reaction of t-butyl (S)-[1-[2-amino-butanoyl]-piperidin-4-yloxy]acetate (prepared analogously as described in J. Med. Chem.
1992, 35, 4393-4407) with 4-cyanobenzoyl chloride gives tert-butyl (S)-[1-[2-[4-cyano-benzoylamino]-butyryl]-piperidin-4-yloxy]acetate. MS (El): 429 (M+).

s1 ~13~~f~
b) Reaction of the product of the preceding step with hydroxylamine hydrochloride gives tert-butyl (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-butyryl]-piperidin-s 4-yloxyJacetate. MS (ISP): 463 (M+H)+.
c) Treatment of the product of the preceding step with formic acid gives (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-butyryl]-piperidin-4-yloxy]acetic acid in the form io of a colourless foam. MS (ISP): 407 (M+H)+.
Reference Exam la a 107 Starting from tert-butyl 4-piperidinyloxy-acetate and Z-Me-Ala-OH there is obtained in the manner described in J. Med.
Chem. 1992, 35, 4393-4407 (S)-[1-[2-[[4-(amino-imino-methyl)-benzoyl]-methyl-aminoJ-propionylJ-piperidin-4-yloxy]acetic acid as a colourless resin. MS (ISP): 391 (M+H)+.
2o Exam Ip a 108 From 1-tert-butoxycarbonyl-piperidin-4-yloxy-acetic acid (Example 73) and tert-butyl 1-[[L-alanyl]-4-piperidinyloxy]-acetate (Example 66) there is obtained in the manner described in Example 73 (S)-[1-[2-(piperidin-4-yloxy-acetamido)-propionyl]-piperidin-4-yloxy]acetic acid in the form of a colourless foam.
MS (ISN): 370 (M-H)+.
Exam~he 109 By reacting ethyl (S)-3-[1-[2-[4-cyano-benzoyl-aminoJ-propionyl]-piperidin-4-yl]propionate with hydroxylamine hydrochloride as described in Example 75 there is obtained ethyl (Z)-(S)-3-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoyl-aminoJ-propionyl]-piperidin-4-yl]propionate in the form of colourless crystals. M.p. 194-195°C. [aJ p = +75.6° (c = 1, acetic acid). MS (ISP): 419 (M+H)+.

z~~~uu The starting material can be prepared as follows:
a) Esterification of 3-[piperidin-4-yl]-propionic acid (J. Org.
Chem. 1945, 10, 562) with ethanol in the presence of conc.
s sulphuric acid followed by coupling with Z-Ala-OH in the presence of 1-ethyloxycarbonyl-2-isobutyloxy-1,2-dihydroquinoline (EEDQ) in dichloromethane gives ethyl 3-[1-(2-benzyloxycarbonylamino-propionyl)-piperidin-4-yl]-propionate as a colourless oil. MS (ISP): 391 (M+H)+.
w b) By catalytically hydrogenating the product of the preceding step in ethanol in the presence of 10% Pd/C followed by reaction with 4-cyanobenzoyl chloride there is obtained ethyl (S)-3-[1-[2-[4-cyano-benzoyl-amino]-propionyl]-piperidin-4-yl]propionate in the form of colourless crystals. M.p. 108-109~C. MS (El): 385 (M)+.
Example 110 2o By catalytically hydrogenating (Z)-(S)-[[acetyl-1-[2-[4-(amino-hydroxyimino-methyl)-benzoyl-amino]-propionyl]-piperidin-4-yl]-amino]acetic acid in water/acetic acid 9:1 in the presence of 10% Pd/C there is obtained (S)-[[acetyl-1-[2-[4-(amino-imino-methyl)-benzoyl-amino]-propionyl]-piperidin-4-25 yl]-amino]acetic acid as a colourless powder. M.p. above 230~C
(dec.). MS (ISP): 418 (M+H)+.
The starting material can be prepared as follows:
3o a) Reaction of N-benzyloxycarbonyl-4-piperidone with glycine ethyl ester hydrochloride in the presence of sodium borhydride followed by acylation of the product with acetic anhydride gives ethyl acetyl-[1-[benzyloxycarbonylJ-piperidin-4-yl]-amino-acetate as a colourless oil.
b) By catalytically hydrogenating the product of the preceding step in the presence of 10% Pd/C in ethanol followed by coupling with Z-Ala-OH in the presence of 1-ethoxycarbonyl-2-ethoxy-83 ~136~Ja3 1,2-dihydroquinoline (EEDQ) there is obtained ethyl (S)-[[[acetyl-1-[2-benzyloxycarbonyl-amino]-propionyl]-piperidin-4-yl]-amino]acetate as a colourless oil. MS (ISP): 456 (M+Na)+.
s c) By catalytically hydrogenating the product of the preceding step over 10% Pd/C in ethanol in the presence of acetic acid followed by reaction with 4-cyanobenzoyl chloride in a two-phase mixture of dichloromethane and saturated sodium hydrogen carbonate solution there is obtained ethyl (S)-[[acetyl-1-[2-[4-w cyan-benzoyl-amino]-propionyl]-piperidin-4-yl]-amino]acetate as a colourless foam. MS (ISP): 428 (M+H)+.
d) By reacting the product of the preceding step with hydroxylamine hydrochloride followed by saponification with sodium hydroxide solution there is obtained (Z)-(S)-[[acetyl-1-[2-[4-(amino-hydroxyimino-methyl)-benzoyl-amino]-propionyl]-piperidin-4-ylJ-amino]acetic acid in the form of colourless crystals. M.p. above 270~C (dec.). MS (lSP): 434 (M+H)+.
2o Exam Ip a 111 In an analogous manner to that described in Example 110, there is obtained using di-tert-butyl Bicarbonate in place of acetic anhydride ethyl (Z)-(R/S)-[[tert-butoxycarbonyl-1-[2-[4-2s (amino-hydroxylmino-methyl)-benzoyl-amino]-propionyl]-piperidin-4-ylJ-amino]acetate as a colourless foam. MS (ISP):
520 (M+H)+.
Exam Ip a 112 By esterifying (Z)-[1-[2-[4-[amino-hydroxyimino-methyl]-phenylcarbamoyl]-acetyl]-piperidin-4-yloxy]-acetic acid with ethanol there is obtained ethyl (Z)-[1-[2-[4-[amino-hydroxy-imino-methyl]-phenylcarbamoyl]-acetyl]-piperidin-4-yloxy]-acetate in the form of colourless crystals. M.p. 180~C (dec.). MS
(ISP): 407 (M+H)+.
The starting material can be prepared as follows:

~1~690~

a) Reaction of 4-amino-benzonitrile with Meldrum's acid gives 2-[4-cyano-phenylcarbamoyl]-acetic acid.
s b) By coupling the product of the preceding step with tert-butyl 4-piperidinyloxy-acetate (J. Med. Chem. 1992, 35, 4393-4407) in the presence of O-benzotriazol-1-yl-N,N,N',N'-tetra-methyluronium hexafluorophosphate (HBTU) and N-methylmorpho-line there is obtained tert-butyl [1-[2-[4-cyano-phenylcarba-lo moyl]-acetyl]-piperidin-4-yloxy]-acetate. MS (El): 401 (M)+.
c) Reaction of the product of the preceding step with hydroxylaminehydrochloride as described in Example 75 gives tert-butyl (Z)-[1-[2-[4-[amino-hydroxyimino-methyl]-phenyl-carbamoyl]-acetylJ-piperidin-4-yloxyJ-acetate. M.p. 161-163~C.
MS (ISP): 435 (M+H)+.
d) By treating the product of the preceding step with formic acid there is obtained (Z)-[1-[2-[4-[amino-hydroxyimino-methyl]-2o phenylcarbamoyl]-acetyl]-piperidin-4-yloxyJ-acetic acid in the form of colourless crystals. M.p. 133-135~C. MS (ISN): 377 (M-H)+.
Exam Ip a 113 By catalyticallly hydrogenating ethyl (Z)-[1-[2-[4-[amino-hydroxyimino-methylJ-phenylcarbamoyl]-acetyl]-piperidin-4-yloxy]-acetate (Example 112) in the presence of 10% Pd/C in ethanol/acetic acid 15:1 there is obtained the acetate of ethyl [1-30 [2-[4-[amino-imino-methyl]-phenylcarbamoyl]-acetyl]-piperidin-4-yloxy]-acetate in the form of colourless crystals. M.p. 191-192~C. MS (ISP): 391 (M+H)+.
Example 114 By reacting ethyl [1-[2-[4-[amino-imino-methyl]-phenyl-carbamoyl]-acetyl]-piperidin-4-yloxy]-acetate (Example 113) with ethyl chloroformate in the presence of 0.2N sodium zi~sso~
hydroxide solution there is obtained ethyl (E/Z)-[1-[2-[4-[amino-ethoxycarbonylimino-methyl]-phenylcarbamoyl]-acetyl]-piperidin-4-yloxy]-acetate as a colourless powder. M.p. 96-102~C. MS (ISP): 463 (M+H)+.
s Example 115 By esterifying (Z)-(S)-[1-[2-[4-[amino-hydroxyimino-methyl]-benzyloxy]-propionyl]-piperidin-4-yloxy]-acetic acid w with ethanol there is obtained ethyl (Z)-(S)-[1-[2-[4-[amino-hydroxyimino-methyl]-benzyloxy]-propionyl]-piperidin-4-yloxy]-acetate in the form of colourless crystals. [a] p = -27.3 (c = 1 , ethanol). M.p. 137-138~C. MS (ISP): 408 (M+H)+.
The starting material can be prepared as follows:
a) Reaction of ethyl L-(-)-lactate with 4-bromomethyl-benzonitrile in DMF in the presence of silver oxide followed by saponification of the product with 1 N sodium hydroxide solution ~o gives (S)-2-(4-cyano-benzyloxy)-propionic acid as a light yellow oil. MS (El): 160 (M-COOH)+.
b) By reacting the product of the preceding step in the same manner as described in Example 112b), c) and d) there is obtained 25 (Z)-(S)-[1-[2-[4-[amino-hydroxyimino-methyl]-benzyloxy]-propionyl]-piper.idin-4-yloxy]-acetic acid. MS (!SP): 380 (M+H)+.
Example 116 so 170 mg of hydroxylamine hydrochloride, 10.8 ml of DMSO
and 0.71 ml of triethylamine are stirred at 20~C for 10 min., treated with 578 mg of [1-[4-(4-cyano-phenyl)-4-oxo-butyryl]-piperidin-4-yloxy]-acetate and stirred at 20~C for 20 hrs. The reaction mixture is diluted with ethyl acetate and the solution is a5 washed with water and saturated sodium chloride solution, dried and evaporated in a vacuum. Chromatography of the residue on silica gel with methylene chloride-alcohol 96:4 gives 343 mg of zi~s~o~

ethyl (E)/(Z)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, m.p. 166-167~C .
The starting material can be obtained as follows:
s a. Tert.-butyl [1-[4-(4-cyano-phenyl)-4-oxo-butyryl]-piperidin-4-yloxy]-acetate (Example 77a) is cleaved in formic acid at 50~C to [1-[4-(4-cyano-phenyl)-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid, m.p. 160-165~C.
b. In 5N ethanolic hydrochloric acid there is obtained therefrom ethyl [1-[4-(4-cyano-phenyl)-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, m.p. 79-83~C .
~5 Example 117 In analogy to Example 79, from isopropyl (RS)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate hydrochloride and di-tert.-butyl 2o dicarbonate there is obtained isopropyl (RS)-[1-[4-[4-(tert.-butoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate as a resinous foam, MS: 518 (100, M+H).
25 Example 118 279 mg of ethyl (E)/(Z)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, 2.8 ml of DMSO, 140 mg of hydroxylamine hydrochloride and 0.28 ml of triethylamine are stirred at 20~C for two days. The solution is diluted with ethyl acetate, washed with water and sodium chloride solution, dried and evaporated in a vacuum.
Chromatography of the residue on silica gel with hexane-acetone 1:2 gives 207 mg of ethyl [1-[4-[4-(E)/(Z)-(amino-hydroxyimino-methyl)-phenyl]-4-(E)/(Z)-hydroxyimino-butyryl]-piperidin-4-yloxy]-acetate as a resinous foam, MS: 421 (100, M+H).

~1~~'~0~3 Exam Ip a 119 190 mg of ethyl (E)/(Z)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-4-oxo-b utyryl]-piperidi n-4-yloxy]-acetate, s 3.8 ml of methylene chloride and 0.05 ml of acetic anhydride are stirred at 20~C for four hours. After the addition of 0.25 ml of ethanol the solution is stirred for a further 20 min. and then evaporated. From ethanol there are obtained 170 mg of ethyl (E)/(Z)-[1-[4-[4-(acetoxyimino-amino-methyl)-phenylJ-4-oxo-w butyryl]-piperidin-4-yloxy]-acetate of m.p. 134-135~C .
Example 120 180 mg of ethyl (E)/(Z)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, 3.52 ml of acetone and 0.88 ml of formic acid are stirred at 60~C for 24 hrs. The reaction mixture is evaporated to dryness and the residue is chromatographed on silica gel with methylene chloride-ethanol 97:3. 152 mg of ethyl [1-[4-[4-(5,5-dimethyl-2~ 4,5-dihydro-1,2,4-oxadiazol-3-yl)-phenylJ-4-oxo-butyrylJ-piperidin-4-yloxy]-acetate are obtained as a foam. MS: 445 (50, M+H).
Exam~he 121 In analogy to Example 116, from ethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyrylJ-piperidin-4-yloxy]-acetate there is obtained ethyl (R)-(E)/(Z)-[1-[4-[4-(amino-hydroxy-imino-methyl)-phenylJ-2-methyl-4-oxo-butyryl]-piperidin-4-3o yloxy]-acetate, m.p. 172-173~C, [a] p = +83.2 (MeOH, c = 0.5%).
The starting material can be obtained as follows:
a. By cleaving tert.-butyl 4-piperidinyloxy-acetate in formic a5 acid there is obtained 4-piperidinyloxy-acetic acid, m.p. >270~C .
b. This is converted in 5N ethanolic HCI into the hydrochloride of ethyl 4-piperidinyloxy-acetate, m.p. 104-106~C .

~13690~

c. From tert.-butyl 3-(4-cyano-phenyl)-3-oxo-propionate and isobutyl (R)-2-trifluoromethylsulphonyloxy-propionate in tetrahydrofuran in the presence of sodium bis-(trimethylsilyl)-s amide there is obtained isobutyl 2-(R)-3(R,S)-3-tert.-butoxy-carbonyl-4-(4-cyano-phenyl)-2-methyl-4-oxo-butyrate.
d. By heating to 45~C in formic acid there is obtained there-from isobutyl (R)-4-(4-cyano-phenyl)-2-methyl-4-oxo-butyrate, w [a] p = +21 c (methanol, c = 0.5%).
e. This is saponified in aqueous THF with lithium hydroxyde to (R)-4-(4-cyano-phenyl)-2-methyl-4-oxo-butyric acid. M.p. 125-126~C, [a] o = +37.4 (methanol, c = 0.5%).
f. By coupling (R)-4-(4-cyano-phenyl)-2-methyl-4-oxo-butyric acid with the hydrochloride of ethyl 4-piperidinyloxy-acetate there is obtained ethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, m.p. 97-98~C, 20 [a] p = +91.8 (methanol, c = 0.5%).
Exam Ip a 122 In analogy to Example 116, from tert.-butyl [1-[4-(4-cyano-25 phenyl)-4-oxo-butyryl]-piperidin-4-yloxy]-acetate there is obtained tert.-butyl (E)/(Z)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, m.p.
188~C.
~o Exam Ip a 123 434 mg of tert.-butyl (R)-[1-[4-[4-(tert.-butoxycarbonyl-amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate are stirred at 20~C for one hour in 4.4 ml of methylene chloride and 4.4 ml of trifluoroacetic acid.
The solvent is evaporated, the residue is dissolved in water and the solution is again evaporated. From acetonitrile there crystallize 332 mg of (R)-[1-[4-[4-(amino-imino-methyl)-~m~~o phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid trifluoroacetate (1:1 ), m.p. 212~C, [a] p = +69.0, (methanol, c =
0.5%) .
s The starting material can be prepared as follows:
a. By coupling (R)-4-(4-cyano-phenyl)-2-methyl-4-oxo-butyric acid with tert.-butyl piperidin-4-yloxy-acetate there is obtained tert.-butyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-io butyryl]-piperidin-4-yloxy]-acetate, m.p. 142~C, [a] p = +83.2 (methanol, c = 0.5%).
b. With hydrogen sulphide in pyridine/triethylamine there is obtained therefrom tert.-butyl (R)-[1-[2-methyl-4-oxo-4-(4-thiocarbamoyl-phenyl)-butyryl]-piperidin-4-yloxy]-acetate as a yellow resin, MS: 449 (63, M+H), [a] p = +76.4 (methanol, c =
0.5%).
c. This is converted firstly with methyl iodide in acetone, 2o then with ammonium acetate and acetic acid in methanol and finally with di-tert.-butyl Bicarbonate in methylene chloride and aqueous sodium carbonate solution into the starting material; MS:
532 (100, M+H), [a] p = +64.4 (methanol, c = 0.5%).
2s Exam Ip a 124 In analogy to Example 116, from ethyl (RS) [1-[4-(4-cyano-phenyl)-3-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate there is obtained ethyl (E)/(Z)-(RS)-[1-[4-[4-(amino-hydroxy-imino-methyl)-phenyl]-3-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate as a foam, MS: 420 (100, M+H).
The starting material can be obtained as follows:
a. (RS)-4-(4-Amino-phenyl)-3-methyl-4-oxo-butyric acid is converted according to Sandmeyer into (RS)-4-(4-cyano-phenyl)-3-methyl-4-oxo-butyric acid, m.p 110-113~C .

90 ~1~6~0~
b. This is coupled with the hydrochloride of ethyl 4-piperid-inyloxy-acetate to give ethyl (RS) [1-[4-(4-cyano-phenyl)-3-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate; MS: 387 (100, M+H).
s Exam Ip a 125 In analogy to Example 116, from pyridin-3-ylmethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-y1-w oxy]-acetate there is obtained pyridin-3-ylmethyl (R)-(E)/(Z)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate as a resin, MS: 483 (100, M+H), [a]2p = +69.8 (methanol, c = 0.5%).
The starting material can be obtained in the folllowing manner:
a. tert.-Butyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate is cleaved in formic acid to 20 (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid, m.p. 185-186, [a] p = +91.6 (methanol, c =
0.5%).
b. This is esterified in pyridine in the presence of DCC and 2s pTSOH with 3-pyridylmethanol to pyridin-3-ylmethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, m.p. 123-124~C, [a] p = +77.6 (methanol, c = 0.5%).
Exam Ip a 126 In analogy to Example 78, from ethyl (RS)-[1-[4-[4-(tert.-butoxycarbonylamino-imino-methyl)-phenyl]-3-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate there is obtained ethyl (RS)-[1-[4-[4-(amino-imino-methyl)-phenyl]-3-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate as the trifluoroacetate (1:1.9), MS: 404 (100, M+H).
The starting material can be obtained as follows:

a. Ethyl (RS) [1-[4-(4-cyano-phenyl)-3-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate in pyridine/triethylamine is converted with hydrogen sulphide into ethyl (RS)-[1-[3-methyl-4-s oxo-4-(4-thiocarbamoyl-phenyl)-butyryl]-piperidin-4-yloxy]-acetate. MS: 386 (0.5, M-H2S).
b. This is converted firstly with methyl iodide in acetone, then with ammonium acetate/acetic acid in methanol and finally ~o with di-tert.-butyl Bicarbonate in methylene chloride/water/
sodium carbonate into ethyl (RS)-[1-[4-[4-(tert.-butoxycarbonyl-amino-imino-methyl)-phenyl]-3-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, MS: 504 (100, M+H).
Example 127 200 mg of ethyl (RS)-[1-[4-[4-(amino-imino-methyl)-phenyl]-3-methyl-4-oxo-b utyryl]-piperidi n-4-yloxy]-acetate trifluoroacetate are stirred in 20 ml of 25 percent hydrochloric 2o acid for 4 hours. The reaction mixture is evaporated to dryness in a vacuum, the residue is taken up in water and again evaporated to dryness. There are obtained 144 mg of (RS)-[1-[4-[4-(amino-imino-methyl)-phenyl]-3-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid hydrate (2:3) hydrochloride (8:9), m.p. 173-25 175~C.
Exam Ip a 128 In analogy to Example 79, from ethyl (RS)-[1-[4-[4-(amino-3o imino-methyl)-phenyl]-3-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate trifluoroacetate with isobutyl chloroformate there is obtained ethyl (RS)-[1-[4-[4-(imino-isobutoxycarbonyl-amino-methyl)-phenyl]-3-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate as a foam, MS: 504 (100, M+H).

~13~903 Exam Ip a 129 In analogy to Example 79, from ethyl (R)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-s yloxy]-acetate acetate/iodide and ethyl chloroformate there is obtained ethyl (R)-[1-[4-[4-(ethoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate as a resin; MS: 476 (36, M+H), [a] p = +72.6 (methanol, c =
0.5%) .
w The starting material can be obtained as follows:
a. Ethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate is converted with hydrogen sulphide in pyridine and triethylamine into ethyl (R)-[1-[2-methyl-4-oxo-4-(4-thiocarbamoyl-phenyl)-butyryl]-piperidin-4-yloxy]-acetate, m.p. 171-172~C, [a] p = +88.4 (methanol, c = 0.5%).
b. By reaction with methyl iodide in acetone and subsequent 2o reaction with ammonium acetate and acetic acid in methanol there is obtained therefrom ethyl (R)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate acetate/iodide.
25 Example 130 Likewise as in Example 129 there is prepared ethyl (R)-[1-[4-[4-(imino-isobutoxycarbonylamino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate. MS: 504 (100, M+H), [a]2p = +70.25 (methanol, c = 0.4%).
Example 131 In analogy to Example 116, from pyridin-4-ylmethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate there is obtained pyridin-4-ylmethyl (R)-(E)/(Z)-[1-[4-[4-(am i no-hyd roxyi m i no-methyl)-phenyl]-2-meth yl-4-oxo-~1~690 butyryl]-piperidin-4-yloxy]-acetate as a resin, MS: 483 (100, M+H), [a] p = +71.8 (methanol, c = 0.5%).
The starting material is obtained from (R)-[1-[4-(4-cyano s phenyl)-2-methyl-4-oxo-butyrylJ-piperidin-4-yloxy]-acetic acid and 4-pyridylmethanol in pyridine in the presence of DCC and pTSOH. M.p. 99-104oC, [a] p = +69.8 (methanol, c = 0.5%).
Example 132 w In analogy to Example 116, from tent-butyl (RS)-3-[1-[(R)-4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy-acetoxymethyl]-piperidine-1-carboxylate there is obtained tert-butyl (E)- or (Z)-(RS)-3-[1-[(R)-4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxyacetoxymethyl]-piperidine-1-carboxylate; MS: 589 (100, M+H), [a] p = +60~ (methanol, c = 0.5%).
The starting material is obtained from (R)-[1-[4-(4-cyano-2o phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid and tert-butyl (RS)-3-(hydroxymethyl)-piperidine-1-carboxylate in pyridine in the presence of DCC and pTSOH. MS: 556 (100, M+H), [a] p = +56~ (methanol, c = 0.5%).
25 Exam Ip a 133 Likewise as described in Example 129 there is prepared ethyl (R)-[1-[4-[4-(imino-isopropoxycarbonylamino-methyl) phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate.
3o MS: 490 (100, M+H), [a] p = +72~ (methanol, c = 0.4%).
Example 134 In analogy to Example 78, from ethyl (R)-[1-[4-[4-(tert-butoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate there is obtained ethyl (R)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate trifluoroacetate, m.p. 186~C, [a] p = +67.4 (methanol, c = 0.5%).
The starting material is obtained from ethyl (R)-[1-[4-[4-s (amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate acetate/iodide and di-tert-butyl Bicarbonate in methylene chloride/water/Na2C03; MS: 504 (91, M+H), [a] p = +66~ (methanol, c = 0.5%).
w Exam Ip a 135 259 mg of ethyl (R)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate trifluoroacetate, 3.9 ml of DMF, 0.14 ml of triethylamine and 159 mg of 4-nitrophenoxycarbonyloxymethyl benzoate are stirred at room temperature for three hours. The reaction mixture is evaporated to dryness in a vacuum. Chromatography of the residue on silica gel with methylene chloride-isopropanol 19:1 gives 223 mg of ethyl (R)-[1-[4-[4-(benzoyloxymethoxycarbonyl-~o amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, MS: 582 (100, M+H), [a] o = +67.4 (methanol, c = 0.5%).
The 4-nitrophenoxycarbonyloxymethyl benzoate can be 2s obtained from iodomethyl 4-nitrophenyl carbonate and silver benzoate in boiling benzene.
Exam~he 136 3o Likewise as described in Example 135, from ethyl (R)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate trifluoroacetate with 4-nitrophenoxy-carbonyloxymethyl pivalate there is obtained ethyl (R)-[1-[4-[4-(imino-pivaloyloxymethoxycarbonylamino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate as a foam, MS:
562 (100, M+H), [a] o = +60.8 (methanol, c = 0.5%).

The 4-nitrophenoxycarbonyloxymethyl pivalate can be obtained from iodomethyl 4-nitrophenyl carbonate and silver pivalate in boiling benzene.
s Exam Ip a 137 In analogy to Example 116, from 2-(pyridin-2-yl)-ethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate there is obtained 2-(pyridin-2-yl)-ethyl (R)-w (E)/(Z)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, MS: 497 (100, M+H), [a] o = +670 (methanol, c = 0.5%).
The starting material is obtained from (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid and 2-(pyridin-2-yl)-ethanol in pyridine in the presence of DCC
and pTSOH. MS: 464 (100, M+H), [a] p = +72.8 (methanol, c =
0.5%) .
2o Fxam Ip a 138 In analogy to Example 116, from 2-(pyridin-3-yl)-ethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate there is obtained 2-(pyridin-3-yl)-ethyl (R)-25 (E)/(Z)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, MS: 497 (100, M+H), [a] p = +65.8 (methanol, c = 0.5%).
The starting material is obtained from (R)-[1-[4-(4-cyano-3o phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid and 2-(pyridin-3-yl)-ethanol in pyridine in the presence of DCC
and pTSOH. MS: 464 (100, M+H), [a]Zp = +70.8 (methanol, c =
0.5%).
Exam Ip a 139 In analogy to Example 78, from tert-butyl (E)- or (Z)-(RS)-3-[1-[(R)-4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-~13fi9U3 4-oxo-butyryl]-piperidin-4-yloxyacetoxymethyl]-piperidine-1-carboxylate there is obtained (RS)-piperidin-3-yl-methyl (E) or (Z)-(R)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy-acetate as the s trifluoroacetate (1:2), MS: 489 (100, M+H), [a] o = +45.75 (methanol, c = 0.4%).
Exam Ip a 140 w In analogy to Example 116, from tent-butyl (R)-4-[[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetoxymethyl]-piperidine-1-carboxylate there is obtained tert-butyl (E)- or (Z)-(R)-4-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxyacetoxy-methyl]-piperidine-1-carboxylate; MS: 589 (100, M+H), [a] p -+58.6~ (methanol, c = 0.5%).
The starting material is obtained from (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid 2o and tert-butyl 4-(hydroxymethyl)-piperidine-1-carboxylate in pyridine in the presence of DCC and pTSOH. MS: 556 (100, M+H), [a] p = + 63.3 (methanol, c = 0.3%).
Example 141 In analogy to Example 78, from tert-butyl (E)- or (Z)-(R)-4 [1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo butyryl]-piperidin-4-yloxyacetoxymethyl]-piperidine-1-carboxy late there is obtained piperidin-4-yl-methyl (E) or (Z) -(R)-[1-[4 30 [4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo butyryl]-piperidin-4-yloxy]-acetate as the trifluoroacetate (1:3), MS: 489 (100, M+H), [a] p = +41.5 (methanol, c = 0.4%).
Exam Ip a 142 In analogy to Example 116, from 2-(pyridin-4-yl)-ethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate there is obtained 2-(pyridin-4-yl)-ethyl (E)/(Z)-97 zms~o~
(R)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, MS: 497 (100, M+H), [a] o = +67~ (methanol, c = 0.5%).
s The starting material is obtained from (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid and 2-(pyridin-4-yl)-ethanol in pyridine in the presence of DCC
and pTSOH.
w Exam Ip a 143 In analogy to Example 116, from (R)-1-phenyl-ethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate there is obtained (R)-1-phenyl-ethyl (E)/(Z)-(R)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, m.p. 94~C, [a] p = + 111.6 (methanol, c = 0.5%).
The starting material is obtained from (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid and (R)-1-phenyl-ethanol in pyridine in the presence of DCC and pTSOH; [a] p = +96.6 (methanol, c = 0.5%).
Example 144 In analogy to Example 116, from (S)-1-phenyl-ethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyrylJ-piperidin-4-yloxyJ-acetate there is obtained (S)-1-phenyl-ethyl (E)/(Z)-(R)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-3o butyryl]-piperidin-4-yloxy]-acetate, m.p. 127~C, [a] o = + 32.8 (methanol, c = 0.5%).
The starting material is obtained from (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyrylJ-piperidin-4-yloxy]-acetic acid and (S)-1-phenyl-ethanol in pyridine in the presence of DCC and pTSOH; m.p. 98~C, [a] p = + 33.8 (methanol, c = 0.5%).

98 ~1~6J~
Exam I
In analogy to Example 116, from (S)-1-(pyridin-4-yl)-ethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-s 4-yloxy]-acetate there is obtained (S)-1-(pyridin-4-yl)-ethyl (E)/(Z)-{R)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, [a]p = +41~
{methanol, c = 0.5%).
~o The starting material is obtained from (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid and (S)-1-(4-pyridyl)-ethanol in pyridine in the presence of DCC
and pTSOH; m.p. 115~C, [a] p = +45.8 (methanol, c = 0.5%).
Example 146 In analogy to Example 116, from (R)-1-(pyridin-4-yl)-ethyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate there is obtained (R)-1-(pyridin-4-yl)-ethyl 20 (E)/(Z)-(R)-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, MS: 497 (100, M+H), [a] p = +96.8 (methanol, c = 0.5%).
The starting material is obtained from {R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyrylJ-piperidin-4-yloxy]-acetic acid and (R}-1-(4-pyridyl)-ethanol in pyridine in the presence of DCC
and pTSOH; m.p. 11 S~C, [a] o = +112.4 (methanol, c = 0.5%).
Example 147 In analogy to Example 116, from methyl (R)-[i-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate there is obtained methyl (E)/(Z)-(R)-[1-[4-[4-(amino-hydroxy-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-a~ yloxy]-acetate, m.p. 147-149~C, [a] p = +86~ (methanol, c = 0.5%).
The starting material is obtained from (R}-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid ~1~69U~3 and methanol in pyridine in the presence of DCC and pTSOH as the (2:1 ) adduct with dicyclohexylurea, m.p. 101 ~C, [a] p = +76.2 (methanol, c = 0.5%).
s Example 148 In analogy to Example 79, from methyl (R)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate acetate/iodide and methyl chloroformate there is w obtained methyl (R)-[1-[4-[4-(imino-methoxycarbonylamino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, MS: 448 (100, M+H), [a] p = +75.4° (methanol, c = 0.5%).
The starting material can be prepared as follows:
a. Methyl (R)-[1-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate is converted with hydrogen sulphide in pyridine and triethylamine into methyl (R)-[1-[2-methyl-4-oxo-4-(4-thiocarbamoyl-phenyl)-butyryl]-piperidin-4-2o yloxy]-acetate, m.p. 172-177~C.
b. By reaction with methyl iodide in acetone and subsequent reaction with ammonium acetate and acetic acid in methanol there is obtained therefrom methyl (R)-[1-[4-[4-(amino-imino-2s methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate acetate/iodide.
Exam lip a 149 3o In analogy to Example 79, from methyl (R)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate acetate/iodide and ethyl chloroformate there is obtained methyl (R)-[1-[4-[4-(ethoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, MS: 462 (100, M+H), [a] p = +660 (methanol, c = 0.5%).

~13b90~

Example 150 214 mg of a mixture of pyridin-3-ylmethyl (R)-[1-[4-[4-[tert-butoxycarbonylimino-(isobutoxycarbonyl-tert-butoxy-s carbonyl-amino)-methyl]-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate and pyridin-3-ylmethyl (R)-[1-[4-[4-[{di-tert-butoxycarbonyl-amino)-isobutoxycarbonylimino-methyl]-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate are stirred at 20~C for 2 hrs. in 1.2 ml of methylene w chloride and 1.2 ml of trifluoroacetic acid. The solvent is evaporated in a vacuum, the residue is dissolved in ethyl acetate and washed in succession with dilute NaHC03 solution, water and saturated NaCI solution, dried and evaporated in a vacuum. There are obtained 151 mg of pyridin-3-ylmethyl (R)-[1-[4-[4-(imino-isobutoxycarbonylamino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate as a foam, MS: 567 (100, M+H), [a] p = +610 (methanol, c = 0.2%).
The starting material can be obtained as follows:
a. Ethyl (R)-[1-[4-[4-(imino-isobutoxycarbonylamino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate is converted in acetonitrile in the presence of 4-dimethylamino-pyridine with di-tert-butyl Bicarbonate into a mixture of ethyl 25 (R)-[1-[4-[4-[tert-butoxycarbonylimino-(isobutoxycarbonyl-tert-butoxycarbonyl-amino)-methyl]-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate and ethyl (R)-[1-[4-[4-[(di-tert-butoxycarbonyl-amino)-isobutoxycarbonylimino-methyl]-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate.
b. By saponification with LiOH in aqueous THF there is obtained therefrom a mixture of (R)-[1-[4-[4-[tert-butoxy-carbonylimino-(isobutoxycarbonyl-tert-butoxycarbonyl-amino)-methyl]-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid and (R)-[1-[4-[4-[(di-tert-butoxycarbonyl-amino)-isobutoxycarbonylimino-methyl]-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetic acid.

c. This is converted in pyridine with 3-hydroxymethyl-pyridine, DCC and p-TsOH into a mixture of pyridin-3-ylmethyl (R)-[1-[4-[4-[tert-butoxycarbonylimino-(isobutoxycarbonyl-tert-butoxycarbonyl-amino)-methyl]-phenyl]-2-methyl-4-oxo-s butyryl]-piperidin-4-yloxy]-acetate and pyridin-3-ylmethyl (R)-[1-[4-[4-[(di-tert-butoxycarbonyl-amino)-isobutoxycarbonyl-imino-methyl]-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate.
w Exam Ip a 151 In analogy to Example 79, from tent-butyl (RS)-3-[[1-[(R)-4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetoxymethyl]-piperidine-1-carboxylate acetate/iodide and methyl chloroformate there is obtained tert-butyl (RS)-3-[[1-[(R)-4-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetoxymethyl]-piperidine-1-carboxylate, MS: 631 (100, M+H), [a] p = +57.2 (methanol, c = 0.5%).
The starting material can be obtained as follows:
a. tert-Butyl (RS)-3-[1-[(R)-4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy-acetoxymethyl]-piperidine-1-2~ carboxylate is converted with H2S in pyridine and triethylamine into tert-butyl (RS)-3-[[1-[(R)-2-methyl-4-oxo-4-(4-thiocarb-amoyl-phenyl)-butyryl]-piperidin-4-yloxy]-acetoxymethyl]-piperidine-1-carboxylate; MS: 590 (100, M+H), [a] p = +58.8 (methanol, c = 0.5%).
b. By reaction with methyl iodide in acetone and subsequent reaction with ammonium acetate and acetic acid in methanol there is obtained tert-butyl (RS)-3-[[1-[(R)-4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetoxymethyl]-piperidine-1-carboxylate acetate/iodide.

Exam Ip a 152 In analogy to Example 79, from tert-butyl (RS)-3-[[1-[(R)-4-[4-(amino-imino-methyl)-phenylJ-2-methyl-4-oxo-butyryl]-s piperidin-4-yloxyJacetoxymethyl]-piperidine-1-carboxylate acetate/iodide and ethyl chloroformate there is obtained tert-butyl (RS)-3-[[1-[(R)-4-[4-(ethoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyrylJ-piperidin-4-yloxy]-acetoxy-methyl]-piperidine-1-carboxylate, MS: 645 (100, M+H), [a] p = +
~0 56.2 (methanol, c = 0.5%).
Exam IR a 153 In analogy to Example 79, from ethyl (R)-[1-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate acetate/iodide and methyl chloroformate there is obtained ethyl (R)-[1-[4-[4-(imino-methoxycarbonylamino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate.
Example 154 In analogy to Example 116, from ethyl [4-[4-(4-cyano-phenyl)-4-oxo-butyryl]-phenoxy]-acetate there is obtained ethyl 25 (E)/(Z)-[4-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-4-oxo-butyryl]-phenoxyJ-acetate, m.p. 174-175~C.
Exam Ip a 155 3o In analogy to Example 116, from ethyl (RS)-[4-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyrylJ-phenoxyJ-acetate there is obtained ethyl (E)/(Z)-(RS)-[4-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-phenoxy]-acetate, m.p.
166-167~C.
The starting material can be prepared as follows:

a. From ethyl [4-(1-oxo-propyl)-phenoxy]-acetate and bromine in acetic acid there is obtained ethyl (RS)-[4-(2-bromo-1-oxo-propyl)-phenoxy]-acetate, m.p. 72-76~C.
s b. This is converted in acetone in the presence of sodium bis-(trimethylsilyl)-amide with tert.-butyl 3-(4-cyano-phenyl)-3-oxo-propionate into ethyl [4-[3-tert.-butoxycarbonyl-3-(4-cyanobenzoyl)-2-methyl-propionyl]-phenoxy]-acetate (racemic diastereomer mixture); MS: 406 (1.7, M - COOC2H5).
w c. In formic acid there is obtained therefrom ethyl (RS)-[4-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-phenoxy]-acetate, m.p. 117-123~C.
~.5 Exam Ip a 156 365 mg of ethyl [4-[4-(4-cyano-phenyl)-4-oxo-butyrylJ-phenoxy]-acetate are stirred at 20~C for 4 days in 20 ml of 0.1 N
ethanolic hydroxylamine solution. The reaction mixture is 2o concentrated in a vacuum, diluted with ethyl acetate and washed with water and saturated sodium chloride solution. The ethyl acetate solution is dried over Na2S04 and evaporated in a vacuum.
Chromatography on silica gel with CH2C12-ethanol 98:2 gives 111 mg of ethyl [4-[(E)/(Z)-4-[(E)/(Z)-4-(amino-hydroxyimino-25 methyl)-phenylJ-1-hydroxyimino-4-oxo-butyl]-phenoxy]-acetate, m.p. 180-181 ~C.
Example 157 ao 84 mg [4-[4-[4-(tert-butoxycarbonylamino-imino-methyl)-phenylJ-4-oxo-butyrylJ-phenoxy]-acetic acid and 1.7 ml of formic acid are stirred at 20~C for seven hours. The reaction mixture is evaporated, the residue is taken up in water and again evaporated.
The solid residue is suspended in water, adjusted to pH 8 with ammonia, filtered off under suction, washed with water and dried. There are obtained 50 mg of [4-[4-(amino-imino-methyl)-phenyl]-4-oxo-butyryl]-phenoxyJ-acetic acid, m.p. 284~C .

The starting material can be obtained as follows:
a. Ethyl [4-[4-[4-(amino-imino-methyl)-phenyl]-4-oxo-butyryl]-phenoxy]-acetate (1:1 ) in CH2C12 and water is converted s with di-tert-butyl Bicarbonate in the presence of Na2C03 into ethyl [4-[4-[4-(tert-butoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]-phenoxy]-acetate, m.p. 164~C.
b. By saponification with NaOH in EtOH there is obtained w therefrom [4-[4-[4-(tert-butoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]-phenoxy]-acetic acid, m.p. 284~C (dec.).
Exam Ip a 158 278 mg of hydroxylamine hydrochloride, 4 ml of DMSO and 0.56 ml of triethylamine are stirred at 20~C for 10 min. After the addition of 146 mg of ethyl [4-[4-(4-cyano-phenyl)-4-oxo-butyryl]-phenoxy]-acetate the mixture is stirred at 20~C for 3 days. The reaction mixture is diluted with ethyl acetate, ~o washed with water and sodium chloride solution, dried and evaporated. Chromatography on silica gel with CH2C12-EtOH 9:1 gives 42 mg of ethyl [4-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-1,4-bis-hydroxyimino-butyl]-phenoxy]-acetate (all oxime:
E or Z), m.p. 210~C (dec.).
Exam~he 159 In analogy to Example 116, from ethyl (RS)-[4-[2-(2-acetoxy-ethyl)-4-(4-cyano-phenyl)-4-oxo-butyryl]-phenoxy]-3o acetate there is obtained ethyl (E/Z)-(RS)-[4-[2-(2-acetoxy-ethyl)-4-[4-(amino-hydroxyimino-methyl)-phenyl]-4-oxo-butyryl]-phenoxy]-acetate as a colourless resin, MS: 485 (100, M+H).
The starting material can be prepared as follows:
a. From 4-hydroxy-1-(4-hydroxy-phenyl)-butan-1-one and ethyl bromoacetate in acetone in the presence of K2C03 there is obtained ethyl [4-(4-hydroxy-butyryl)-phenoxy]-acetate, m.p. 64-66~C.
b. With acetic anhydride in pyridine there is obtained there-s from ethyl [4-(4-acetoxy-butyryl)-phenoxy]-acetate, m.p. 94-96~C.
c. This is converted with bromine in acetic acid into ethyl [4-(4-acetoxy-2-bromo-butyryl)-phenoxy]-acetate.
w d. The latter is converted in acetone in the presence of sodium bis-(trimethylsilyl)-amide with tert.-butyl 3-(4-cyano-phenyl)-3-oxo-propionate into tert.-butyl 5-acetoxy-2-(4-cyano-benzoyl)-3-(4-ethoxycarbonylmethoxy-benzoyl)-pentanoate (racemic diastereomer mixture), MS: 478 (0.2, M-C02Et).
e. By heating in formic acid to 40~C and subsequent chroma-tography there is obtained therefrom ethyl (RS)-[4-[2-(2-acetoxy-ethyl)-4-(4-cyano-phenyl)-4-oxo-butyryl]-phenoxy]-2o acetate, m.p. 102-104~C.
Exam Ip a 160 425 mg of ethyl (RS)-[4-[4-[4-(tert-butoxycarbonylamino-25 imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-phenoxy]-acetate are heated to 40~C in 40 ml of acetic acid for 2.5 hours.
The reaction mixture is evaporated to dryness in a vacuum. From ethyl acetate-ether there are obtained 239 mg of ethyl (RS)-[4-[4-[4-(amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-so phenoxy]-acetate as the acetate (1:1), m.p. 198~C.
The starting material can be obtained as follows:
a. Ethyl (RS)-[4-[4-(4-cyano-phenyl)-2-methyl-4-oxo-butyryl]-phenoxy]-acetate is converted with H2S in pyridine and triethylamine into ethyl (RS)-[4-[2-methyl-4-oxo-4-(4-thio-carbamoyl-phenyl)-butyryl]-phenoxy]-acetate, m.p. 112-113~C.

b. This is converted firstly with methyl iodide in acetone, subsequently with ammonium acetate and acetic acid in methanol and finally with di-tert.-butyl Bicarbonate in methylene chloride/
water/Na2C03 into ethyl (RS)-[4-[4-[4-(tert-butoxycarbonyl-s amino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-phenoxy]-acetate; MS: 497 (100, M+H).
Exam Ip a 161 ~o In analogy to Example 79, from ethyl (RS)-[4-[4-[4-(amino-imino-methyl)-phenylJ-2-methyl-4-oxo-butyryl]-phenoxyJ-acetate and isobutyl chloroformate there is obtained ethyl (RS)-[4-[4-[4-(imino-isobutoxycarbonylamino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-phenoxy]-acetate as a resin. MS: 497 15 (100, M+H).
Exam~~le 162 In analogy to Example 160, from ethyl (RS)-[4-[2-(2-acetoxy-ethyl)-4-[4-(tert.-butoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyrylJ-phenoxy]-acetate there is obtained ethyl (RS)-[4-[2-(2-acetoxy-ethyl)-4-[4-(amino-imino-methyl)-phenyl]-4-oxo-butyryl]-phenoxy]-acetate as the acetate (1:1 ), m.p. 183~C.
The starting material can be obtained as follows:
a. From ethyl (RS)-[4-[2-(2-acetoxy-ethyl)-4-(4-cyano-phenyl)-4-oxo-butyryl]-phenoxy]-acetate with H2S in pyridine ~o and triethylamine there is obtained ethyl (RS)-[4-[2-(2-acetoxy-ethyl)-4-oxo-4-(4-thiocarbamoyl-phenyl)-butyrylJ-phenoxy]-acetate, MS: 508 (100, M+Na).
b. This is converted firstly with methyl iodide in acetone, subsequently with ammonium acetate and acetic acid in methanol and finally with di-tert.-butyl Bicarbonate in methylene chloride/
water/Na2C03 into ethyl (RS)-[4-[2-(2-acetoxy-ethyl)-4-[4-~13~~03 (tert.-butoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]-phenoxy]-acetate, MS: 569 (100, M+H).
Exam Ip a 163 A solution of 413 mg of ethyl (Z)-(S)-[4-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-phenoxy]-acetate and 120 mg of 4-methylmorpholine in 10 ml of dichloromethane is treated with 98 mg of triphosgene in 10 ml w of dichloromethane at O~C and stirred at room temperature for 2 h. The reaction solution is washed with water, dried and concentrated. The residue is suspended in ether and filtered off under suction. There are obtained 50 mg of ethyl (S)-[4-[2-[4-(5-Oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-benzoylamino]-~5 propionyl]-phenoxy]-acetate, MS (ISP): 440 (M+H)+.
Exam I,p a 164 A solution of 120 mg of S-ethyl-chlorothioformate in 2 ml ~o of dichloromethane is added to a suspension of 650 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoroacetate in 10 ml of dichloromethane and ml of saturated NaHC03 solution and the mixture is subsequently stirred at room temperature for 47 h. The aqueous 25 phase is extracted with dichloromethane, the dichloromethane phases are washed with water, dried and concentrated. After chromatography of the residue on silica gel (hexane/ethyl acetate 1:2) there are obtained 230 mg of ethyl (S)-[4-[2-[4-(amino-ethylsulphanylcarbonylimino-methyl)-benzoylamino]-propionyl]-3o phenoxy]-acetate, [a] p = +75.1 ~ (c = 0.7, chloroform).
Exam to a 165 A solution of 190 mg of ethyl (S)-4-[2-[4-[(amino-(2-tert-s5 butyl-dimethylsilanyloxy-ethoxycarbonylimino)-methyl]-benzoyl-amino]-propionyl]-phenoxy-acetate in 10 ml of tetrahydrofuran is treated at -20~C with 0.3 ml of tetrabutylammonium fluoride (1 M in tetrahydrofuran) and stirred at room temperature for 2 h.

The reaction mixture is diluted with ethyl acetate, extracted with water, dried and concentrated. Chromatography of the residue on silica gel (ethyl acetate/5% ethanol) gives 56 mg of ethyl (S)-[4-[2-[4-[amino-(2-hydroxy-ethoxycarbonylimino)-s methyl]-benzoylamino]-propionyl]-phenoxy]-acetate, MS (ISP):
486 (M+H)+.
The starting material can be prepared as follows:
w 98 mg of triphosgene dissolved in 4 ml of dichloromethane are added at O~C to a solution of 230 mg of 2-(tert-butyl-dimethyl-silanyloxy)-ethanol and 101 mg of 4-methylmorpholine in 8 ml of dichloromethane and the mixture is stirred at room temperature for 2 h. The reaction solution is subsequently added to a suspension of 510 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoro-acetate in 10 ml of dichloromethane and 10 ml of saturated Na2C03 solution. After stirring at room temperature for 10 min.
the phases are separated, the organic phase is washed with 2o water, dried and concentrated. Chromatography of the residue on silica gel (hexane/ethyl acetate 1:2) gives 200 mg of ethyl (S)-[4-[2-[4-[(amino-(2-tert-butyl-dimethylsilanyloxy-ethoxy-carbonylimino)-methyl]-benzoylamino]-propionyl]-phenoxy]-acetate, Rf = 0.73 (ethyl acetate).
Exam Ip a 166 In analogy to Example 165 a), from 511 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxy-3o acetate trifluoroacetate and 104 mg of 2-acetoxyethanol there are obtained after chromatography on silica gel (hexane/ethyl acetate 1:4) 75 mg of ethyl (S)-[4-[2-[4-[(2-acetoxy-ethoxy-carbonylimino)-amino-methyl]-benzoylamino]-propionyl]-phenoxy]-acetate, MS (ISP): 528 (M+H)+.

~~~b~0 Example 167 In analogy to Example 165 a), from 511 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxy-s acetate trifluoroacetate and 118 mg of 2-hydroxy-ethyl prop-ionate there are obtained after chromatography on silica gel (hexane/ethyl acetate 1:4) 175 mg of (S)-2-[[4-[2-(4-ethoxy-carbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoyl]-phenyl]-imino-methylcarbamoyloxy]-ethyl propionate, MS (ISP):
w 542 (M+H)+.
Exam Ip a 168 In analogy to Example 165 a), from 511 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxy-acetate trifluoroacetate and 132 mg of 2-hydroxy-ethyl iso-butyrate there are obtained after chromatography on silica gel (hexane/ethyl acetate 1:2) 42 mg of (S)-2-[[4-[2-(4-ethoxy-carbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoyl]-2o phenyl]-imino-methylcarbamoyloxy]-ethyl 2-methylpropionate, MS (ISP): 556 (M+H)+.
Example 169 25 In analogy to Example 165 a), from 511 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxy-acetate trifluoroacetate and 130 mg of 2-hydroxy-ethyl meth-acrylate there are obtained after chromatography an silica gel (hexane/ethyl acetate 1:3) 160 mg of (S)-2-[[4-[2-(4-ethoxy-3o carbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoyl]-phenyl]-imino-methylcarbamoyloxy]-ethyl 2-methyl-acrylate, MS
(ISP): 554 (M+H)+.
Example 170 In analogy to Example 165 a), from 511 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxy-acetate trifluoroacetate and 166 mg of 2-hydroxy-ethyl benzoate ~I~b99~

there are obtained after chromatography on silica gel (hexane/
ethyl acetate 1:2) 130 mg of (S)-2-[[4-[2-(4-ethoxycarbonyl-methoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoyl]-phenyl]-imino-methylcarbamoyloxy]-ethyl benzoate, MS (ISP): 590 (M+H)+.
Exam Ip a 171 In analogy to Example 165 a), from 511 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxy-w acetate trifluoroacetate and 224 mg of 2-hydroxy-ethyl 2-acet-oxybenzoate there are obtained after chromatography on silica gel (hexane/ethyl acetate 1:4) 210 mg of (S)-2-[[4-[2-(4-ethoxy-carbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoyl]-phenyl]-imino-methylcarbamoyloxy]-ethyl 2-acetoxybenzoate, MS
i.5 (ISP): 648 (M+H)+.
Example 172 In analogy to Example 165 a), from 511 mg of ethyl (S)-4-[2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxy-acetate trifluoroacetate and 103 mg of acetic acid 2-hydroxy-ethyl amide there are obtained after chromatography an silica gel (ethyl acetate) 54 mg of ethyl (S)-[4-[2-[4-[(2-acetylamino-ethoxycarbonylimino)-amino-methyl]-benzoylamino]-propionyl]-25 phenoxy]-acetate, MS (ISP): 527 (M+H)+.
Exam Ip a 173 A suspension of 263 mg of ethyl (S)-4-[2-[4-(amino-imino-3o methyl)-benzoylamino]-propionyl]-phenoxyacetate trifluoro-acetate, 217 mg of 4-nitro-phenoxycarbonyloxymethyl acetate and 165 ml of 4-methylmorpholine in 5 ml of dichloromethane and 5 ml of tetrahydrofuran is stirred at room temperature for 16 h. Concentration of the reaction mixture and chromatography of the residue on silica gel (hexane/ethyl acetate 1:4) gives 193 mg of ethyl (S)-[4-[2-[4-(acetoxymethoxycarbonylimino-amino-methyl)-benzoylamino]-propionyl]-phenoxy]-acetate, [a] p = +65.0 (c = 0.6, Chloroform).

Exam Ip a 174 In analogy to Example 165 a), from 250 mg of ethyl (S)-4-s [2-[4-(amino-imino-methyl)-benzoylamino]-propionyl]-phenoxy-acetate trifluoroacetate and 104 mg of ethyl (S)-lactate there are obtained after chromatography on silica gel (hexane/ ethyl acetate 1:2) 160 mg of methyl (S)-2-[[4-[(S)-2-(4-ethoxy-carbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoyl]-w phenyl]-imino-methylcarbamoyloxy]-propionate, MS (ISP): 528 (M+H)+.
Exam Ip a 175 Analogously to Example 31, from 380 mg of methyl 1-(8-cyano-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-ylacetyl)-piperidin-4-yloxyacetate there are obtained after reaction with ammonium acetate, concentration of the reaction solution and precipitation of the product with ether 130 mg of methyl 1-[8-~o (amino-imino-methyl)-5-oxo-2,3,4,5-tetrahydro-1,4-benzox-azepin-4-ylacetyl]-piperidin-4-yloxyacetate acetate, MS (ISP):
419 (M+H)+.
The starting material can be prepared as follows:
a) A solution of 1.63 g of 4-cyanosalicylic acid and 1.26 g of N-hydroxysuccinimide in 25 ml of dichloromethane and 25 ml of dimethylformamide is treated at O~C with 2.06 g of dicyclo-hexylcarbodiimide and stirred at O~C for 16 h. The precipitate is so filtered off under suction. 1.4 ml of triethylamine and 1.38 g of N-(2-hydroxyethyl)glycine tert-butyl ester (EP 288256) are added to the mother liquor and the mixture is stirred at room temper-ature for 1 h. Concentration of the reaction solution and chroma-tography of the residue on silica gel (hexane/ethyl acetate 1:2) gives 475 mg of tert-butyl [(4-cyano-2-hydroxy-benzoyl)-(2-hydroxy-ethyl)-amino]-acetate, MS (ISP): 321 (M+H)+.

Z13e~0~

b) 378 mg of diethyl azodicarboxylate in 5 ml of tetra-hydrofuran are added dropwise at O~C to a solution of 464 mg of tert-butyl [(4-cyano-2-hydroxy-benzoyl)-(2-hydroxy-ethyl)-amino]-acetate and 570 mg of triphenylphosphine in 10 ml of s tetrahydrofuran and the mixture is stirred at room temperature for 1 h. Concentration of the solution and chromatography of the residue on silica gel (hexane/ethyl acetate 2:1 ) gives 300 mg of tert-butyl 8-cyano-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl-acetate, MS (El): 246 (M-56).
w c) Cleavage of the ester group in 300 mg of the preceding step product in 4 ml of dichloromethane and 2 ml of trifluoroacetic acid is effected at room temperature. The solution is concen-trated, the residue is filtered off under suction with ether, dissolved in 50 ml of dimethylformamide and treated with 292 mg of 4-methylmorpholine, 597 mg of O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate and 330 mg of methyl 4-piperidinoxyacetate hydrochloride. After stirring at room temperature for 16 h. the solution is concentrated, the 2o residue is taken up in ethyl acetate, the organic phase is washed with 1 M KHS04 solution and sat. NaCI solution, dried and concen-trated. Chromatography of the residue on silica gel (ethyl acetate) gives 400 mg of methyl 1-(8-cyano-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-ylacetyl)-piperidin-4-yloxy-25 acetate, MS (ISP): 402 (M+H)+.
Exam Ip a 176 A) By treating 350 mg of ethyl (S)-[1-[2-(8-cyano-5-oxo-30 2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl)-propionyl]-piperidin-4-yloxy]-acetate with hydrogen sulphide, methyl iodide and ammonium acetate there are obtained, after chromatography on silylated silica gel RP18, 163 mg of ethyl (S)-[1-[2-[8-(amino-imino-methyl)-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]-propionyl]-piperidin-4-yloxy]-acetate trifluoroacetate, MS
(ISP): 447 (M+H)+.

B) 29 mg of ethyl chloroformate are added to a suspension of 135 mg of ethyl (S)-[1-[2-[8-(amino-imino-methyl)-5-oxo-2,3, 4,5-tetrahydro-1 ,4-benzoxazepin-4-yl]-propionyl]-piperidin-4-yloxy]-acetate trifluoroacetate in 3 ml of dichloromethane and s 3 ml of saturated NaHC03 solution and the mixture is subse-quently stirred at room temperature for 5 min. The aqueous phase is extracted with dichloromethane, the dichloromethane phases are washed with water, dried and concentrated. After chromatography of the residue on silica gel (ethyl acetate) there w are obtained 86 mg of ethyl {S)-[1-[2-[8-(amino-ethoxycarbonyl-imino-methyl)-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]-propionyl]-piperidin-4-yloxy]-acetate, MS (/SP): 519 (M+H)+.
The starting material can be prepared as follows:
a) A solution of 1 g of tert-butyl D-lactate and 0.95 ml of triethylamine in 10 ml of dichloromethane is treated at O~C with 1.93 g of trifluoromethanesulphonic anhydride, stirred at O~C for 1 h., again treated with 0.95 ml of triethylamine and with ~0 1.43 g of O-tert-butyl-dimethylsilyl-aminoethanol. After stirring at room temperature for 2 h. the reaction mixture is concentrated and the residue is chromatographed on silica gel (hexane/ethyl acetate 2:1 ). There are obtained 990 mg of tert-butyl (S)-2-[2-(tert-butyl-dimethyl-silanyloxy)-ethylamino]-25 propionate, MS {El): 246 (M-57).
b) In analogy to Example 175 a), 5 g of 4-cyanosalicylic acid are reacted with 4.36 g of the preceding step product and the evaporation residue is chromatographed on silica get (hexane/
3o tert-butyl methyl ether 2:1 ). There are obtained 1.19 g of tert-butyl (S)-2-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-{4-cyano-2-hydroxy-benzoyl)-amino]-propionate, MS (El): 449 (M+H)+.
c) A solution of 1.19 g of the preceding step product in 25 ml of ether is treated with 2.7 ml of tetrabutylammonium fluoride (1 M in tetrahydrofuran), stirred at room temperature for 16 h., washed with 1 M H3P04 solution and sat. NaCI solution, dried and concentrated. Chromatography of the residue on silica gel (ethyl 114 ~1~~1~~~
acetate) gives 704 mg of tert-butyl (S)-2-[(4-cyano-2-hydroxy-benzoyl)-(2-hydroxy-ethyl)-amino]-propionate, MS (ISP): 335 (M+H)+.
s d) Reaction of 669 mg of the preceding step product in analogy to Example 175 b) gives, after chromatography on silica gel (hexane/ethyl acetate 2:1 ), 345 mg of tert-butyl (S)-2-(8-cyano-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl)-propionate, MS (El): 260 (M-56).
e) In analogy to Example 175 c), 340 mg of the preceding step product are reacted with 243 mg of ethyl 4-piperidinoxyacetate.
After chromatography of the residue on silica gel (hexane/ethyl acetate 1:3) there are obtained 365 mg of ethyl (S)-[1-[2-(8-cyano-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl)-propionyl]-piperidin-4-yloxy]-acetate, [a] p = -18.8 (c = 0.6, Chloroform).
Example 177 Reaction of 80 mg of ethyl (R,S)-4-[2-[4-(amino-imino-methyl)-2-methoxy-benzoylamino]-propionyl]-phenoxyacetate hydroiodide with 22 mg of ethyl chloroformate according to Example 176 B) gives, after chromatography on silica gel 25 (hexane/ethyl acetate 1:3), 58 mg of ethyl (R,S)-[4-[2-[4-(amino-ethoxycarbonylimino-methyl)-2-methoxy-benzoylamino]-propionyl]-phenoxy]-acetate as a colourless oil, MS (ISP): 500 (M+H)+.
3o The starting material can be prepared as follows:
a) A solution of 1.92 g of 4-cyanosalicylic acid and 1.49 g of N-hydroxysuccinimide in 30 ml of dichloromethane and 30 ml of dimethylformamide is treated at O~C with 2.43 g of dicyclo-hexylcarbodiimide and stirred at -14~C to 15~C for 16 h. The precipitate is filtered off under suction and the mother liquor containing the 4-cyanosalicylic acid hydroxysuccinimide ester is used directly in the next step.

_ 115 b) Cleavage of the BOC group in 4.1 g of ethyl (S)-4-(2-tert-butoxycarbonylamino-propionyl)-phenoxy acetate (Example 23 a) is effected with 1.75 ml of trimethylsilyl iodide at O~C in 40 ml of dichloromethane. After the addition of 8 ml of 4N HCI in s dioxan the reaction solution is concentrated, the residue is dissolved in 40 ml of tetrahydrofuran and added together with 2.6 ml of 4-methylmorpholine to the mother liquor which is obtained in the preceding step and which contains the 4-cyano-salicylic acid hydroxysuccinimide ester. After 16 hours at room w temperature the mixture is concentrated and the residue is chromatographed on silica gel (hexane/ethyl acetate 3:1 ). There are obtained 2.98 g of ethyl (S)-[4-[2-(4-cyano-2-hydroxy-benzoylamino)-propionyl]-phenoxy]-acetate, MS (ISP): 397 (M+H)+.
c) Alkylation of 792 mg of the preceding step product with 0.19 ml of methyl iodide in the presence of 830 mg of potassium carbonate in 20 ml of dimethylformamide for 2 h. at room temp-erature gives, after concentration of the solution and chroma-tography of the residue on silica gel (hexane/ethyl acetate 3:1 ), 20 580 mg of ethyl (R,S)-[4-[2-(4-cyano-2-methoxy-benzoylamino)-propionyl]-phenoxy]-acetate, MS (ISP): 411 (M+H)+.
d) In analogy to Example 31, 290 mg of the preceding step product are reacted with hydrogen sulphide, methyl iodide and 25 ammonium acetate, the reaction solution is concentrated to half and the product is precipitated by the addition of ether. There are obtained 183 mg of ethyl (R,S)-[4-[2-[4-(amino-imino-methyl)-2-methoxy-benzoylamino]-propionyl]-phenoxy]-acetate hydro-iodide, MS (ISP): 428 (M+H)+.
Example 178 Reaction of 1.4 g of ethyl (R,S)-[4-[2-(4-cyano-phenyl)-1-methyl-2-oxo-ethylcarbamoyl]-phenoxy]-acetate with hydrogen sulphide, methyl iodide and ammonium acetate in analogy to Example 31 gives, after chromatography of the evaporation residue on silylated silica gel RP 18 (water/tetrahydrofuran gradient), 410 mg of ethyl (R,S)-[4-[2-[4-(amino-imino-methyl)-116 i~~~~o~
phenylJ-1-methyl-2-oxo-ethylcarbamoyl]-phenoxyJ-acetate hydroiodide, MS (ISP): 398 (M+H)+.
The starting material can be prepared as follows:
s a) A solution of 10.92 g of 4-bromobenzonitrile in 80 ml of tetrahydrofuran is added dropwise at -78~C to 37.5 ml of 1.6 N
n-butyllithium. The resulting suspension is stirred at -78~ for 30 min., added at the same temperature to 4.65 g of (S)-2-tert-~o butoxycarbonylamino-N-methoxy-N-methyl-propionamide in 80 ml of tetrahydrofuran and stirred at -78~C for 1 h. The red reaction solution is poured into 1 M H3P04. Extraction with ether, washing of the organic phases with sat. NaCI solution, drying and concentration of the solution gives a residue which, after chrom-atography on silica gel, leads to 3.68 g of tert-butyl (S)-2-(4-cyano-phenyl)-1-methyl-2-oxo-ethylcarbamate, [aJ p = -57~ (c =
1, chloroform).
b) Cleavage of the BOC group in 1.92 g of the preceding step 2o product is effected analogously to Example 177 b). The resulting amine hydrochloride is added at O~C to 1.89 g 4-tert-butyl-dimethyl-silanyloxy-benzoyl chloride in 20 ml of pyridine and the mixture is stirred at room temperature for 16 h.
Concentration of the solution and chromatography of the residue 25 on silica gel (hexane/ ethyl acetate 2:1 ) gives 1.84 g of (S)-4-(tert-butyl-dimethyl-silanyloxy)-N-[2-(4-cyano-phenyl)-1-methyl-2-oxo-ethylJ-benzamide, [aJ p = +45.9 (c = 0.7, chloroform).
3o c) Deprotection of 1.81 g of the preceding step product gives 1.4 g of (R,S)-N-[2-(4-cyano-phenyl)-1-methyl-2-oxo-ethyl-4-hydroxy-benzamide, MS (ISP): 293 (M-H)+.
d) Alkylation of 1.4 g of the preceding step product with a~ 0.65 ml of ethyl bromoacetate in the presence of K2C03 in dimethylformamide at room temperature for 2 h. gives, after removal of the solvent and chromatography on silica gel (hexane/
ethyl acetate 1:1 ), 1.23 g of ethyl (R,S)-[4-[2-(4-cyano-phenyl)-1-methyl-2-oxo-ethylcarbamoyl]-phenoxy]-acetate, MS (ISP): 381 (M+H)+.
Example 179 A solution of 50 mg of ethyl (R,S)-[4-[2-[4-[amino-(tert-butyl-dimethyl-silanyloxyimino)-methyl]-phenyl]-1-methyl-2-oxo-ethylcarbamoyl]-phenoxy]-acetate in 1 ml of ether is stirred at O~C for 1 h. with 0.1 ml of tetrabutylammonium fluoride (1 M
~o in tetrahydrofuran), concentrated and the residue is chromato-graphed on silica gel (hexane/ethyl acetate 1:2). There are obtained 11 mg of ethyl (R,S)-[4-[2-[4-(amino-hydroxyimino-methyl)-phenyl]-1-methyl-2-oxo-ethylcarbamoyl]-phenoxy]-acetate, MS {ISP): 414 (M+H)+.
The starting material can be prepared as follows:
In analogy to Example 31, 0.6 g of ethyl (R,S)-[4-[2-(4-cyano-phenyl)-1-methyl-2-oxo-ethylcarbamoyl]-phenoxy]-2a acetate is reacted with hydrogen sulphide and methyl iodide.
147 mg of O-tert-butyl-dimethyl-silyl-hydroxylamine are stirred at room temperature for 2 h. with the resulting methylthioimine in 6 ml of tetrahydrofuran. Chromatography of the residue on silica gel (hexane/ethyl acetate 3:2) leads to 25 50 mg of ethyl (R,S)-[4-[2-[4-[amino-(tert-butyl-dimethyl-silanyloxyimino)-methyl]-phenyl]-1-methyl-2-oxo-ethyl-carbamoyl]-phenoxy]-acetate, MS {ISP): 414 (M-113).
Examlhe 180 From 743 mg of ethyl (S)-4-(2-piperidin-4-yloxyacetyl-amino-propionyl)-phenoxy-acetate hydrochloride in 20 ml of ethanol and 20 ml of acrylonitrile there are obtained after 5 days at 80~C and after chromatography of the evaporation residue on silica gel (dichloromethane/5% methanol) 250 mg of ethyl (S)-[4-[2-[1-(2-cyano-ethyl)-piperidin-4-yloxyacetylamino]-propionyl]-phenoxy]-acetate, MS {ISP): 446 {M+H)+.

A solution of 250 mg of ethyl (S)-[4-[2-[1-(2-cyano-ethyl)-piperidin-4-yloxyacetylamino]-propionylJ-phenoxy]-acetate in 10 ml of dichloromethane is treated at O~C with 128 mg of meta-chloroperbenzoic acid and stirred at O~C for 1 h.
s The reaction solution is washed with sat. NaHC03 solution and sat. NaCI solution, dried and concentrated. Chromatography of the residue on silica gel gives 140 mg of ethyl (S)-[4-[2-(1-hydroxy-piperidin-4-yloxyacetylamino)-propionyl]-phenoxy]-acetate, MS
(ISP): 409 (M+H)+.
w Exam Ip a 181 A solution of 285 mg of ethyl (S)-4-(2-piperidin-4-yloxy-acetylamino-propionyl)-phenoxy acetate, 0.11 ml of 4-methyl-morpholine and 217 mg of 4-nitro-phenoxycarbonyloxymethyl acetate is stirred at room temperature for 5 h., concentrated and the residue is chromatographed on silica gel (hexane/ethyl acetate 1:2). There are obtained 205 mg of acetoxymethyl (S)-4-[2-(4-ethoxycarbonylmethoxy-phenyl)-1-methyl-2-oxo-ethyl-~o carbamoylmethoxy]-piperidine-1-carboxylate, [a] p = +23.7 (c =
0.35, chloroform).
example 182 25 Cleavage of the BOC protecting group in 3.45 g of tert-butyl (S)-4-[1-tert-butoxymethyl-2-(4-ethoxycarbonylmethoxy-phenyl)-2-oxo-ethylcarbamoylmethoxy]-piperidine-1-carboxylate in 60 ml of dichloromethane and 30 ml of trifluoroacetic acid gives, after concentration of the solvent and chromatography of ~o the residue on silylated silica gel RP 18 (water/tetrahydrofuran gradient), 1.9 g of ethyl (S)-[4-[3-hydroxy-2-(2-piperidin-4-yloxy-acetylamino)-propionyl]-phenoxy]-acetate trifluoroacetate, MS (ISP): 409 (M+H)+.
The starting material can be prepared as follows:
a) In analogy to Example 177 b) the BOC group is cleaved in 3.5 g of ethyl (S)-4-[3-tert-butoxy-2-tert-butoxycarbonyl-amino-propionyl]-phenoxy acetate (Example 7 d) and the resulting amine is stirred at room temperature for 16 h. with 2.57 g of 1-tert-butoxycarbonylpiperidin-4-yl-oxyacetic acid in the presence of 2.95 g of TPTU and 1.82 ml of 4-methylmorpholine in 60 ml s of dichloromethane. After removal of the solvent and chroma-tography of the residue on silica gel (hexane/ethyl acetate 1:2) there are obtained 3.5 g of tert-butyl (S)-4-[1-tert-butoxy-methyl-2-(4-ethoxycarbonylmethoxy-phenyl)-2-oxo-ethyl-carbamoylmethoxy]-piperidine-1-carboxylate as a yellow oil, MS
w (ISP): 565 (M+H)+.
Exam Ip a 183 Analogously to Example 181, 480 mg of ethyl (S)-[4-[3-hydroxy-2-(2-piperidin-4-yloxy-acetylamino)-propionyl]-phenoxy]-acetate are reacted with 367 mg of 4-nitro-phenoxy-carbonyloxymethyl acetate and the residue is chromatographed on silica gel (ethyl acetate). There are obtained 161 mg of ethyl (S)-[4-[2-[(1-Acetoxymethoxycarbonyl-piperidin-4-yloxy)-2o acetylamino]-3-hydroxy-propionyl]-phenoxy] acetate as a colourless oil, MS (ISP): 525 (M+H)+.
Exam Ip a 184 25 A solution of 800 mg of tert-butyl (S)-4-[[2-(4-ethoxy-carbonylmethoxy-phenyl)-1-methyl-2-oxo-ethyl]-methyl-carbamoylmethoxy]-piperidine-1-carboxylate in 10 ml of dichloromethane and 5 ml of trifluoroacetic acid is stirred at room temperature for 1 h. and concentrated. Chromatography of ~o the residue on silylated silica gel RP 18 (water/tetrahydrofuran gradient) gives 509 mg of ethyl (S)-4-[2-[methyl-(piperidin-4-yloxy-acetyl)-amino]-propionyl]-phenoxy]-acetate trifluoro-acetate, MS (ISP): 407 (M+H)+.
The starting material can be prepared as follows:
a) Coupling of 5 g of (S)-N-tert-butoxycarbonyl-N-methyl-2-amino-propionic acid with 2.88 g of N,O-dimethylhydroxylamine ,20 zi3soo~
hydrochloride in 100 ml of dichloromethane in the presence of 8.77 g of TPTU and 5.96 ml of 4-methylmorpholine gives, after stirring at room temperature for 16 h., concentration of the reaction solution and chromatography of the residue on silica gel s (hexane/ethyl acetate 2:1 ), 4.43 g of tert-butyl (S)-[1-(methoxy-methyl-carbamoyl)-ethyl]-methylcarbamate, [a]p = -62.3 (c = 1, chloroform).
b) After reacting 4.1 g of the preceding step product with p-w bromo-tert-butyl-dimethylsilylphenol analogously to Example 3 a) and chromatography of the residue on silica gel (hexane/ethyl acetate 95:5) there are obtained 2.82 g of tert-butyl (S)-[2-(4-tert-butyl-dimethyl-silanyloxy)-phenyl]-1-methyl-2-oxo-ethyl]-methylcarbamate as a colourless oil, [a] p = -127.0 (c = 0.5, chloroform).
c) Deprotection of 2.2 g of the preceding step product analogously to Example 3 b) gives 1.41 g of tert-butyl (S)-[2-(4-hydroxy-phenyl)-1-methyl-2-oxo-ethyl]-methylcarbamate, 20 [a] p = -179.4 (c = 0.7, chloroform).
d) Alkylation of 615 mg of the preceding step product analo-gously to Example 3 c) and chromatogaphy of the evaporation residue on silica gel (hexane/ethyl acetate 3:1 ) gives 674 mg of 25 ethyl (S)-[4-[2-(tert-butoxycarbonyl-methyl-amino)-propionyl]-phenoxy]-acetate, [a] p = -135.0 (c = 0.5, chloroform).
e) Cleavage of the BOC protecting group in 810 mg of the preceding step product is effected analogously to Example 177 b) so at -78~C. The resulting amine is stirred at room temperature for 20 h. with 498 mg of 1-tert-butoxycarbonylpiperidin-4-yl-oxyacetic acid in the presence of 570 mg of TPTU and 0.39 ml of 4-methylmorpholine in 30 ml of dichloromethane. After removal of the solvent and chromatography of the residue on silica gel there are obtained 890 mg of tert-butyl (S)-4-[[2-(4-ethoxy-carbonylmethoxy-phenyl)-1-methyl-2-oxo-ethyl]-methyl-carbamoylmethoxy]-piperidin-1-carboxylate as a colourless oil, MS (ISP): 507 (M+H)+.

Exam Ip a 185 A solution of 850 mg of tert-butyl (S)-4-[2-[2-(4-s ethoxycarbonylmethoxy-phenyl)-1-methyl-2-oxo-ethyl-carbamoyl]-ethyl]-piperidine-1-carboxylate in 5 ml of dichloro-methane and 2.5 ml of trifluoroacetic acid is stirred at room temperature for 1 h. and concentrated. There are obtained 760 mg of ethyl (S)-[4-[2-(3-piperidin-4-yl-propionylamino)-w propionyl]-phenoxy]-acetate trifluoroacetate as a colourless oil, MS (ISP): 391 (M+H)+.
The starting material can be prepared as follows:
Cleavage of the BOC protecting group in 740 mg of ethyl (S)-4-(2-tert-butoxycarbonylamino-propionyl)-phenoxyacetate is effected analogously to Example 177 b). The resulting amine is stirred at room temperature for 16 h. with 500 mg of 1-tert-butoxycarbonylpiperidin-4-yl-propionic acid in the presence of 20 570 mg of TPTU and 0.46 ml of 4-methylmorpholine in 10 ml of dichloromethane. After removal of the solvent and chromatog-raphy of the residue on silica gel (hexane/ethyl acetate 2:3) there are obtained 890 mg of tert-butyl (S)-4-[2-[2-(4-ethoxy-carbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoyl]-25 ethyl]-piperidine-1-carboxylate as a yellow oil, MS (ISP): 491 (M+H)+.
ExamQle 186 3o Starting from 300 mg of ethyl (S)-[4-[2-(3-piperidin-4-yl-propionylamino)-propionyl]-phenoxy]-acetate trifluoroacetate there are obtained, analogously to Example 181 and after chroma-tography on silica gel (hexane/ethyl acetate 1:2) 140 mg of ethyl (S)-4-[2-[3-(1-acetoxymethoxycarbonyl-piperidin-4-yl)-3s propionylamino]-propionyl]-phenoxy]-acetate, MS (ISP): 507 (M+H)+.

Example 187 A solution of 100 mg of tert-butyl (R)-3-[(S)-1-(4-ethoxy-carbonylmethoxy-benzoyl)-ethylcarbamoyl methoxy]-pyrrolidine-s 1-carboxylate in 2 ml of dichloromethane and 1 ml of trifluoro-acetic acid is stirred at room temperature for 2 h., concentrated and the residue is chromatographed on silylated silica gel RP 18 (water/tetrahydrofuran gradient). There are obtained 70 mg of ethyl [4-[(S)-2-[(R)-2-pyrrolidin-3-yloxy-acetylamino]-~o propionyl]-phenoxy]-acetate trifluoroacetate, MS (ISP): 379 (M+H)+.
The starting material can be prepared as follows:
a) The phase transer reaction of 4.1 g of tert-butyl (R)-3-hydroxy-pyrrolidine-1-carboxylate with 3.85 ml of tert-butyl bromoacetate in 50 ml of toluene and 50 ml of 50% NaOH in the presence of 500 mg of tetrabutylammonium hydrogen sulphate has finished after 1 h. Washing of the organic phase with sat.
2o NaCI solution, drying and concentration gives a residue which, after chromatogaphy on silica gel (hexane/ethyl acetate 3:1 ), leads to 4.98 g of tert-butyl (R)-3-tert-butoxycarbonylmethoxy-pyrrolidine-1-carboxylate, MS (ISP): 302 (M+H)+.
2s b) A solution of 4.95 g of the preceding step product in 50 ml of dichloromethane and 25 ml of trifluoroacetic acid is stirred at room temperature for 3 h. and concentrated. The residue is dissolved in 40 ml of dioxan and 40 ml of 1 N NaOH, treated at room temperature with 4.3 g of di-tert-butyl Bicarbonate in 30 40 ml of dioxan and stirred for 1.5 h. The reaction mixture is diluted with ether, the organic phase is washed with 1 N NaOH and the aqueous phase is acidified with 3N HCI. Extraction of the aqueous phase with ether, washing, drying and concentration of the ether phase gives 0.72 g of tert-butyl (R)-3-carboxymethyl-pyrrolidine-1-carboxylate. 360 mg of this are reacted with ethyl (S)-4-(2-tert-butoxycarbonylamino-propionyl) phenoxy-acetate, deprotected according to Example 177 b), in 15 ml of dichloromethane in the presence of 446 mg of TPTU and 0.33 ml 123 r~~.~,~, of 4-methylmorpholine. Concentration of the reaction solution and chromatography of the residue gives 100 mg of tert-butyl (R)-3-[(S)-1-(4-ethoxycarbonylmethoxy-benzoyl)-ethyl-carbamoylmethoxy]-pyrrolidine-1-carboxylate, MS (ISP): 479 s (M+H)+.
Exama~le 188 A solution of 290 mg of tert-butyl (S)-6-[2-(4-ethoxy-w carbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoyl]-1,2,3,4-tetrahydro-isoquinoline-2-carboxylate in 4 ml of dichloromethane and 2 ml of trifluoroacetic acid is stirred at room temperature for 1 h., concentrated and the residue is chromatographed on silylated silica gel RP 18 (water/tetra-hydrofuran gradient). There are obtained 174 mg of ethyl (S)-[4-[2-(1,2,3,4-tetrahydro-isoquinoline-6-ylcarbonylamino)-propionyl]-phenoxy]-acetate trifluoroacetate, [a] o = +51.7 (c =
0.6, DMSO).
2o The starting material can be prepared as follows:
a) 1.38 g of di-tert-butyl Bicarbonate in 10 ml of dioxan and ml of 1 N NaOH are added simultaneously at O~C to a solution of 1.46 g of 6-hydroxy-1,2,3,4-tetrahydro-isoquinoline hydro-2s bromide in 10 ml of dioxan and 2 ml of 1 N NaOH. After stirring at room temperature for 3 h. the reaction mixture is adjusted to pH 5 with 1 N HCI, extracted with ether, the ether phases are washed with sat. NaCI solution, dried and concentrated. Chroma-tography of the residue on silica gel gives 1.07 g of tert-butyl 6-3o hydroxy-1,2,3,4-tetrahydro-isoquinoline-2-carboxylate, MS (El):
192 (M-57).
b) At -15~C a solution of 918 mg of the preceding step product in 10 ml dichloromethane is treated with 1.2 ml of triethylamine and subsequently with 0.7 ml of trifluoro-methanesulphonic anhydride and stirred at room temperature for 2 h. The precipitate is filtered off under suction, the filtrate is concentrated and the residue is chromatographed on silica gel ~I~b~~~

(hexane/ethyl acetate 7:1 ). There are obtained 1.02 g of tert-butyl 6-trifluoromethylsulphonyloxy-1,2,3,4-tetrahydro-isoquinoline-2-carboxylate, MS (El): 324 (M-57).
s c) 950 mg of the preceding step product are reacted at 80~C
for 2 h. with CO in the presence of 17 mg of palladium acetate, 32 mg of 1,3-bis-(diphenylphosphino)-propane and 0.4 ml of triethylamine in 4 ml of DMSO and 2.6 ml of methanol. The reaction solution is diluted with sat. NaCI solution, extracted ~o with ether, the ether phases are washed with sat. NaCI solution, dried and concentrated. Chromatography of the residue on silica gel gives 443 mg of 2-tert-butyl 6-methyl 1,2,3,4-tetrahydro-isoquinoline-2,6-dicarboxylate, MS (ISP): 292 (M+H)+.
d) Saponification of 387 mg of the preceding step product with 213 mg of NaOH in 9 ml of methanol and 1 ml of water is effected at room temperature for 6 h. The reaction solution is concentrated and diluted with water. The aqueous phase is extracted with ether, adjusted to pH 5 with 1 N HCI and the 2o precipitate is filtered off under suction. After washing the crystals with water and drying there are obtained 274 mg of 1,2,3,4-tetrahydro-isoquinoline-2,6-dicarboxylic acid 2-tert-butyl ester, MS (El}: 220 (M-57).
25 e) Cleavage of the BOC protecting group in 313 mg of ethyl (S)-4-(2-test-butoxycarbonylamino-propionyl)-phenoxy acetate analogously to Example 177 b) gives the amine. This is stirred at room temperature for 48 h. with 247 mg of the preceding step product, 264 mg of TPTU and 0.20 ml of 4-methylmorpholine in 30 10 ml of dichloromethane. After chromatography of the evapor-ation residue on silica gel (hexane/ethyl acetate 1:1 } there are obtained 444 mg of tert-butyl (S)-6-[2-(4-ethoxycarbonyl-methoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoyl~-1,2,3,4-tetrahydro-isoquinoline-2-carboxylate, [a] p = + 51.3 (c = 0.4, chloroform).

~~.~~6 J 03 Exa mule 189 A solution of 106 mg of methyl 1-[8-(amino-imino-methyl)-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-s ylacetyl]-piperidin-4-yloxyacetate acetate (Example 175) and 18 mg of lithium hydroxide in 5 ml of methanol and 0.5 ml of water is stirred at room temperature for 16 h., adjusted to pH 3 with 1 N HCI and concentrated. Chromatography of the residue on silylated silica gel RP 18 (water/tetrahydrofuran gradient) gives io 60 mg of 1-[8-(amino-imino-methyl)-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-ylacetyl]-piperidin-4-yloxyacetic acid as white crystals, MS (ISP): 405 (M+H)+.
ExamQle 190 A solution of 200 mg of tert-butyl (R)-3-[(S)-1-(4-tert-butoxycarbonylmethoxy-benzoyl)-ethylcarbamoylmethoxy]-pyrrolidine-1-carboxylate in 2 ml of dichloromethane and 1 ml of trifluoroacetic acid is stirred at room temperature for 4 h., 2o concentrated and the residue is chromatographed on silylated silica gel RP 18 (water/tetrahydrofuran gradient). There are obained 113 mg of [4-[(S)-2-[(R)-2-pyrrolidin-3-yloxy-acetyl-amino]-propionyl]-phenoxy]-acetic acid trifluoroacetate, MS
(ISP): 351 (M+H)+.
The starting material can be prepared as follows:
Coupling of 360 mg of tert-butyl (R)-3-carboxymethoxy-pyrrolidine-1-carboxylate ( Example 187 b) with 569 mg of tert-3o butyl (S)-4-(2-tert-butoxycarbonylamino-propionyl)-phenoxy-acetate, deprotected according to Example 177 b), in 15 ml of dichloromethane in the presence of 446 mg of TPTU and 0.33 ml of 4-methylmorpholine gives, after concentration of the reaction solution and chromatogaphy of the residue on silica gel (hexane/
a5 ethyl acetate 1:3), 200 mg of tert-butyl (R)-3-[(S)-1-(4-tert-butoxycarbo nylmethoxy-benzoyl)-ethylcarbamoylmethoxy]-pyrrolidine-1-carboxylate, MS (ISP): 507 (M+H)+.

z~~~~o~

_Exam Ip a 191 In analogy to Example 185, 231 mg of tert-butyl (S)-4-[[2 (4-tert-butoxycarbonylmethoxy-phenyl)-1-methyl-2-oxo-ethyl]
s methyl-carbamoylmethoxy]-piperidine-1-carboxylate are deprotected and chromatographed on silylated silica gel RP 18 (water/tetrahydrofuran gradient). There are obtained 113 mg of (S)-4-[2-[methyl-(piperidin-4-yloxy-acetyl)-amino]-propionyl]-phenoxy]-acetic acid trifluoroacetate, MS (ISP): 379 (M+H)+.
w The starting material can be prepared as follows:
a) Alkylation of 723 mg of tert-butyl (S)-[2-(4-hydroxy-phenyl)-1-methyl-2-oxo-ethyl]-methylcarbamate analogously to Example 3 c) and chromatography of the evaporation residue on silica gel (hexane/ethyl acetate 5:1 ) gives 990 mg of tert-butyl (S)-[4-[2-(tert-butoxycarbonyl-methyl-amino)-propionyl]-phenoxy]-acetate, [a] p = -124.5 (c = 0.4, chloroform).
2o b) Cleavage of the BOC protecting group in 394 mg of the preceding step product is effected analogously to Example 177 b) at -78~C. The resulting amine is stirred at room temperature for 20 h. with 311 mg of 1-tert-butoxycarbonylpiperidine-4-yl-oxyacetic acid in the presence of 356 mg of TPTU and 222 mg of 2~ 4-methylmorpholine in 45 ml of dichloromethane. After removal of the solvent and chromatography of the residue on silica gel (tert-butyl methyl ether/hexane 4:1 ) there are obtained 179 mg of tert-butyl (S)-4-[[2-(4-tert-butoxycarbonylmethoxy-phenyl)-1-methyl-2-oxo-ethyl]-methyl-carbamoylmethoxy]-piperidine-1-~o carboxylate as a pale yellow oil, [a] p = -1207 (c = 0.3, chloroform).
Exam Ip a A
A compound of formula I can be used in a manner known per se as the active substance for the manufacture of tablets of the following composition:

Per tablet Active substance 200 mg microcrystalline cellulose 155 mg Corn starch 25 mg s Talc 25 mg Hydroxypropylmethylcellulose 20 ma 425 mg Exam Ip a B
w A compound of formula I can be used in a manner known per se as the active substance for the manufacture of capsules of the folowing compositon:
Per c Ds ule Active substance 100.0 mg Corn starch 20.0 mg Lactose 95.0 mg Talc 4.5 mg Magnesium stearate 0.

220.0 mg

Claims (46)

1, An acetic acid derivative of the formula wherein L is a group of formula L1 to L5:
in which a carbonyl group present in the L group and/or between the L and M groups which is not bonded in the form of an amide can also be present as an oxime, A is a group of formula A1 to A4:

E1 and E2 are H, lower-alkyl, OH, lower-alkoxy, lower-alkoxy-lower-alkyl, carboxy-lower-alkyl, P(O)(O-lower-alkyl)2, C(O)OR1, OC(O)R1, OC(O)OR1 or C(O)SR1, provided that at least one of E1 and E2 is H, or E1 and E2 together with the N atoms to which they are attached are a (5,5-dimethyl or 5-oxo)-4,5-dihydro-1,2,4-oxadiazol-3-yl group, R1 is lower-alkoxy-lower-alkyl, lower-alkyl, lower-alkyl substituted by OH, CO4H, lower-alkoxycarbonyl, lower-alkanoyloxy, lower-alkenoyloxy, optionally substituted benzoyloxy or lower-alkyl-CONH, or phenyl which is optionally substituted and optionally bonded via lower-alkylene, or cycloalkyl optionally interupted by O, one of X and Y is CH and the other is CH, C-lower-alkyl, C-lower-alkoxy or N, D is a group (CH2)s or (CH2)t O, s is 1 to 4, m and n are 0 to 5 and t is 0 to 3,but m+ n are 1 to 5 and each of m + t and n + t is at least 1, p and q are 0 to 5, but p + q is 2 to 5, a W1 is CH2, alkyl-CH, lower-alkyl-OC(O)CH, NH, lower-alkyl-N or lower-alkoxy-lower-alkyl-N, W2 is O, NH, acyl-N or lower-alkyl-OC(O)-N, G is hydrogen, methyl, isopropyl, -CH2CH(CH3)2, -CH(CH3)CH2CH3, benzyl, p-hydroxybenzyl, -CH20H, -CH(OH)CH3, -CH2SH, -CH2CH2-S-CH3, -CH2COOH; -CH2C(O)-NH2, -CH2CH2COOH, -CH2CH2C(O)NH2, -CH2CH2CH2NHC(=NH)NH2, -CH2(CH2)2CH2NH2, or G is a lower alkyl group optionally substituted by (a) OH, SH, lower-alkylthio, an unsubstituted or substituted aryl, NH2, NHR a, NR a R b or OR a, wherein R a and R b are lower alkyl, lower alkoxy-lower-alkyl, acyl or lower-alkoxycarbonyl, or (b) CONH2 or CONH-lower-alkyl, 130a M is 1,4-piperidinylene bonded via the N atom to the keto group or 1,4-phenylene optionally substituted by lower-alkyl, lower-alkoxy, OCH2COOH or OCH2COO-lower-alkyl, Q is O, CH2, NH, acyl-N or lower-alkyl OC(O)N, T is NH2, NH-lower-alkyl, NH-lower-alkyl-COOH, NH-lower-alkyl-COO-flower-alkyl, lower-alkoxy or lower-alkenyloxy substituted by lower-alkoxy, COOH, COO-lower-alkyl, lower-alkyl-COO or lower-alkyl-OCOO, or a group OT, T' is H, lower-alkyl, phenyl or pyridyl optionally bonded via lower-alkylene or cycloalkyl optionally bonded via lower-alkylene and optionally interrupted by O, NH or NCOO-lower-alkyl, with the provisos that a) T' is different from H, lower-alkyl and phenyl-lower-alkyl where L is a group of the formula A is a group of the formula one of E1 and E2 is hydrogen and the other is hydrogen, tert-butoxycarbonyl or benzyloxycarbonyl, one of X and Y is CH and the other is CH or N and W1 is NH, lower-alkyl-N or lower-alkoxy-lower-alkyl-N, G has the above significance, M is 1,4-piperidinylene bonded via the N atom to the keto group and Q is O, and b) T' is different from H, lower-alkyl, phenyl and phenyl-lower-alkyl where L is a group of formula L11, L31 or L41:
A is a group of the formula one of E1 and E2 is hydrogen and the other is hydrogen, tert-butoxycarbonyl or benzyloxycarbonyl, one of X and Y is CH and the other is CH, C-lower-alkyl, C-lower-alkoxy o r N, R o and G o are H or lower-alkyl, W4 is C=O or C=NOH, M is 1,4-phenylene optionally substituted by lower-alkyl, lower-alkoxy, OCH2COOH or OCH2COO-lower-alkyl and Q is O, CH2 or NH, or a hydrate, a solvate, or a physiologically usable salt thereof.
2. The acetic acid derivative according to claim 1, wherein L is a group of the formula A is a group A1, A2 or A30:
one of E1 and E2 is H and the other is H, lower-alkyl, OH, lower-alkoxy, lower-alkoxy-lower-alkyl, carboxy-lower-alkyl, PO(O-lower-alkyl)2, C(O)OR1 or OC(O)OR1, R1 is lower-alkoxy-lower-alkyl, lower-alkyl, lower-alkyl substituted by OH, COOH or lower-alkenoyloxy, or phenyl which is optionally substituted and option-ally bonded via lower-alkylene, or cycloalkyl option-ally interrupted by O, one of X and Y is CH and the other is CH or N, m and n are 0 to 5 and t is 0 to 3, but m + n is 1 to 5 and each of m + t and n + t is at least 1, W1 is CH2, lower-alkyl-OCOCH, NH, lower-alkyl-N or lower-alkoxy-lower-alkyl-N, G is hydrogen, methyl, isopropyl, -CH2CH(CH3)2, -CH(CH3)CH2CH3, benzyl, p-hydroxybenzyl, -CH2OH, -CH(OH)CH3, -CH2SH, -CH2CH2-S-CH3, -CH2COOH; -CH2C(O)-NH2, -CH2CH2COOH, -CH2CH2C(O)NH2, -CH2CH2CH2NHC(=NH)NH2, -CH2(CH2)2CH2NH2, or G is a lower alkyl group optionally substituted by (a) OH, SH, lower-alkylthio, an unsubstituted or substituted aryl, NH2, NHR a, NR a R b or OR a, wherein R a and R b are lower alkyl, lower alkoxy-lower-alkyl, acyl or lower-alkoxycarbonyl, or (b) CONH2 or CONH-lower-alkyl, 133a M has the same significance as in claim 1, Q is oxygen, T is a group OT" and T" is H, lower-alkyl, lower-alkoxy-lower-alkyl or cyclo-alkyl optionally bonded via lower-alkylene and option-ally interrupted by O, with the provisos that a) T" is different from H, lower-alkyl and phenyl-lower-alkyl where A is a group of the formula E1 and E2 are hydrogen, tert-butoxycarbonyl or benzyloxy-carbonyl, X, Y, G and Q have the above significance, W1 is NH, lower-alkyl-N or lower-alkoxy-lower-alkyl-N
and M is 1,4-piperidinylene bonded via the N atom to the keto group, and b) T" is different from H, lower-alkyl, phenyl and phenyl-lower-alkyl where L is a group of formula L11:
A is a group of the formula E1 and E2 are hydrogen, tert-butoxycarbonyl or benzyloxy-carbonyl, X, Y and Q have the above significance, R o and G o are H or lower-alkyl and M is 1,4-phenylene optionally substituted by lower-alkyl, lower-alkoxy, OCH2COOH or OCH2COO-lower-alkyl, or a physiologically usable salt thereof.
3. The acetic acid derivative according to claim 1, wherein L is a group L1 in which A is a group A1, namely of the formula wherein E1, E2, X, Y, W1, G, M, Q and T have the same significance as in claim 1.
4. The acetic acid derivative according to claim 1 or 3, wherein one of E1 and E2 is H 'and the other is H, OH, C(O)OR1 or OC(O)OR1.
5. The acetic acid derivative according to claim 4, wherein R1 is lower-alkyl, lower-alkoxy-lower-alkyl, lower alkyl substituted by benzoyloxy or lower-alkanoyloxy, acetoxymethyl, acetoxyethyl or pivaloyloxymethyl, or phenyl.
6. The acetic acid derivative according to claim 1, 3, 4 or 5, wherein one of X and Y is CH and the other is CH or N and/or wherein W1 is NH or CH2 and/or wherein Q is O or CH2.
7. The acetic acid derivative according to any one of claims 1 and 3-6, wherein. G is H, lower-alkyl, or lower-alkoxycarbonylamino-lower-alkyl.
8. The acetic acid derivative according to any one of claims 1 and 3-7, wherein M is 1,4-piperidinylene bonded via the N atom to the keto group, 1,4-phenylene or 1,4-phenylene substituted by OCH2COO-lower-alkyl,
9. The acetic acid derivative according to any one of claims 1 and 3-8, wherein T is lower-alkoxy, lower-alkoxy-lower-alkoxy, lower-alkenyloxy substituted by COO-lower-alkyl, lower-alkoxy substituted by lower-alkyl-COO, lower-alkoxy substituted by lower-alkyl-OCOO, cycloalkoxy optionally interrupted by O, pyridyl bonded via lower-alkyleneoxy, or cycloalkyl bonded via lower-alkyleneoxy and optionally interrupted by NCOO-lower-alkyl.
10. The acetic acid derivative according to any one of claims 1-9, wherein the acetic acid derivative is selected from the group consisting of:
Ethyl (S)-4-[2-[4-[imino-2-(methoxy-ethoxycarbonyl-amino)-methyl]-benzoylamino]-propionyl]-phenoxyacetate, ethyl (Z)-(R,S)-4-[2-[4-[amino-hydroxylmino-methyl]-benzoylamino]-propionyl]-phenoxyacetate, tetrahydropyran-4-yl (S)-4-[2-[4-(ethoxycarbonylamino-imino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, ethyl (Z)-(R,S)-4-[2-[4-[amino-ethoxycarbonyloximino-methyl]-benzoylamino]-propionyl]-phenoxyacetate, ethyl (S)-4-[2-[4-(imino-phenoxycarbonylamino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, 2-methoxy-ethyl (S)-4-[2-[4-[imino-(2-methoxy-ethoxy-carbonylamino)-methyl]-benzoylamino]-propionyl]-phenoxy-acetate, ethyl (Z)-(S)-4-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-phenoxyacetate, isopropyl (E/Z)-(S)-1-[2-[4-(amino-ethoxycarbonylimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate, isopropyl (E/Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate, isopropyl [1-[4-[4-(ethoxycarbonylamino-imino-methyl)-phenyl]-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, isopropyl (RS)-j1-j4-[4-(isobutoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate and ethyl (E/Z)-(S)-1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxyacetate.
11. The acetic acid derivative according to any one of claims 1 and 3-9, wherein the acetic acid derivative is selected from the group consisting of:
(R/S)-1-Isopropoxycarbonyloxy-ethyl (Z)-(S)-[1-[2-[4-(amino-hydroxyimino-methyl)-benzoylamino]-propionyl]-piperidin-4-yloxy]acetate;
pyridin-3-ylmethyl (R)-(E)/(Z)-[1-[4-[4-(amino-hydroxy-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, pyridin-4-ylmethyl (R)-(E)/(Z)-[1-[4-[4-(amino-hydroxy-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, tert-butyl (E)- or (Z)-(RS)-3-[1-[(R)-4-[4-(amino-hydroxy-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxyacetoxymethyl]-piperidine-1-carboxylate, ethyl (R)-[1-[4-[4-(benzoyloxymethoxycarbonylamino-imino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, ethyl (R)-[1-[4-[4-(imino-pivaloyloxymethoxycarbonyl-amino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy]-acetate, tert-butyl (E)- or (Z)-(R)-4-[1-[4-[4-(amino-hydroxyimino-methyl)-phenyl]-2-methyl-4-oxo-butyryl]-piperidin-4-yloxy-acetoxymethyl]-piperidine-1-carboxylate and ethyl (S)-[4-[2-[4-[(2-acetoxy-ethoxy-carbonylimino)-amino-methyl]-benzoylamino]-propionyl]-phenoxy]-acetate.
12. The acetic acid derivative according to claim 1, wherein L is a group L1 in which A is a group A3, namely of the formula wherein E1, m, n, D, W1, G, M, Q and T have the same significance as in claim 1.
13. The acetic acid derivative according to claim 1 or 12, wherein E1 is H, OH or C(O)OR1, m and n are the number 2 and/or D
and Q are O and/or W1 is NH and/or G is lower-alkyl, and/or M is 1,4-phenylene and/or T is lower-alkoxy.
14. The acetic acid derivative according to claim 13, wherein E1 is lower-alkanoyloxy-lower-alkoxycarbonyl.
15. The acetic acid derivative according to claim 12, 13 or 14, acetoxymethyl (S)-4-j2-(4-ethoxycarbonylmethoxy-phenyl)-1-methyl-2-oxo-ethylcarbamoylmethoxy]-piperidine-1-carboxylate.
16. The acetic acid derivative according to claim 1, wherein L is a group L1 in which A is a group A2, namely of the formula wherein E1, X, Y, W1, G, M, Q and T have the same significance as in claim 1.
17. The acetic acid derivative according t0 claim 1, wherein L is a group L1 in which A is a group A4, namely of the formula wherein E1, p, q, W1, G, M, Q and T have the same signific-ance as in claim 1.
18. The acetic acid derivative according to Claim 1, wherein L is a group L2 in which A is a group A1, namely of the formula wherein E1, E2, X, Y, W2, G, M, Q and T have the same significance as in claim 1.
19. The acetic acid derivative according to Claim 1, wherein L is a group L3 in which A is a group A1, namely of the formula wherein E1, E2, X, Y, G, M, Q and T have the same signif-icance as in claim 1.
20. The acetic acid derivative according to claim 1, wherein L is a group L4 in which A is a group A1, namely of the formula wherein E1, E2, X, Y, G, M, Q and T have the same signif-icance as in claim 1.
21. The acetic acid derivative according to claim 1, wherein L is a group L5, namely of the formula wherein E1, E2, G, M, Q and T have the same significance as in claim 1.
22. The acetic acid derivative acccording t0 any one of claims 1-21 for use in inhibiting blood platelet aggregation.
23. A process for the manufacture of the acetic acid derivative according to claim 1, which process comprises a) cleaving the protected amino or amidino group in a compound of the formula wherein L0 is a group of one of formulae L10 to L50 in which A0 is a group A containing a protected amino or amidino group, A, W1, W2, G, M, Q and T have the same significance as in claim 1 and A01 is a protected amidino group, or b) converting the free amidino group in a compound of formula III

wherein L100 is a group of one of formulae L101 to L501 in which A100 is a group A containing a free amidino group and A, W1, W2, G, M, Q and T have the same significance as in claim 1, or in a salt thereof into an amidino group substituted by a group E1 or E2, or c) converting the cyano group present in L11 in a compound of formula IV

wherein L11 is a group of one of formulae L111 to L115 in which X, Y, W1, W2, G, M, Q and T have the same significance as in claim 1, into an amidino group optionally substituted by E1 or E2, or d) reacting an amine of the formula wherein R2 is H, lower-alkyl or lower-alkoxy-lower-alkyl and G, M, Q and T have the same significance as in claim 1, with an acid A-COOH or a functional derivative thereof, or e) if desired, cleaving a lower-alkoxycarbonyl group or an ether group, or converting an unsubstituted amidino group present in a group A1 or L5 into a substituted amidino group, or converting a hydroxy group present in a group A1 or L5 into a R1OC(O)O group, wherein A1, L5 and R1 are as defined in claim 1, in a compound of formula 1 as defined in claim 1, and f) if desired, converting a compound of formula I into a physiologically compatible salt or converting a salt of a compound of formula I into the free acid or base.
24. A pharmaceutical preparation for inhibiting blood platelet aggregation, comprising the compound according to any one of claims 1-21 as the active substance, and a suitable diluent or carrier.
25. A use of the compound according to any one of claims 1-21 for the production of a medicament for inhibiting blood platelet aggregation.
26. The acetic acid derivative according to claim 5, wherein R1 is a lower alkyl selected from the group consisting of ethyl, butyl and isobutyl.
27. The acetic acid derivative according to claim 5, wherein R1 is methoxyethyl.
28. The acetic acid derivative according to claim 5, wherein R1 is benzoyloxymethyl.
29. The acetic acid derivative according to claim 7, wherein G is methyl or ethyl.
30. The acetic acid derivative according to claim 7, wherein G is ethoxycarbonylaminopropyl.
31. The acetic acid derivative according to claim 8, wherein M is methoxycarbonylmethoxy.
32. The acetic acid derivative according to claim 9, wherein T is a lower alkoxy selected from the group consisting of methoxy, ethoxy, isopropoxy, isobutoxy, tert-butoxy and hexyloxy.
33. The acetic acid derivative according to claim 9, wherein T is methoxyethoxy.
34. The acetic acid derivative according to claim 9, wherein T is 2-isobutoxycarbonyl-2-pentenyloxy.
35. The acetic acid derivative according to claim 9, wherein T is pivaloyloxymethoxy.
36. The acetic acid derivative according to claim 9, wherein T is 1-isopropoxycarbonyloxy-ethoxy.
37. The acetic acid derivative according to claim 9, wherein T is tetrahydropyranyloxy.
38. The acetic acid derivative according to claim 9, wherein T is 3-or 4-pyridylmethoxy.
39. The acetic acid derivative according to claim 9, wherein T is 1-tert-butoxycarbonyl-3 or 4-piperidylmethoxy.
40. The acetic acid derivative according to claim 13, wherein G is methyl.
41. The acetic acid derivative according to claim 13 or 40, wherein T
is ethoxy.
42. The acetic acid derivative according to claim 14, wherein E1 is acetoxymethoxycarbonyl.
43. The acetic acid derivative according to claim 16, wherein Q is O
and T is OH or lower-alkoxy.
44. The acetic acid derivative according to claim 17 or 20, wherein M is 1,4-phenylene, Q is O and T is lower-alkoxy.
45. The acetic acid derivative according to claim 18, 19 or 21, wherein M is 1,4-piperidinylene bonded via the N atom to the keto group, Q is O and T is lower-alkoxy.
46. A use of a pharmaceutical composition comprising the compound according to any one of claims 1-21 and a pharmaceutically acceptable diluent or carrier, for inhibiting blood platelet aggregation.
CA002136903A 1993-12-03 1994-11-29 Acetic acid derivatives Expired - Fee Related CA2136903C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH3609/93 1993-12-03
CH360993 1993-12-03
CH3198/94 1994-10-25
CH319894 1994-10-25

Publications (2)

Publication Number Publication Date
CA2136903A1 CA2136903A1 (en) 1995-06-04
CA2136903C true CA2136903C (en) 2006-06-06

Family

ID=25692439

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002136903A Expired - Fee Related CA2136903C (en) 1993-12-03 1994-11-29 Acetic acid derivatives

Country Status (29)

Country Link
US (2) US5726185A (en)
EP (1) EP0656348B1 (en)
JP (1) JP2901509B2 (en)
KR (1) KR100335541B1 (en)
CN (1) CN1075062C (en)
AT (1) ATE192430T1 (en)
AU (1) AU687905B2 (en)
BG (1) BG62399B1 (en)
CA (1) CA2136903C (en)
CZ (1) CZ290024B6 (en)
DE (1) DE59409322D1 (en)
DK (1) DK0656348T3 (en)
ES (1) ES2147210T3 (en)
FI (2) FI945688A (en)
GR (1) GR3034111T3 (en)
HU (1) HUT71332A (en)
IL (1) IL111784A0 (en)
IS (1) IS4237A (en)
LV (1) LV11318B (en)
MY (1) MY112417A (en)
NO (1) NO302169B1 (en)
NZ (1) NZ270020A (en)
PT (1) PT656348E (en)
RO (1) RO117846B1 (en)
RU (1) RU2151768C1 (en)
SI (1) SI0656348T1 (en)
SK (1) SK282058B6 (en)
TW (1) TW472042B (en)
UA (1) UA35592C2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69520876T2 (en) * 1994-10-07 2002-02-21 Meiji Seika Co GAMMA DIKETONE COMPOUND WITH THROMBOZYTE AGGREGATION-INHIBITING EFFECT
JPH08325263A (en) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd New 2-amino-3-phenylpropionic acid derivative
US6013651A (en) * 1995-08-30 2000-01-11 G. D. Searle & Co. Meta-azacyclic amino benzoic acid compounds and derivatives thereof
ATE203234T1 (en) 1995-08-30 2001-08-15 Searle & Co META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINOBENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
JP2000506538A (en) * 1996-03-29 2000-05-30 ジー.ディー.サール アンド カンパニー Meta-substituted phenylene derivatives
DE19622189A1 (en) * 1996-06-03 1997-12-04 Bayer Ag 3-cyanaryl pyrazole
AU747293B2 (en) * 1997-02-06 2002-05-16 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
WO2000037107A2 (en) 1998-12-23 2000-06-29 G.D. Searle & Co. Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
HU226998B1 (en) * 2000-11-23 2010-04-28 Richter Gedeon Nyrt Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7759387B2 (en) 2003-10-08 2010-07-20 Piramal Life Sciences Limited Fibrinogen receptor antagonists and their use
US7314938B2 (en) * 2003-11-05 2008-01-01 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
EP2444079B1 (en) 2005-05-17 2016-11-30 SARcode Bioscience Inc. Compositions and Methods for Treatment of Eye Disorders
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
MX2010004281A (en) 2007-10-19 2010-09-10 Sarcode Corp Compositions and methods for treatment of diabetic retinopathy.
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
JP2011518155A (en) * 2008-04-15 2011-06-23 サーコード コーポレイション Aerosolized LFA-1 antagonist for use in local treatment of immune related disorders
JP2011521896A (en) * 2008-04-15 2011-07-28 サーコード コーポレイション Topical LFA-1 antagonists for use in local treatment for immune related disorders
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
KR102027287B1 (en) 2011-08-30 2019-10-01 씨에이치디아이 파운데이션, 인코포레이티드 Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2751086A4 (en) 2011-08-30 2015-09-16 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2879982C (en) 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
DE102014108210A1 (en) 2014-06-11 2015-12-17 Dietrich Gulba rodenticide
JP2017520610A (en) 2014-07-17 2017-07-27 シーエイチディーアイ ファウンデーション,インコーポレーテッド Methods and compositions for treating HIV related disorders
WO2020059812A1 (en) 2018-09-20 2020-03-26 小野薬品工業株式会社 Novel salt of 4-(\{(4s)-1-(4-carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-l-prolyl\}amino)benzoic acid, and and novel crystal form of said salt
CN113075343B (en) * 2020-01-04 2024-02-23 东莞市东阳光仿制药研发有限公司 Hydroxylamine and detection method of hydroxylamine salt
EP4070658A1 (en) 2021-04-06 2022-10-12 BIORoxx GmbH Use of anticoagulant active compounds as rodenticide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5256812A (en) * 1989-01-31 1993-10-26 Hoffmann-La Roche Inc. Carboxamides and sulfonamides
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
UA39849C2 (en) * 1991-03-26 2001-07-16 Ф.Хоффманн-Ля Рош Аг DERIVATIVES OF N-ACYL- <font face = "Symbol"> a </font> -AMINO ACIDS OR THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS, SIMPLE OR COMPLEX ETHERS, AMIDICES OR HYMICHIDICS OR
DE4213919A1 (en) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K CYCLIC IMINODERIVATES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
JPH08505391A (en) * 1992-12-30 1996-06-11 スミスクライン・ビーチャム・コーポレイション Compound
CA2136007C (en) 1993-03-17 1999-12-14 Kiyoaki Katano Novel compound with platelet aggregation inhibitor activity
GB9313269D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Allophanic acid derivatives
US5607948A (en) * 1993-06-30 1997-03-04 Sumitomo Pharmaceuticals Co., Ltd. Dipiperidine derivatives

Also Published As

Publication number Publication date
KR100335541B1 (en) 2003-06-11
NO944650D0 (en) 1994-12-02
RU2151768C1 (en) 2000-06-27
CZ301194A3 (en) 1995-09-13
EP0656348B1 (en) 2000-05-03
EP0656348A2 (en) 1995-06-07
BG62399B1 (en) 1999-10-29
PT656348E (en) 2000-10-31
UA35592C2 (en) 2001-04-16
NZ270020A (en) 1997-05-26
SK145894A3 (en) 1995-09-13
GR3034111T3 (en) 2000-11-30
KR950017928A (en) 1995-07-20
NO302169B1 (en) 1998-02-02
JP2901509B2 (en) 1999-06-07
RO117846B1 (en) 2002-08-30
US5973188A (en) 1999-10-26
AU7909094A (en) 1995-06-08
SI0656348T1 (en) 2000-08-31
LV11318B (en) 1996-10-20
DK0656348T3 (en) 2000-09-11
AU687905B2 (en) 1998-03-05
FI20011980A (en) 2001-10-11
US5726185A (en) 1998-03-10
IS4237A (en) 1995-06-04
CA2136903A1 (en) 1995-06-04
ES2147210T3 (en) 2000-09-01
CZ290024B6 (en) 2002-05-15
BG99233A (en) 1995-09-29
DE59409322D1 (en) 2000-06-08
HUT71332A (en) 1995-11-28
NO944650L (en) 1995-06-06
SK282058B6 (en) 2001-10-08
FI945688A0 (en) 1994-12-02
ATE192430T1 (en) 2000-05-15
CN1075062C (en) 2001-11-21
RU94042929A (en) 1996-10-27
JPH07196592A (en) 1995-08-01
LV11318A (en) 1996-06-20
EP0656348A3 (en) 1995-09-06
CN1112104A (en) 1995-11-22
MY112417A (en) 2001-06-30
FI945688A (en) 1995-06-04
IL111784A0 (en) 1995-01-24
HU9403441D0 (en) 1995-02-28
TW472042B (en) 2002-01-11

Similar Documents

Publication Publication Date Title
CA2136903C (en) Acetic acid derivatives
AU684255B2 (en) Arylsulfonamido-substituted hydroxamic acids
US5932595A (en) Matrix metalloprotease inhibitors
EP0873123B1 (en) Inhibitors of protein isoprenyl transferases
US6221898B1 (en) Amidino derivatives and their use as thrombin inhibitors
US5210266A (en) N-substituted mercaptopropanamide derivatives
JPH11501910A (en) Arylsulfonylaminohydroxamic acid derivatives
AU7946198A (en) New amidino derivatives and their use as thrombin inhibitors
US5179125A (en) N-substituted mercaptopropanamide derivatives
DE69915686T2 (en) AMIDINODERIVATES AND THEIR USE AS THROMBIN INHIBITORS
MXPA02006315A (en) Ox(adi)azolylhydroxamic acids useful as procollagen cproteinase inhibitors.
HU207043B (en) Process for producing sulfonamide derivatives and pharmaceutical compositions comprising such compounds
US20040072871A1 (en) Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them
US20040147502A1 (en) Beta lactam compounds and their use as inhibitors of tryptase
US6482827B1 (en) Matrix metalloproteinase inhibitors
AU4973500A (en) Alpha-amino-beta-sulfonyl hydroxamic acid compounds
EP1283825A1 (en) N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
US4863938A (en) Pyridine derivatives and their use as nootropic agents
HRP940961A2 (en) Acetic acid derivatives
US20040209822A1 (en) Novel compounds

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed